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The endogenous cannabinoids (endocannabinoids) arachidonoyl ethanolamide (AEA) 
and 2-arachidonoyl glycerol (2-AG) regulate neurotransmission and inflammation by 
activating the CB1 cannabinoid receptors in the central nervous system and the CB2 
cannabinoid receptors on immune cells. Endocannabinoids are inactivated via a 2-step 
process: firstly undergoing reuptake into the cell and then hydrolysis by fatty acid 
amide hydrolase (FAAH) for AEA or by monoacylglycerol lipase (MAGL) for 2-AG. 
Inhibition of FAAH is an effective treatment for inflammatory pain and is a target for 
the development of novel analgesics. 
 
FAAH and MAGL produce arachidonic acid by hydrolysis of endocannabinoids. In 
inflammation arachidonic acid is oxidised by cyclooxygenase 2 (COX-2) to synthesise 
the prostaglandins. Both FAAH and MAGL inhibition were showed to indirectly suppress 
prostaglandin E2 synthesis in activated macrophages. This effect was found to be 
dependent on the amount of lipopolysaccharide used to activate the macrophages. 
 
The FAAH substrates, AEA, oleoyl ethanolamide (OEA) and palmitoyl ethanolamide 
(PEA), were measured in samples from an in vivo model of inflammatory pain to 
screen various FAAH inhibitors to prove their mechanism of action. Liquid 
chromatography-tandem mass spectrometry methods were developed and validated 
for the measurement of these three substrates in brain and whole blood. Blood OEA 
and PEA concentrations were found to be indicative of brain FAAH activity and brain 
AEA concentrations.  
 
FAAH is capable of conjugating arachidonic acid to paracetamol to form the active 
metabolite AM404, an inhibitor of AEA reuptake. It was shown that FAAH can also 
conjugate oleic acid and palmitic acid to paracetamol, producing novel metabolites. A 
clinical trial was conducted to comprehensively investigate the pharmacokinetics, 
metabolism and mechanism of action of intravenous paracetamol in cerebrospinal fluid 
and plasma. Paracetamol, its major metabolites, AM404, prostaglandin E2, leukotriene 
B4, serotonin and the FAAH substrates were measured. For the first time AM404 was 
demonstrated to be formed by humans and be present in the cerebrospinal fluid. 
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1.1. Pain and analgesia 
 
For the purpose of survival, all life is capable of sensing and responding to the 
hostilities of its environment.1 Pain, the unpleasant sensory and emotional experience 
caused by the presence of noxious stimuli, is one aspect of this response mechanism.2 
The classification of pain is based on its cause, type, region and duration. The most 
common pain-causing conditions in descending order are arthritis (rheumatoid and 
osteoarthritis), spinal disc herniation, injury/trauma, headache/migraine, nerve injury 
and surgery.3 The most common locations of pain in descending order are back, knee, 
head, leg, joints, shoulder, neck, hip and hands.3  
 
While many conditions can produce pain, its cause can be simplified as being due to 
noxious stimuli, inflammation or nerve injury.4 Each of these causes will produce their 
own types of pain, either nociceptive, inflammatory or neuropathic respectively.5 
Nociceptive pain is the stimulation of peripheral nerve fibres by noxious stimuli, such 
as mechanical pain from pressure or movement, thermal pain from heat or cold, or 
chemical pain from acid. If noxious stimuli were to subsequently cause tissue injury, or 
if infection was to occur, then this would result in a release of inflammatory mediators 
that leads to inflammatory pain. Direct damage to the nervous system caused by 
injury to the nerves or spinal cord will result in neuropathic pain.5  
 
The duration of pain is classified as either acute or chronic, with acute pain being of a 
rapid on-set and typically of a short duration, while chronic pain potentially lasts many 
months and years and hence beyond the expected time of healing. Nociceptive pain is 
often short lasting and ends once the noxious stimulus has been removed. 
Inflammatory pain lasts as long as it takes for the inflammation to resolve. The failure 
of inflammatory resolution can lead to chronic inflammation, and consequently chronic 
pain. Neuropathic pain is a longer lasting pain and may never completely cease.6 
 
1.1.1. Nociception 
 
Pain begins with the detection of a stimulus by nociceptors (Figure 1.1.). These are 
pain specific receptors expressed on sensory neurons of the peripheral nervous system 
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that express various ion channels and receptors, such as the transient receptor 
potential (TRP) channels and the voltage-gated sodium channels. Nociceptors are 
present in the skin, muscles and joints with various levels of sensitivity.7  
 
 
 
Figure 1.1. – Pain signalling pathways. Nociceptors detect and relay noxious stimuli via the 
dorsal root ganglion and spinal cord to the brain. Inflammatory mediators released by 
inflammatory leukocytes amplify this response. Image redrawn from Scholz et al. 5 
 
Upon sensation of pain, a signal is sent from the periphery to the central nervous 
system (CNS). Connections between neurons are known synapses. It is at the synapse 
that signals are passed between neurons. While a signal is not being sent a resting cell 
membrane potential is maintained, which is characterised by high intracellular 
concentrations of K+ (139 mM) and high extracellular concentrations of Na+ (145 
mM).8 During the relay of a signal an action potential, travelling along the neuron, will 
reaches the synapse. This causes an influx of cations, such as Na+ and Ca2+, thereby 
depolarising the neuron. At resting potential the voltage-gated calcium channels are 
closed.8 Depolarisation increases the Ca2+ permeability of the presynapse, triggering 
vesicles filled with neurotransmitters to fuse with the membrane and release their 
contents into the synapse.8 Neurotransmitters, then bind to their receptors on the 
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opposing postsynapse, in a process known as neurotransmission. On completion of 
their action these neurotransmitters undergo reuptake back into the presynapse. 
Neurotransmission results in either the continuation of the action potential along 
adjacent neuron, or in a longer term change such as the sensitisation of the neuron.8 
Eventually the signal is relayed to the dorsal horn, up the spinal cord and brain stem 
into the brain. The consequent processing of pain is complex, involving the signal 
transduction of the stimuli and additional cognitive and emotional processing.9 
 
The sensory fibres responsible for relaying pain signals from the periphery extend from 
the cell bodies of trigeminal ganglia and dorsal root ganglia (DRG).6 There are a 
number of types of sensory fibres located in the periphery, differentiated by their size 
and degree of myelination. The larger Aα and Aβ-fibres do not convey pain signals, this 
is the role of the smaller Aδ and the smaller still C-fibres.8 Myelin, composed of 
predominately lipids, water and protein, serves to insulate the nerves to prevent ion 
leakages and weak signalling. The conduction velocity of an unmyelinated axon is 
between 0.5 to 10 m/s, while myelinated axons are faster, conducting at velocities up 
to 150 m/s.10 Therefore the thinly myelinated Aδ fibres relay pain the fastest, whilst 
the unmyelinated C-fibres are slower.8 While some nociceptors are thinly myelinated, 
the majority are unmyelinated.11 
 
Sensitivity of these fibres is not fixed and can be increased (hypersensitivity) by 
inflammatory mediators and decreased (diminished sensitivity), both affecting the 
perception of pain. Normally this pain threshold is high enough to allow for normal 
activity, but low enough so that noxious stimuli can be detected.5 Diminished 
sensitivity and hypersensitivity mean that noxious stimuli will not always cause pain 
and that pain will not always have been caused by noxious stimuli. Such sensitisation 
of neurons is due to a repeated stimulus that will cause the signal that it sends to be 
progressively amplified. Sensitisation is further differentiated as central and 
peripheral.6 Central sensitisation is the heightened response of sensory neurons to 
pain. Peripheral sensitisation is a reduced threshold for the activation of sensory 
neurons. The sensitisation of neurons, both central and peripheral, results in allodynia 
and hyperalgesia. Allodynia is defined as the pain caused by a normally innocuous 
stimuli, while hyperalgesia is defined as an exaggerated pain in response to noxious 
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stimuli due to a reduction in the pain threshold. Hyperalgesia is further differentiated 
into primary and secondary, with primary being a reduced pain threshold at the site of 
injury and secondary being a reduced pain threshold in surrounding uninjured tissue. 
 
1.1.2. Inflammatory pain 
 
Inflammation is triggered by infection or injury to the microvasculature, the vessels 
responsible for blood distribution within tissue. Inflammation was first characterised by 
Celsus (25 BC – 50 AD) as the four cardinal signs: redness, swelling, heat and pain.12 
Inflammation is a beneficial process, with the ultimate aims of the inflammatory 
response being to remove the causing factor, to prevent tissue damage, to restore 
normal physiological function and to develop immunity, so that future encounters are 
met with a faster and more specific response.13 As a response to infection/injury the 
tissue-resident cells, such as macrophages, lymphocytes and endothelial cells, release 
pro-inflammatory mediators that include peptides (e.g. cytokines, substance P and 
tumour necrosis factor alpha), neurotransmitters (e.g. histamine and serotonin) and 
lipids (e.g. leukotriene B4 and prostaglandin E2) (Figures 1.2. & 1.3.). 
 
 
Figure 1.2. – Structure of Leukotriene B4. LTB4 is a chemoattractant responsible for 
neutrophil infiltration to the site of inflammation.  
 
 
Figure 1.3. – Structure of Prostaglandin E2. PGE2 is pro-inflammatory by increasing vascular 
permeability, causes vasodilation and hyperalgesia, and also anti-inflammatory by inhibiting 
leukocyte phagocytosis and triggering production of anti-inflammatory/pro-resolution mediators.  
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Arachidonic acid is oxidised in inflammation by the inducible cycloxygenase-2 (COX-2) 
and microsomal prostaglandin E synthase 1 (mPGES-1) enzymes to synthesise 
prostaglandin E2 (PGE2) (Figure 1.4.).14, 15 COX has two active sites. The oxidising site 
converts arachidonic acid to prostaglandin G2 (PGG2). The peroxidase site then 
converts PGG2 to prostaglandin H2 (PGH2). mPGES-1 isomerises PGH2 into PGE2. 
mPGES-1 is closely associated with COX-2 and is also induced under inflammatory 
conditions.15 Phospholipase A2 is responsible for producing the majority of arachidonic 
acid used in prostaglandin synthesis. Arachidonic acid exists esterified in the 
membrane phospholipids of the cell membrane. Phospholipase A2 hydrolyses the sn-2 
acyl ester bond of membrane phospholipids to release arachidonic acid.16 Disposition 
and calcium dependence divide the phospholipase A2 enzymes into three classes, 
which include the inducible cytosolic phospholipase A2 (cPLA2), the secretory 
phospholipase A2 (sPLA2) and the Ca
2+-independent (iPLA2).
17 Most of the arachidonic 
acid used in PGE2 synthesis by activated macrophages is released via a Ca2+-
dependent mechanism by cPLA2.
18 Upon activation, cPLA2 in macrophages translocates 
to the membranes of the nucleus and endoplasmic reticulum.19 Through its activation 
of its four prostaglandin E (EP) receptors, PGE2 has the pro-inflammatory effect of 
increasing vascular permeability,20 facilitating oedema formation and causing 
vasodilation (widening of the blood vessels).21 
 
 
Figure 1.4. – Prostaglandin biosynthesis. Phospholipase A2 hydrolyses the sn-2 acyl ester 
bond of membrane phospholipids to release arachidonic acid. COX and prostaglandin E synthase 
oxidise arachidonic acid to form prostaglandin E2, which through its four EP receptors exerts its 
pro-inflammatory effects.  
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Inflammatory cytokines such as tumour necrosis factor alpha (TNF-α), interleukin-1β 
(IL-1β) and interleukin-6 (IL-6) are produced to activate the endothelium and induce 
the acute phase inflammatory response.22 Additionally IL-6 can cross the blood-brain 
barrier to induce production of prostaglandins in the CNS, causing fever.23 The 
neuropeptide substance P causes vasodilation (widening of the blood vessels) and 
triggers nociception.24 The neurotransmitters/vasoactive amines histamine and 
serotonin causes vasodilation and increase vascular permeability, allowing for the flow 
of cells out of blood vessels.22 Leukotriene B4 (LTB4) is a potent chemoattractant 
responsible for the migration of neutrophils to the site of inflammation.25 The lipid 
mediator platelet-activating factor is a mediator of platelet aggregation, and also 
functions in leukocyte recruitment, vasodilation and increased vascular permeability.22 
These mediators cause vasodilation and increase vascular permeability by triggering a 
release of the free radical nitric oxide (NO) from the endothelium.26 The result of its 
action is increases blood flow to the inflamed tissue, producing the clinical signs of 
redness and heat, and facilitating exudation and the extravasation of leukocytes. 
Exudation is the accumulation of fluid, mostly plasma containing leukocytes, platelets 
and plasma proteins. This fluid is responsible for the clinical sign of tissue swelling, 
forming what is known as oedema.  
 
Through the increased permeability of the vasculature and release of chemoattractants 
by resident cells, leukocyte extravasation, which is the trafficking of leukocytes from 
the circulation towards the site of inflammation, is made possible.27 Neutrophils are 
the first leukocytes to arrive at the site of inflammation,28 having migrated through 
blood vessels by chemotaxis. The neutrophils follow mediators released from the site 
of inflammation, such as the chemoattractant leukotriene B4.29 Neutrophil infiltration is 
followed by the arrival of monocytes, which later differentiate into macrophages.28 
Once at the site of inflammation, the neutrophils and macrophages begin to isolate 
and phagocytose foreign microorganisms, clear debris and release further pro-
inflammatory mediators.30  
 
Macrophages are the major source of PGE2, a key mediator in inflammatory pain. The 
molecular mechanisms of inflammation have been well studied in lipopolysaccharide 
(LPS)-stimulated macrophages.31 Macrophages are produced by monocyte 
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differentiation.32 In inflammation they enter an activated state, becoming more readily 
able to engulf and digest pathogenic cells, and also becoming more sensitive to their 
environment by changing the expression of their surface receptors. Macrophages are 
one of the first cells to respond to infection and inflammation. They migrate into 
tissues where they secrete pro-inflammatory mediators. There is additionally an 
inflammatory resolution phase macrophage that functions in the restoration of tissue 
homeostasis.33 One of the most potent initiators of inflammation and activators of 
macrophages is LPS. It is embedded on the outer membrane of Gram-negative 
bacterial pathogens. Chemically it consists of a hydrophobic group (lipid A) and a 
hydrophilic polysaccharide chain, with the lipid A attached to the cell wall and the 
polysaccharide exposed to the extracellular environment. The recognition of LPS and 
consequent macrophage activation is mediated by a complex of three proteins: CD14, 
toll-like receptor 4 (TLR4) and myeloid differentiation-2 (MD-2).34 
 
Macrophages produce both PGE2 and TXA2, with resting macrophages producing TXA2 
in favour of PGE2, as COX-2 is not expressed in unactivated macrophages.35 Initiators 
of inflammation, like LPS, induce COX-2 expression through activation of nuclear 
factor-kB (NF-kB).35 Expression of COX-2 is also regulated by multiple cytokines and 
growth factors via activation of transcriptional regulatory proteins that act on its 
gene’s promoter sites. PGE2 produced by activated macrophages is integral to 
inflammatory pain.36 Activated macrophages additionally release numerous other 
mediators including cytokines and nitric oxide. 
 
Inflammatory pain is the result of both peripheral and central processes that are 
initiated by the pro-inflammatory mediators PGE2 and IL-1β. Peripherally PGE2 does 
not directly cause pain, instead it lowers the pain threshold through their sensitisation 
of neurons, leading to hyperalgesia and allodynia.37 Specifically PGE2 produces 
hyperalgesia by reducing the threshold for stimulation of the pain-sensing receptors 
transient receptor potential vanilloid 1 (TRPV1) and the voltage-gated sodium channel 
NaV1.8.
38, 39 Furthermore it is estimated that 15% of all C-fibres are ‘sleeping’, in that 
they are only activated upon exposure to mediators, such as PGE2.7 
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Pro-inflammatory mediators modulate nociceptor function by causing reversible 
changes in sensory neurons. Prolonged exposure of sensory neurons to pro-
inflammatory mediators is thought to be the mechanism by which acute pain becomes 
chronic pain.7 This results in the nociceptors being modified, as opposed to just 
modulated. Modification of sensory fibres triggers long lasting changes in the 
expression of receptors and ion channels and in interneuron connectivity.7  
 
Inflammatory pain also involves a central process, mediated by IL-1ß. This cytokine is 
capable of crossing the blood-brain barrier, allowing for it to travel into the CNS from 
the inflamed tissue where it was initially produced.40 Upon entry into the CNS, IL-1ß 
induces production of PGE2, further increasing pain sensitivity and ultimately leading 
to central sensitisation.41 Drugs that either reduce the synthesis of PGE2, such as 
inhibitors of COX-2 and mPGES-1, or block the action of PGE2, such as antagonists of 
TRPV1, NaV1.8 and the EP receptors, have therapeutic potential in analgesia and 
inflammation.42 
 
The failure of inflammation to resolve can lead to chronic inflammation,43 which can 
ultimately result in auto-immunity and loss of function.44 Continuing on from Celsus, 
Galen (129 – 200 AD) made loss of function the fifth cardinal sign of inflammation.12 
Once the cause of inflammation has been neutralised the highly co-ordinated process 
of inflammatory resolution can begin.45 Inflammatory resolution serves to prevent 
tissue damage, loss of function and auto-immunity.27 Having completed their task the 
extravasted inflammatory leukocytes are eliminated. Neutrophils undergo 
apoptosis/necrosis and then are either phagocytosed by macrophages 46 or 
recirculated.47 Removal of macrophages is instead via lymphatic drainage.48 This 
elimination of inflammatory leukocytes allows for the once inflamed tissue to be 
repopulated with resident lymphocytes, ultimately returning to their pre-inflammation 
numbers and cell state.49 At this stage there also appears to be a macrophage type 
unique to inflammatory resolution, which aids in both the elimination of neutrophils 
and the repopulation of tissue lymphocytes.33 Resolution continues with the reversal of 
vasodilation and the permeability of the vasculature returning to normal.  
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Resolution is controlled by specific pro-resolution lipid mediators, such as the resolvins 
and lipoxins. The resolvins inhibit further recruitment of leukocytes and the release of 
pro-inflammatory mediators.50 Lipoxins block entry of neutrophils to the site of 
inflammation,51 reduce vascular permeability,52 and stimulate macrophages to ingest 
and clear apoptotic neutrophils.53 PGE2 also exerts an anti-inflammatory effect by 
inhibiting leukocyte phagocytosis,54 inhibiting production of pro-inflammatory 
mediators,55 and triggering production of anti-inflammatory cytokines and pro-
resolution mediators.56 In addition to the on-set of inflammation, COX-2 is also 
induced during the resolution phase, where it synthesises the anti-inflammatory 
prostaglandins PGD2 and 5deoxy∆12–14 PGJ2.57 Induction of sPLA2 in inflammatory 
resolution provides the arachidonic acid required for the syntheses of these pro-
resolution prostaglandins.58 
 
1.1.3. Neuropathic pain 
 
Neuropathic pain results from damage to the peripheral or central nervous system. 
Nerve injury leads to sensitisation of neurons and the local release of inflammatory 
mediators. The continuous sensitisation of the neurons increases sensitivity of the 
dorsal horn resulting in central sensitisation.59 Changes in the dorsal root ganglion and 
dorsal horn are also seen with neuropathic pain. Following nerve injury microglia, the 
macrophages of the brain and spinal cord, are recruited and activated to help initiate 
and maintain a chronic pain state.60 While nociceptive pain and inflammatory pain 
have essential protective roles, neuropathic pain is normally becomes chronic and 
serves no useful purpose as often persist long after the initial injury has healed.61 
Common causes of neuropathic pain include stroke, trigeminal neuralgia, multiple 
sclerosis and injury to the spinal cord.3 
 
1.1.4. Analgesia 
 
Despite the importance of pain, relief from it is often required to make injury bearable, 
to allow physiological function to return to normal and to improve quality of life. Not all 
pain is protective, such as in chronic cases where pain continues after healing is 
complete.62 Analgesia, the relief of pain, is induced either by treating the cause of the 
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pain, such as inflammation, or by reducing the sensory response to the pain. The 
majority of analgesic drugs come under two classes: the cyclooxygenase (COX) 
inhibitors and the opioid receptor agonists. Other classes of drugs, less specific to pain 
such as steroids, anaesthetics, antidepressants, anticonvulsants and muscle relaxants 
are also used in the treatment of pain. 
 
1.1.5. COX inhibitors 
 
Non-steroidal anti-inflammatory drugs (NSAID) are a class of analgesics that inhibit 
COX (EC 1.14.99.1), either non-selectively inhibiting both the COX-1 and COX-2 
isoforms or selectively inhibiting just COX-2. COX-1 expression is constitutive and 
functions under normal non-pathological conditions, while COX-2 expression is 
inducible by pro-inflammatory stimuli and functions in inflammation.63 However there 
are examples of COX-1 being induced under inflammatory conditions in the kidney,64 
and COX-2 being constitutively expressed in parts of the CNS,65 specifically the spinal 
cord.66  
 
COX synthesises PGH2, via the intermediate PGG2. PGH2 is a substrate for a number 
of synthases, including prostaglandin E2 (PGE2) synthase (EC 5.3.99.3),67, 68 
prostaglandin D2 (PGD2) synthase (EC 5.3.99.2), thromboxane A2 (TXA2) synthase 
(EC 5.3.99.5) and prostacyclin synthase (EC 5.3.99.4). The therapeutic effect of COX 
inhibition is due to the action of PGE2 being blocked, reducing the inflammatory 
response. By treating the cause of the pain, i.e. the inflammation, the pain is relieved. 
Inhibitors of COX-1 & 2 include aspirin, ibuprofen, paracetamol, diclofenac, naproxen 
and indomethacin (Table 1.1.). Although mostly used for the treatment of 
inflammatory pain, they are also effective in treating neuropathic pain.69  
 
Inhibitors of COX represent 68% of drugs used for treatment of chronic pain.3 A 
significant disadvantage of the NSAIDs is that they can cause gastrointestinal damage, 
including the formation of ulcers and bleeding.70 The reason for this is thought to be 
because COX-1 is expressed in the gut. Thus inhibition of COX-1 by NSAIDs blocks the 
formation of the protective eicosanoids, PGE2 and prostacyclin, by the gastric mucosal 
tissue leading to these adverse effects.71 Prostacyclin inhibits platelet activation and 
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also acts as a vasodilator. Nausea, vomiting, renal related hypertension and congestive 
heart failure are also associated with their use.72 By selectively inhibiting COX-2, it was 
thought that only production of prostaglandins at the site of inflammation would be 
blocked, thus avoiding the adverse effects associated with the NSAIDs. Unfortunately 
the COX-2 inhibitors were found to cause hypertension.73 The reason for this is 
thought to be because COX-2 inhibition favours production of thromboxane over 
prostacyclin, increasing the risk of cardiovascular thrombotic events.74, 75 
Thromboxane facilitates platelet aggregation and also acts as a vasodilator. 
 
Table 1.1. – Selectivity of COX inhibitors for either isoform expressed as IC50 
(nmol/mL). 
 COX-1 COX-2 Ratio 
Aspirin 1.7 ± 1.1  278 ± 56 166 
Ibuprofen 0.05 ± 0.005  2.9 ± 0.4 60 
Paracetamol 18 ± 13  132 ± 80 7.4 
Diclofenac 1.7 + 0.7  1.2 ± 0.5 0.7 
Naproxen 10 ± 4  6 ± 4  0.6 
Indomethacin 0.03 ± 0.003  2.0 ± 0.2 60 
Data derived from Mitchell et al.76 Values are the concentrations required to inhibit 50% of COX 
activity in J774.2 murine macrophages activated with 1 µg/mL LPS (for COX-2) or without (for 
COX-1). 
 
1.1.6. Opioid receptor agonists 
 
The opioids, often described as the most effective analgesics available,77 are agonists 
of the opioid receptors and represent 28% of drugs used for treatment of chronic 
pain.3 Of the three opioid receptors: µ, k and δ, it is the µ-opioid receptor that is the 
target of many of the opioid analgesics. The endogenous opioids for these receptors 
are the neuropeptides β-endorphin, leu-enkephalin, met-enkephalin and dynorphin. 
The endorphins act as endogenous analgesics, being released in response to pain to 
help suppress its signal transduction.5 
 
The main opioid analgesics are morphine, codeine and methadone. Their activation of 
the opioid receptors initiates analgesia by reducing neuronal excitability, inhibiting 
neurotransmitter release and suppressing the firing of neurons. Whilst the opioids are 
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powerful analgesics, they frequently cause nausea, vomiting, constipation (hence the 
low dose use of morphine as a treatment for diarrhea) and can alter cognitive 
function.78 The target of the opioids, the µ-receptor, mediates both the analgesia and 
its adverse effects, including dependence.79 A further serious risk is tolerance, the 
progressive decline in a drug’s ability to induce its desired effect with prolonged use.  
 
1.1.7. Glucocorticoids 
 
Glucocorticoids, such as cortisol and dexamethasone, are steroids that suppress the 
expression of pro-inflammatory cytokines and induce the expression of anti-
inflammatory cytokines via the glucocorticoid receptors.80 Additionally through the 
inhibition of phospholipase A2 (EC 3.1.1.4) and suppression of COX-2 expression, they 
reduce both prostaglandin and leukotriene biosynthesis.81 Adverse effects of the 
glucocorticoids include ulcers, gastrointestinal bleeding and insulin resistance.82 
Steroids represent only 2% of the drugs used for treatment of chronic pain.3 
 
1.1.8. Anaesthetics 
 
Anaesthetics are used to cause a reversible loss of sensory perception, including pain 
sensation. This action is in contrast to that of analgesics, which are used to relieve 
pain with no other loss of sensation. Typically anaesthetics are intracellular Na+ 
channel blockers, which work by decreasing the rate of depolarisation and 
repolarisation of sensory neurons. This is achieved through inhibition of Na+ influx 
through voltage-gated Na+ channels, which consequently prevents action potentials 
and the relay of signals.83 By preventing signal transduction anaesthetics are capable 
of blocking the action of nociceptors.  
 
Local anaesthetics are effective in treating the site of pain, with lidocaine being an 
example of such an anaesthetic that is routinely used topically to relieve pain.84 
Another routinely used class of anaesthetics are the NMDA receptor antagonists. N-
methyl-D-aspartic acid (NMDA) is an amino acid derivative that acts as an agonist for 
the ionotropic NMDA receptor. When the receptor is open signal transfer can occur 
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from neurons through to the brain. NMDA receptor antagonists are used to stop the 
relay of this signal through the blocking of the channel.85  
 
1.1.9. Antidepressants 
 
Antidepressants, whilst normally used in the treatment of depression and related 
disorders, are also used in the long-term treatment of chronic neuropathic pain. 
Antidepressants, such as the tricyclic antidepressants, work as serotonin-
norepinephrine reuptake inhibitors (SNRI).86 By preventing reuptake of serotonin and 
norepinephrine, antidepressants increase the synaptic availability of these two 
neurotransmitters, enhancing neurotransmission and consequently increasing the pain 
threshold.87 Selective serotonin reuptake inhibitors (SSRI) are often preferred as they 
typically have fewer adverse effects than the SNRIs. Amitriptyline is the most 
frequently used of the antidepressants as an analgesic. Antidepressants represent 3% 
of drugs used for treatment of chronic pain.3  
 
1.1.10. Anticonvulsants 
 
Anticonvulsants are normally used in the treatment of seizures, but are also effective 
for pain. Their mechanism of action is to block voltage-gated Ca2+ channels to reduce 
Ca2+ influx and in doing so reduce synaptic release of neurotransmitters such as 
glutamate, norepinephrine and substance P.88, 89 Anticonvulsants reduce pain through 
this effect on signal transduction.90 Widely used anticonvulsants for treatment of 
neuropathic pain include GABApentin, its more potent successor pregabalin and 
carbamazepine. Anticonvulsants only represent 2% of drugs used for treatment of 
chronic pain.3 
 
1.1.11. Muscle relaxants 
 
Muscle relaxants are normally used for the treatment of spasm. The reason for their 
use as analgesics is due to pain often causing muscle spasm, which can result in a 
cycle of spasm causing more pain and pain causing more spasm. Muscle relaxants can 
be used to break this cycle. Routinely used muscle relaxants for pain include 
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carisoprodol, cyclobenzaprine and metaxalone.91 Muscle relaxants only represent 1% 
of drugs used for treatment of chronic pain.3 
 
1.1.12. An alternative analgesic pathway 
 
To avoid the adverse effects associated with the various analgesics an approach known 
as multimodal analgesia is often used.92 This involves a balanced combination of 
analgesia via multiple mechanisms, rather than through a single pathway. The concept 
being that instead of administering a large dose of an opioid, a lower dose could be 
used in combination with a second analgesic such as a COX inhibitor or paracetamol. 
This should minimise the likelihood of toxicity and associated adverse effects. However 
this approach does not always translate into improved function and a return to 
normality.92 
 
The World Health Organisation suggests a three-step analgesic "ladder" in treating 
pain.93 The first step starts with paracetamol and the NSAIDs for the treatment of mild 
pain. This is followed by weak opioids, such as codeine, for the treatment of moderate 
pain. Finally strong opioids, such as morphine, are used for the treatment of severe 
pain. Each step suggests the use of an adjuvant to complement the analgesic, such as 
antidepressants, anticonvulsants, steroids or muscle relaxants. The principle of the 
analgesic ladder is to progress through each step if pain is still present. This approach 
was found to be effective in 76% of patients undergoing pain treatment, while 12% 
only found the approach to be satisfactory and a further 12% found it inadequate.94 
 
Improvement in the survival rate of major diseases, such as cancer,95 has caused a 
rise in the number of patients requiring disease-related and post-surgery treatment for 
pain. Additionally the result of longer life spans has increased the number of age-
related conditions that require pain management. The population of people requiring 
pain treatment is therefore growing.5 Furthermore a combination of partial efficacy, 
adverse effects and potential for abuse mean that the currently used analgesics are far 
from ideal.  
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In summary, the treatment of pain therefore often relies on balancing the 
effectiveness of the analgesia and the adverse effects of the therapy. There is still a 
need for research into new analgesics that work with less adverse effects and by 
mechanisms more specific to pain. A prominent alternative target for the development 
of novel analgesic and anti-inflammatory drug is the endocannabinoid system. Current 
analgesics and anti-inflammatories mostly inhibit the nociceptive and pro-inflammatory 
pathways that are behind the cause of the pain and inflammation. In contrast drugs 
that target the endocannabinoid system would allow for endogenous analgesic and 
anti-inflammatory pathways to instead be enhanced. 
 
1.2. Endocannabinoid system 
 
For millennia Cannabis has been used in the treatment of pain.96 66 bioactive 
components were identified by Mechoulam, with the majority of the effects of Cannabis 
being found to be produced by ∆9-tetrahydrocannabinol (∆9-THC).97 The binding sites 
of the bioactive components of Cannabis were discovered to be two G-protein coupled 
receptors, which were named the cannabinoid receptors.98, 99 Later the endogenous 
ligands of these receptors were identified,100, 101 followed by the enzymes involved in 
their synthesis and metabolism,102, 103 and the carrier proteins involved in their 
transport.104 Together the cannabinoid receptors, their endogenous ligands and the 
enzymes involved in their biosynthesis and degradation comprise what is now known 
as the endocannabinoid system. 
 
1.2.1. Cannabinoid receptors 
 
The cannabinoid receptors (Figure 1.5.) are G-protein coupled receptors, of which 
there are two subtypes: CB1 105 and CB2.99 CB1 is coded for by the CNR1 gene, which 
is 26,496 bases in length and located on human chromosome 6 at position 6q14-
q15.106 It is highly expressed in the CNS, particularly in the forebrain and to a lesser 
extent in the midbrain, hindbrain and spinal cord.107 CB1 is the most highly expressed 
of the G-protein coupled receptors in the brain,108 functioning in neurotransmission, 
with expression being on pre-synaptic neurons and activation inhibiting 
neurotransmitter release of GABA and glutamate.109  
Chapter 1 
17 
 
Figure 1.5. – Structure of the cannabinoid receptor 1 (CB1). CB1 is a G-protein coupled 
receptor consisting of 7 transmembrane helices. It is predominantly expressed in the CNS where 
it is activated extracellularly by the endocannabinoids. Image reproduced from Shim et al.110 
 
CB2 is coded for by the CNR2 gene, which is 88,534 bases in length and located on 
human chromosome 1 at position 1p36.11.111 It is an important regulator of 
inflammation, with expression mainly being peripheral on immune cells, specifically 
macrophages, neutrophils, B-cells and T-cells.112 Within the CNS CB2 is found primarily 
on microglia, the macrophages of the brain,113 and within the brainstem.114 CB2 
controls immune cell mobility and production of immunomodulators,115 with its 
activation inhibiting the release of pro-inflammatory mediators, such as PGE2, nitric 
oxide and cytokines, and also inhibiting the expression of COX-2.116 
 
CB1 is 472 amino acid residues in length 117 and has a molecular weight of 57 kDa.118 
CB2 is smaller with 360 amino acid residues 119 and a molecular weight of 41 kDa.120 
Both receptors have an extracellular glycosylated N-terminus and an intracellular C-
terminus.119, 121 The two receptors share a sequence homology of 44%.122 After 
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activation, multiple intracellular signal transduction pathways are activated via G-
protein coupling, with activation shown to attenuate pain. 
 
The dissimilarity between CB1 and CB2 receptor activity is not just due to the different 
physiological locations of their expression, but also due to their differing mechanisms 
of signal transduction.123 Upon activation, CB1 mediates the closing of Ca2+ channels 
and the opening of K+ channels via the Gi/o protein. By a separate pathway mediated 
by the Gs protein, CB1 modulates adenylate cyclase (EC 4.6.1.1) activity.
124 In 
contrast, CB2 receptor signalling involves the activation of mitogen-activated protein 
kinase (MAPK) (EC 2.7.11.24) via the binding of the Gi/o protein's Gα subunit. CB2 
activation also stimulates β-endorphins release, which in turn activates µ-opioid 
receptors for inhibition of nociception.125 Despite these separate pathways, a similarity 
shared by both receptors is the ability to inhibit adenylate cyclase via the Gi/o 
protein,126 a coupling used by many G-protein coupled receptors that mediate pain 
transmission.127 
 
1.2.2. Endocannabinoids 
 
Ligands for the cannabinoid receptors are known as cannabinoids, of which five 
endogenous cannabinoids, the endocannabinoids, have been identified (Figure 1.6.). 
These five lipids are all derivatives of arachidonic acid. Typical to lipid signalling 
molecules, and unlike neurotransmitters and hormones, the endocannabinoids are 
synthesised on demand, where they act near the site of their synthesis and are 
eliminated on the completion of their action.103 Unlike the endorphins that are 
produced in response to pain, in vivo studies have shown that the endocannabinoids 
can be increased, decreased and remain unaltered in various pain states.128  
 
Through activation of the CB1 receptor on neurons and the CB2 receptor on immune 
cells, the endocannabinoids are important regulators of neurotransmission and 
inflammation. The principal endocannabinoids are arachidonoyl ethanolamide (AEA, 
anandamide) and 2-arachidonoyl glycerol (2-AG). AEA, the amide of arachidonic acid 
and ethanolamine, was the first endocannabinoid to be identified, where it was 
discovered in brain tissue.100 As well as the cannabinoid receptors, AEA is also an 
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agonist for TRPV1,129 with the descending order of AEA’s affinity for its receptors being 
CB1, TRPV1 and CB2.130  
 
 
Figure 1.6. – Structures of the endocannabinoids alongside arachidonic acid.  
 
2-AG, the ester of arachidonic acid and glycerol, was later also identified in brain 
tissue,101, 131 and has been found to be neuroprotective, being released following brain 
injury.132 Compared to AEA, 2-AG has less affinity for both of the cannabinoid 
receptors.133 The most abundant of the endocannabinoids is 2-AG, which exists at a 
concentration approximately 1000-fold higher than AEA in brain and between 4- and 
40-fold higher in plasma (Table 1.2.).  
 
Noladin ether (2-arachidonylglyceryl ether, 2-AGE), the third endocannabinoid to be 
identified, is a stable analogue of 2-AG and thus has a longer biological half-life.134 It 
was first identified in brain tissue,135 although its presence in this tissue has been 
disputed with conflicting studies reportedly detecting 136 and not detecting the lipid.137 
Noladin ether is only a weak CB2 agonist, binding preferentially to CB1.135  
 
NADA (N-arachidonoyl dopamine), the fourth endocannabinoid to be discovered, is the 
conjugate of arachidonic acid and the neurotransmitter dopamine. It was first 
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synthesised as a dopamine analogue, but was found to have no affinity for the 
dopamine receptors.138 Later it was identified as an endogenous component of brain 
tissue,139 having affinity for the cannabinoid receptors and a 40-fold selectivity for CB1 
over CB2.138  
 
Virodhamine (O-arachidonoyl ethanolamide, O-AEA), the latest endocannabinoid to be 
identified, is an analogue of AEA, where the arachidonic acid is joined to the 
ethanolamine by an ester linkage as opposed to the amide linkage of AEA. It was first 
discovered in brain tissue and functions as a CB2 agonist and a CB1 antagonist.140 
 
Table 1.2. – The endogenous concentration ranges of the endocannabinoids. 
 Rat brain Most abundant brain region Ref. Human plasma Ref. 
AEA 13 – 32 pmol/g Cerebellum 141 0.3 – 1.5 pmol/mL 142 
2-AG 10 – 30 nmol/g Hypothalamus 141 5 – 10 pmol/mL 142 
Noladin ether 4 – 65 pmol/g Thalamus  136 -  
Virodhamine 4 – 20 pmol/g Cerebral cortex 140 -  
NADA 0.2 – 7 pmol/g Striatum  139 -  
Data combined from various referenced sources. Noladin ether, virodhamine and NADA are yet to 
be identified in human plasma. 
 
AEA and 2-AG are the most studied of the five endocannabinoids. The pathways of 
their biosynthesis and degradation by fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL) have been fully elucidated. They are readily detectable 
in numerous tissues and fluids including the brain, plasma, cerebrospinal fluid, 
amniotic fluid and breast milk.143  
 
The other endocannabinoids noladin ether, virodhamine and NADA, remain undetected 
in plasma (Table 1.2.),142 and conflicting reports exist as to whether they are actually 
present in the brain.141 Additionally, unlike AEA and 2-AG, the pathways of their 
biosynthesis and metabolism are currently not elucidated. 
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1.2.3. Endocannabinoid biosynthesis 
 
Endocannabinoid biosynthesis is triggered by either cellular depolarisation or receptor 
activation. Receptors found to trigger AEA synthesis include the TRPV1,144 dopamine 
145 and muscarinic acetylcholine receptors.146 For 2-AG, synthesis can be triggered by 
activation of the NMDA receptor.147 
 
The biosynthesis of AEA begins with the formation of the precursor N-arachidonoyl-
phosphatidyl-ethanolamine (NAPE) from arachidonic acid and a glycerophospholipid by 
acyltransferase. This is followed by the subsequent hydrolysis of NAPE to AEA and 
phosphatidic acid by either NAPE-phospholipase D (NAPE-PLD) (EC 3.1.4.4), 
phospholipase A2 (PLA2), α/β-hydrolase 4 (Abh4) (EC 3.1.1.-) or tyrosine phosphatase 
2 (EC 3.1.3.16).148, 149 There is still uncertainty as to which enzyme is responsible for 
the majority of AEA biosynthesis. This same mechanism has been described as the 
route of synthesis for the structural analogues of AEA, oleoyl ethanolamide (OEA) and 
palmitoyl ethanolamide (PEA), but with precursor formation being instead from oleic 
acid and palmitic acid respectively.150 The generation of AEA from arachidonic acid and 
ethanolamine by reverse FAAH activity has also been proposed.151 Additionally 
mechanisms for AEA recycling exist, whereby the arachidonic acid and ethanolamine 
molecules produced from AEA deactivation are used for AEA re-synthesis and 
release.152  
 
While interconversion between AEA and 2-AG can occur,153 2-AG is primarily formed as 
an intermediate in lipid metabolism. Phospholipase C (EC 3.1.4.3) cleaves membrane 
phospholipids forming diacylglycerol (DAG), which is then Ca2+-dependently 
hydrolysed by diacylglycerol lipase (DAGL) (EC 3.1.1.34) into 2-AG.154  
 
1.2.4. Endocannabinoid metabolism 
 
The main degradative enzymes of the endocannabinoids are the AEA metabolising 
fatty acid amide hydrolase (FAAH) (EC 3.5.1.99) and the 2-AG metabolising 
monoacylglycerol lipase (MAGL) (EC 3.1.1.23), both enzymes of which belong to the 
serine hydrolase enzyme family.  
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FAAH (Figure 1.7.) is an intracellular membrane-bound enzyme that is expressed 
abundantly in the brain and liver, and at lower levels in the kidney, spleen and 
leukocytes.102 It is associated with the microsomal, mitochondrial and plasma 
membranes.155 FAAH is coded for by the FAAH gene, which is 19,584 bases in length 
and located on human chromosome 1 at position 1p35-p34.156 The enzyme’s structure 
is homodimeric, composed of 579 amino acid residues and a molecular mass of 
approximately 63 kDa.157 The function of FAAH is to hydrolyse AEA and its two 
structural analogues: OEA 158 and PEA,159 into their component fatty acid and 
ethanolamine. FAAH degrades AEA with a higher selectivity than for OEA and PEA.160 A 
specific binding pocket exists within the active site to accommodate the long fatty acid 
chains present on its substrates.161 A relatively unselective binding domain is capable 
of accepting various fatty acid chains, with various head groups.162 While the main 
attributed function of FAAH is to hydrolyse AEA, OEA and PEA into arachidonic acid, 
oleic acid and palmitic acid respectively. FAAH has also been demonstrated to 
conjugate arachidonic acid to various small molecules, including ethanolamine, 
dopamine and 4-aminophenol to synthesise AEA,151 NADA 163 and AM404.164  
 
 
Figure 1.7. – Structure of fatty acid amide hydrolase (FAAH). FAAH is a dimeric and 
intracellularly membrane bound enzyme responsible for AEA hydrolysis. Image reproduced from 
Mileni et al.165 
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MAGL (Figure 1.8.) is monomeric and whilst mostly membrane bound, it is also 
present in the cytosol.166 Most tissues express MAGL, such as the kidneys and adipose 
tissue where it is abundant and in the brain and adrenal glands where it is moderately 
expressed.167 MAGL is coded for by the MGLL gene, which is 150,111 bases in length 
and located on human chromosome 3 at position 3q21.3.168 With a length of 313 
amino acid residues and a molecular mass of approximately 33 kDa, MAGL is 
significantly smaller than FAAH.167 Despite FAAH being capable of degrading 2-AG in 
vitro,169 its in vivo degradation is principally catalysed by MAGL, whereby it is cleaved 
into arachidonic acid and glycerol. MAGL catalyses 85% of 2-AG hydrolysis and also 
functions in the hydrolysis of other monoglycerides.166  
 
 
Figure 1.8. – Structure of monoacylglycerol lipase (MAGL). MAGL is a monomeric and 
cytosolic enzyme responsible for 2-AG hydrolysis. Image reproduced from Bertrand et al.170 
 
In addition to hydrolytic metabolism of AEA and 2-AG, multiple routes for oxidative 
metabolism exist via cyclooxygenase (COX), lipoxygenase (LOX) (EC 1.13.11.33) and 
cytochrome P450 (Figure 1.9.).171 COX metabolises AEA and 2-AG to prostaglandin E2 
ethanolamide (PG-EA) 172 and to prostaglandin E2 glycerol (PG-G).173 LOX metabolises 
AEA and 2-AG to hydroperoxyeicosatetraenoic acid ethanolamide (HPETE-EA) 174 and 
Chapter 1 
24 
to HPETE-glyceroyl (HPETE-G).175 Cytochrome P450, specifically the CYP2D6 
isoform,176 metabolises AEA to hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) 
and to epoxyeicosatrienoic acid ethanolamide (EET-EA),177 and metabolises 2-AG to 
HETE-G.178 The studies that identified the oxidative metabolites of AEA used high AEA 
concentrations incubated on either pure enzymes or liver microsomes. Physiological 
production of these metabolites in vivo under normal conditions is yet to be shown. 
 
 
Figure 1.9. – The multiple routes of endocannabinoid metabolism. In addition to 
hydrolysis by FAAH and MAGL, the endocannabinoids can also be oxidised by COX, LOX and 
cytochrome P450. 
 
Arachidonic acid is also oxidised by COX, LOX and cytochrome P450 to form the 
prostaglandins, thromboxane, leukotrienes, lipoxins and epoxyeicosatrienoic acids.56 
These oxidative metabolites of arachidonic acid are all well known endogenous lipid 
mediators.179 In tissue AEA is a lot less concentrated than arachidonic acid, for 
example the brain concentration of arachidonic acid is 8 µmol/g compared to 13 – 32 
pmol/g for AEA.141, 180 Therefore if such metabolites are produced physiologically it is 
likely that they are present only in low amounts, and would require very sensitive 
assays for their detection. 
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A recent study failed to identify oxidative metabolites of AEA in the tissue samples of 
normal untreated rats.179 The only in vivo study to have detected these metabolites 
used FAAH knock-out mice treated with intravenous AEA, which resulted in production 
of the COX derived metabolites PGE2-ethanolamide and PGF2α-ethanolamide in the 
liver, kidney, lung and small intestine.181 However these metabolites were both absent 
in untreated control mice and only PGE2-ethanolamide was present in AEA-treated 
normal mice. Unfortunately this study did not investigate the brain concentrations of 
these metabolites. As AEA concentrations are high in the brain there should also be 
significant amounts of the oxidative metabolites formed here. 
 
There is also indirect evidence for oxidative metabolism of AEA. For example COX-2 
inhibition increases AEA levels 182 and the analgesic effect of COX-2 inhibitors is 
reversed by cannabinoid antagonists.183 Furthermore the clinical trial of the FAAH 
inhibitor PF-04457845 showed that following an 8 mg dose the plasma levels of AEA, 
OEA and PEA returned to normal after 10 days, while FAAH activity only returned to 
normal after 15 days.184 This indicated that there were 5 days when substrate levels 
were being metabolised despite no FAAH activity. Together these studies suggest that 
under specific conditions the metabolism of AEA by COX-2 may be a physiologically 
occurrence. Therefore production of oxidative metabolites of AEA may occur in tissues 
when there are simultaneously high AEA concentrations and high expression of 
oxidising enzymes, although the concentration of such metabolites would be low and 
their physiological relevance is unlikely to be significant. Such conditions are a 
possibility following FAAH inhibition in inflamed tissue and the liver, where high 
concentrations of oxidising enzymes are present alongside significant FAAH expression. 
 
Other endocannabinoid metabolising enzymes include N-acylethanolamine acid 
amidase (NAAA) (EC 3.5.1.-) 185 and the subtype fatty acid amide hydrolase-2 (FAAH-
2).160 Their mechanisms are similar to FAAH in that they both catalyse AEA hydrolysis. 
They are expressed at low levels and are not responsible for the majority of 
endocannabinoid metabolism, therefore they are not seen as integral enzymes in the 
endocannabinoid system.128  
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1.2.5. Endocannabinoid signalling 
 
Neurotransmitters are synthesised and stored intracellularly in vesicles until release. 
Upon release from presynaptic neurons they activate receptors on postsynaptic 
neurons, therefore the presynapse sends signals and postsynapse receives. 
Endocannabinoids work differently. They are classed as retrograde transmitters as 
they travel against the flow of other transmitters. They are released from the 
postsynapse to act on the presynapse. The 6 steps of endocannabinoid signalling are 
(1) trigger of biosynthesis, (2) biosynthesis, (3) postsynaptic endocannabinoid release, 
(4) presynaptic receptor activation, (5) reuptake and finally (6) endocannabinoid 
inactivation (Figure 1.10.). 
 
 
Figure 1.10. – Endocannabinoid signalling. AEA is synthesised and released on demand from 
the postsynapse. Once in the synaptic cleft it is free to activate the adjacent presynaptic CB1 
receptor. On completion of its action it returns to the postsynapse, firstly undergoing reuptake 
and finally metabolism viva FAAH. 
 
The depolarisation of postsynaptic neurons results in a Ca2+ influx that triggers the 
release of a retrograde messenger. The function of this messenger is to suppress 
further neurotransmitter release from the presynaptic cleft.186-188 This is known as 
depolarisation-induced suppression of inhibition and the retrograde messenger has 
now been identified as the endocannabinoids.189 As well as depolarisation, activation of 
Chapter 1 
27 
specific receptors also triggers endocannabinoid biosynthesis and release. While the 
endorphins are clearly produced in response to pain, in in vivo models the 
endocannabinoids increase, decrease and remain unaltered under different pain 
states.128 The endocannabinoids are synthesised in postsynaptic neurons. Due to their 
lipid nature the endocannabinoids are not water soluble and therefore cannot be stored 
in vesicles. The endocannabinoid precursors are present in the plasma membrane, 
allowing for rapid diffusion into the synaptic cleft on completion of their 
biosynthesis.190 It is thought that they leave the cell as soon as they are 
synthesised.190 
 
The endocannabinoids have only a short range of action. Once released from their 
postsynaptic neuron they are free to activate cannabinoid receptors on their adjacent 
presynaptic neuron. The endocannabinoids then cross the cell membrane again to be 
inactivated by their intracellular metabolising enzymes. This process of reuptake is by 
high-affinity membrane transport. Extracellular AEA is transported by a selective 
carrier protein across the membrane in a FAAH independent process 191 before being 
metabolised.192 This creates a concentration gradient that drives AEA uptake.193  
 
AEA transport has not been fully elucidated. Transport for other lipids and 
transmitters, such as oleic acid,194 the prostaglandins 195 and serotonin 196 is carrier-
mediated, making it likely that a dedicated transporter exists also for AEA. Additionally 
AEA analogues have been synthesised that increase AEA levels without inhibiting 
FAAH, hence blocking a transport mechanism.96 A high-affinity AEA binding site,197 
brain expressed fatty acid binding proteins (FABP), 198 and a FAAH variant that lacks 
FAAH activity,104 have all been identified as selective AEA carrier proteins. 2-AG uptake 
is also by carrier mediated transport,199, 200 although a protein for this action is yet to 
be identified. 
 
Finally, on completion of their action, endocannabinoids are enzymatically inactivated. 
FAAH is present on postsynaptic neurons, while MAGL is on presynaptic neurons,201 
thus 2-AG is inactivated presynaptically and AEA is inactivated postsynaptically.  
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1.3. Cannabinoid receptor-mediated analgesia 
 
1.3.1. Cannabinoid receptor knock-out and activation 
 
The connection between activation of the cannabinoid receptors and pain relief is well 
established. CB1 knock-out mice have a reduced pain sensation to noxious stimuli 
alongside the adverse effects of hypomotility, catalepsy and an increased mortality.202 
Selective agonists for CB1 are effective in the treatment of nociceptive,122 
inflammatory 122 and neuropathic pain.203 CB2 knock-out mice also exhibit a lower 
than normal pain threshold to noxious stimuli.204 Due to the receptor’s important role 
in immunomodulation, CB2 knock-out mice lose their normal immune response.205 
Interestingly CB2 expression in the spinal cord is increased with nerve injury.206, 207 
Selective agonists for CB2 are effective in the treatment of nociceptive,204 
inflammatory 208, 209 and neuropathic pain.210  
 
While both cannabinoid receptors are clearly integral to the mechanism of pain, the 
CB1 subtype is a major obstacle in the development of cannabinoid analgesics due to 
the receptor’s high expression within the CNS. Activation of this receptor is 
psychotropic, with the adverse effects of dysphoria, amnesia and dizziness. 
Additionally, CB1 agonists induce the “tetrad of behaviours”, which have become 
indicative of CB1’s activation and are defined as hypothermia, catalepsy, hypomotility 
and the desired effect of analgesia.211 Activation of CB1 receptors in the CNS is 
therefore to be avoided. As CB2 is not as highly expressed in the CNS, its activation is 
devoid of the CB1-associated adverse effects.212  
 
The routinely used analgesics, the COX inhibitors, already indirectly target the 
cannabinoid receptors. As COX metabolises the endocannabinoids, the inhibition of 
COX-2 increases AEA 182 and 2-AG 183 levels. The role of the cannabinoid receptors in 
the action of COX inhibitors is supported by in vivo evidence showing that CB1 
antagonism reverses their analgesic effect.183, 213 This suggests that the inhibition of 
COX-mediated endocannabinoid metabolism and the consequent cannabinoid receptor 
activation is just as integral to the action of COX inhibitors as their inhibition of 
prostaglandin biosynthesis. 
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1.3.2. Endogenous cannabinoid receptor ligands 
 
The use of the endocannabinoids in pain therapeutics has been well investigated. In 
vivo administration of AEA (20 mg/kg i.p.) induces analgesia with hypothermia.214 The 
effectiveness of this pain relief is dependent on the location of AEA injection, with 
more potency seen when administered at the site of pain as opposed to systemic 
administration.215 2-AG (30 mg/kg i.v.) also induces analgesia in vivo, but along with 
the other “tetrad of behaviours”.101 There is therefore an apparent difference between 
cannabinoid activation by AEA and by 2-AG, with AEA being devoid of the adverse 
effects seen with 2-AG. The endocannabinoid, virodhamine (2.5 mg/kg i.v.), is a CB1 
antagonist, dampening/blocking receptor activation.50 In vivo virodhamine is a less 
potent analgesic than AEA and 2-AG.140 Noladin ether (20 mg/kg i.p.) causes only mild 
anti-nociception in vivo.135 The in vivo administration of NADA has the opposite effect 
to the other endocannabinoids in that it induces hyperalgesia, an increased sensitivity 
to pain, via TRPV1.139  
 
1.3.3. Other cannabinoid receptor ligands 
 
The non-endogenous cannabinoids are split into the phytocannabinoids and the 
synthetic cannabinoids. The phytocannabinoids are the active components of the 
Cannabis plant, which includes the agonists ∆9-THC and cannabinol (Figure 1.11.). Like 
the endocannabinoids, the phytocannabinoids are lipophilic although they are not 
derivatives of arachidonic acid. These compounds activate CB1 in the CNS, explaining 
their psychotropic effects.216 
 
Figure 1.11. – Structure of cannabinol.  
 
Many synthetic cannabinoids have been synthesised. To avoid the adverse effects 
associated with central CB1 activation, agonists selective for CB2 have been 
developed,212 as have peripherally restricted CB1 agonists that lack the ability to cross 
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the blood-brain barrier.217 Both are effective mechanisms for inducing analgesics 
without the associated adverse effect. In summary, activation of the cannabinoid 
receptors induces an analgesic and anti-inflammatory response, but adverse effects 
are seen with CB1 activation in the CNS. Alternative routes have been sought to avoid 
this, including selective CB2 agonists and peripherally restricted CB1 agonists. 
However more potent analgesia can be achieved through the inhibition of the 
endocannabinoid metabolising enzymes. 
 
1.4. FAAH-mediated analgesia 
 
Inhibition of the enzymes involved in the degradation of the endocannabinoids allows 
for increased activation of the cannabinoid receptors without the use of direct 
cannabinoid agonists. FAAH and MAGL have become potential drug targets as their 
inhibition increases AEA and 2-AG levels respectively, and consequently increases 
cannabinoid receptor activation. Inhibition should also preserve the endocannabinoid 
levels where cannabinoid signalling is already occurring, enhancing their action. 
 
1.4.1. The preference of FAAH over MAGL for the development of analgesics 
 
For the purpose of analgesia the inhibition of FAAH is preferred to MAGL for several 
reasons. The selective MAGL inhibitor, JZL184 (Figure 1.12), has been shown in vivo to 
increase the brain concentration of 2-AG 8-fold without altering levels of AEA.218 
Therefore the action of MAGL is exerted via 2-AG, not AEA.  
 
Figure 1.12. – Structure of JZL184. 
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The accumulation of 2-AG as a result of MAGL inhibition increases cannabinoid 
receptor activation resulting in analgesia, but also hypothermia and hypomotility. 
Unlike 2-AG, activation of the cannabinoid receptors by AEA does not cause these 
adverse effects, highlighting a difference in action between these two 
endocannabinoids. This is due to a difference in receptor activation, which is 
demonstrated by the finding that chronic inhibition of MAGL causes desensitisation of 
the CB1 receptors in the brain and consequently, over time, the analgesic effect is 
diminished.219 Unlike MAGL, chronic inhibition of FAAH does not cause desensitisation. 
MAGL is an integral enzyme for the degradation of monoglycerides, its inhibition 
results in an unwanted accumulation of other monoglycerides unrelated to pain.220 
Again unlike MAGL, all the substrates that accumulate following FAAH inhibition are 
analgesic and anti-inflammatory. 
 
1.4.2. FAAH knock-out and inhibition 
 
FAAH knock-out mice have a 15-fold higher brain concentration of AEA than normal 
mice,221 without 2-AG levels being disrupted.222 This consequently causes increased 
activation of the cannabinoid receptors and a higher pain threshold. As 2-AG levels are 
not affected by FAAH inhibition, AEA is therefore the sole endocannabinoid responsible 
for this effect. Separately both CB1 and CB2 antagonists reduce the analgesic effect of 
FAAH inhibition in vivo, and together they completely abolish it.223 FAAH inhibitors 
designed to be unable to cross the blood-brain barrier are still effective analgesics,224 
demonstrating the importance of FAAH localised in the periphery not just the CNS. 
These studies verify that it is AEA’s activation of both cannabinoid receptor subtypes 
that causes FAAH-mediated analgesia.  
 
In vivo studies on FAAH inhibition have shown effective treatment of pain and 
inflammation without any disruption of motility, cognition and body temperature.225 In 
vivo FAAH inhibition is an effective treatment of both inflammatory 223, 226 and 
neuropathic pain.227-229 Therefore FAAH has become an attractive target for the 
development of novel analgesics. 
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1.4.3. The multiple mechanisms of FAAH-mediated analgesia 
 
FAAH inhibitors are devoid of the adverse effects seen with cannabinoid agonist. This is 
because analgesia from FAAH inhibition is not just from the cannabinoid receptors. The 
substrates of FAAH (Figure 1.13.), AEA, OEA and PEA, all increase in concentration 
with the enzyme’s inhibition.230 Despite not sharing AEA’s affinity for the cannabinoid 
receptors,231 OEA and PEA also have analgesic and anti-inflammatory action, which 
they exert in the CNS and periphery via other non-cannabinoid pathways. 
 
 
Figure 1.13. – Structures of the FAAH substrates AEA, OEA and PEA. 
 
1.4.4. The action of OEA via the PPAR-α and TRPV1 receptors 
 
OEA is synthesised on demand in the brain and degraded on termination of its action 
in a manner comparable to AEA.232 OEA has been shown to have an analgesic effect in 
both visceral (internal organ) and inflammatory pain,232 through its activation of the 
peroxisome proliferator-activated receptor alpha (PPAR-α). This receptor belongs to 
the nuclear receptor family and functions in the response to extracellular lipid stimuli 
such as fatty acids, leukotrienes and cholesterol.233 The main physiological action of 
PPAR-α is as a transcription factor, modulating expression of specific genes that 
control the inflammatory response, such as those for the cytokines.234 Other ligands of 
the receptor include the endocannabinoids AEA, noladin ether and virodhamine.235 The 
antagonism of PPAR-α reverses the analgesic effect of FAAH inhibition, demonstrating 
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an integral role for PPAR-α in the therapeutic effect of FAAH inhibition.236 Furthermore 
PPAR-α knock-out mice have an overactive inflammatory response, supporting the 
important role of this receptor in inflammation.237  
 
OEA is also an agonist for another pain-associated receptor, TRPV1.238 TRPV1 is a 
cation channel that is exclusively expressed on the nociceptive Aδ and C fibres of the 
peripheral nervous system.239 The receptor is also activated by noxious heat (greater 
than 43oC), acidity and the irritant capsaicin. The receptor can be sensitised, in that its 
response to noxious stimuli is exaggerated in the presence of inflammatory mediators, 
such as the prostaglandins.38, 240 The significance of TRPV1 as a pain receptor has been 
demonstrated with TRPV1 knock-out mice, showing reduced nociception and pain 
sensation to inflammation and noxious stimuli.241, 242 Interestingly both TRPV1 agonists 
and antagonists are effective analgesics.164, 243 In summary, OEA is analgesic and anti-
inflammatory through its binding to PPAR-α and TRPV1. 
 
1.4.5. The action of PEA via the PPAR-α receptor and other pathways 
 
The activity of PEA is much more established than it is for OEA. PEA acts as an anti-
inflammatory 244, 245 and analgesic.246, 247 The anti-inflammatory effect is via both 
control of mast cell activation 244 and activation of the PPAR-α receptor.248, 249 In 
addition to PPAR-α, part of the anti-inflammatory effect of PEA is by PPAR-γ.250 
Interestingly, despite lacking affinity for CB2, the action of PEA is inhibited by CB2 
antagonists.235 This suggests that PEA potentiates the endocannabinoid system by an 
indirect mechanism. Furthermore PEA has a role in neuroinflammation, regulating 
microglial migration at the site of damaged tissue, via a non-cannabinoid Gi/o-protein 
mechanism.251 
 
1.4.6. The action of the FAAH substrates via GPR55 
 
The G-protein coupled receptor GPR55 has been identified as a receptor for OEA and 
PEA. The endocannabinoids and ∆9-THC are also GPR55 ligands, with AEA activating 
GPR55 with the same potency as it does for CB1 and CB2. Interestingly the other 
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endocannabinoids 2-AG, noladin ether and virodhamine all activate GPR55 with higher 
potencies than they do for the cannabinoid receptors (Table 1.3.).252  
 
Table 1.3. – Potencies of the endocannabinoids and FAAH substrates at each receptor 
as EC50 (pmol/mL).  
 CB1 CB2 GPR55 PPAR- α 
Endocannabinoids     
AEA 31 ± 6 27 ± 6 18 ± 3 28,000 
2-AG 519 ± 48 618 ± 45 3 ± 1 - 
Noladin ether 37 ± 5 > 30,000 10 ± 1 10,000 
Virodhamine 2,920 ± 325 381 ± 34 12 ± 3 30,000 
NADA 250 12,000 - - 
     
FAAH substrates     
OEA > 30,000 > 30,000 440 ± 145 120 ± 1 
PEA > 30,000 19,800 ± 2,821 4 ± 1 3,100 ± 400 
The potencies of the endocannabinoids and the FAAH substrates for their receptors are expressed 
as EC50 values, referring to the concentration of each compound that induces a response halfway 
between its baseline and maximum. Data derived from Ryberg et al., 252 Lambert et al.133 and 
Sun et al.235 
 
GPR55 is highly expressed in the adrenal glands, and moderately expressed in parts of 
the CNS and gastrointestinal tract. While it is activated by the endocannabinoids and 
functions in the mechanism of inflammatory and neuropathic pain,253 significant 
differences between GPR55 and the cannabinoid receptors mean that the receptor is 
yet to be classified as either the CB3 receptor or as a member of the endocannabinoid 
system. This is because it shares only a 13.5% sequence homology with CB1 and 
14.4% with CB2,254 its G-protein coupling is via Gα13 instead of Gi/o and considerably 
less expression than the other cannabinoid receptors, with expression being between 
three- and ten-times lower than that of CB1.252  
 
1.4.7. FAAH as a potential source of arachidonic acid for prostaglandin synthesis 
 
Phospholipase A2 produces the majority of arachidonic acid used in prostaglandin 
synthesis. Further potential sources of arachidonic acid for prostaglandin synthesis are 
the endocannabinoid metabolising enzymes FAAH and MAGL. FAAH inhibition has been 
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demonstrated to reduce prostaglandin levels in microglia.255 MAGL catalyses 85% of 2-
AG degradation.166 2-AG is the most concentrated of the endocannabinoids, being 
1000-times higher than AEA in brain and 40-times higher in plasma.141, 142 
Consequently an in vivo study demonstrated MAGL inhibition to reduce unesterified 
arachidonic acid levels in brain by 50%.218 Therefore inhibition of prostaglandin 
synthesis by FAAH and MAGL may explain part of their analgesic and anti-
inflammatory action.  
 
1.4.8. Further analgesic effects of FAAH inhibition 
 
In addition to those described already there are multiple other analgesic and anti-
inflammatory mechanisms attributed to FAAH substrates. Part of the activity of the 
FAAH substrates has been attributed to an ‘entourage’ effect. As the endogenous 
levels of OEA and PEA are significantly higher than AEA, these two substrates compete 
for FAAH hydrolysis. Their higher levels mean they undergo more degradation, 
potentiating the action of AEA.256 This action can also enhance the activity of AEA at 
the TRPV1 receptor.257  
 
FAAH’s synthesis of the endocannabinoid, NADA, is potentially a further way by which 
it may be analgesic.163 NADA induces hyperalgesia via TRPV1,139 thus inhibition of 
FAAH should prevent NADA synthesis, blocking this action.  
 
Pro-inflammatory stimuli, such as lipopolysaccharide, suppress expression of the AEA, 
OEA and PEA synthesising enzyme NAPE-PLD on immune cells, consequently reducing 
their synthesis.258 Therefore in inflamed tissue the FAAH substrates may not exert 
their analgesic and anti-inflammatory effect due to reduced synthesis, thus FAAH 
inhibition should help preserve substrate levels where synthesis is already low.  
 
Additionally, FAAH inhibition in microglia reduces expression of inducible nitric oxide 
synthase (iNOS) (EC 1.14.13.39), the enzyme responsible for the synthesis of the pro-
inflammatory free radical nitric oxide from L-arginine.255 Furthermore FAAH inhibition, 
through its indirect activation of the cannabinoid receptors, attenuates the release of 
the pro-inflammatory cytokines interleukin-1β and TNF-α.259 
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In conclusion the endocannabinoid system FAAH is the most attractive target for the 
development of novel analgesics and anti-inflammatories. In contrast to the 
therapeutics that inhibit nociceptive and pro-inflammatory pathways, FAAH can be 
utilised to bring about resolution from inflammation and pain through its control over 
multiple endogenous analgesic and anti-inflammatory pathways (Figure 1.14.). Instead 
of targeting just the cannabinoid receptors, FAAH inhibition indirectly targets many 
other analgesic and anti-inflammatory pathways outside of the endocannabinoid 
system, including the TRPV1 and GPR55 receptors via AEA, and the PPAR-α and GPR55 
receptors via OEA and PEA. 
  
 
Figure 1.14. – The multiple analgesic and anti-inflammatory pathways controlled by FAAH. AEA, OEA and PEA are agonists of the CB1, CB2, PPAR-α, TRPV1 and 
GPR55 receptors. On completion of their action they are hydrolysed intracellularly by FAAH into arachidonic acid, oleic acid and palmitic acid. 
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1.5. Development of FAAH inhibitors 
 
1.5.1. FAAH inhibitors 
 
Indirectly FAAH is the target of the routinely used analgesics, paracetamol and 
ibuprofen. Paracetamol is conjugated with arachidonic acid by FAAH to form the active 
metabolite, AM404, which functions as an analgesic through its action both as an AEA 
reuptake inhibitor 260 and as a COX-1 & 2 inhibitor.164 As for ibuprofen, routinely used 
oral doses are capable of inhibiting FAAH in certain types of inflamed tissue, possibly 
contributing to its anti-inflammatory action.261, 262  
 
The active site of FAAH is comprised of an amino acid triad: serine-241/serine-
217/lysine-142. FAAH substrates and the majority of FAAH inhibitors forming an 
attachment to the active site’s nucleophilic serine-241 residue.263 The nature of this 
attachment determines whether a FAAH inhibitor is covalent or non-covalent and 
reversible or irreversible. Non-covalent inhibitors that form a reversible attachment 
have been synthesised,264 but due to their inhibition being reversible they have to 
compete with the FAAH substrates for the enzyme’s active site,265 therefore their 
elevation of the FAAH substrate levels is transient.266 As near complete inhibition of 
FAAH is required for significant substrate accumulation covalent inhibitors are 
preferred.267 The therapeutic effect of irreversible covalent inhibitors is long lasting due 
to FAAH activity only returning to normal once a sufficient number of new enzymes 
has been synthesised.268  
 
FAAH is a serine hydrolase, of which there are over 200 other members of this enzyme 
family with varying functions. Novel inhibitors therefore require selectivity for FAAH 
over the other serine hydrolases.266 Currently it is carbamate, urea and ketone based 
inhibitors that have been shown to be the most potent and selective.269 To form the 
covalent attachments necessary for irreversible inhibition the inhibitor requires an 
electrophilic moiety so that it can react with the active site’s nucleophilic amino acid 
residue. The presence of an electrophilic group means a greater likelihood of adverse 
effects if the covalent attachment is not selective. To avoid the risks associated with 
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covalent inhibitors, compounds with high potency are preferred so that low doses can 
be used.270  
 
Figure 1.15. – Structure of URB597. 
 
Figure 1.16. – Structure of PF-3845. 
 
Figure 1.17. – Structure of PF-04457845. 
 
Most of the current FAAH inhibitors, such as URB597 (Figure 1.15.), form irreversible 
covalent attachments to the serine-241 residue of the active site.271 URB597 is the 
most studied FAAH inhibitor (IC50 = 4.6 pmol/mL).
222 It is a cannabinoid receptor-
dependent analgesic devoid of the adverse effects associated with CB1 agonists.223 
This carbamate based molecule however has selectivity for other serine hydrolases, 
specifically peripherally expressed carboxylesterases.272 A more potent inhibitor (IC50 
= 0.23 pmol/mL), the urea based PF-3845 (Figure 1.16.), was later developed with 
10-fold higher affinity for FAAH’s binding site than URB597, a longer duration of action 
and with more selectivity for FAAH over other serine hydrolases, including FAAH-2.225 
Using PF-3845 as a prototype, PF-04457845 (IC50 = 7.2 pmol/mL) (Figure 1.17.), was 
developed and became the first FAAH inhibitor to enter clinical trials and be dosed to 
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humans.268, 273 The first clinical trial of a FAAH inhibitor identified this showing that 24 
hours following a single 0.3 mg dose of PF-04457845, despite the drug no longer being 
detectable in the plasma, FAAH activity was still inhibited by ≥97%.184 Therefore the 
pharmacodynamic effects of FAAH inhibitors outlast their apparent pharmacokinetics. 
In summary, while FAAH can be inhibited by both covalent and non-covalent inhibitors, 
it is the irreversible attachment formed via covalent inhibitors that is preferred due to 
longevity of its action.  
 
1.5.2. The FAAH substrates as a pharmacodynamic parameter 
 
COX inhibitors, opioid agonists and anaesthetics all relieve pain, but by different 
mechanisms. The physiological response to an analgesic will only demonstrate pain 
relief not the drug’s mechanism of action. In the development of novel FAAH inhibitors 
it is important to not just demonstrate that a potential drug is analgesic but to also 
show that it inhibits the target enzyme in vivo. This is of importance as FAAH is a 
member of the serine hydrolase enzyme family, which number over 200. Hence some 
FAAH inhibitors exhibit non-specific selectivity for other serine hydrolases.266 The 
potency of a FAAH inhibitor is dependent on its ability to increase the central and 
peripheral tissue concentrations of AEA, OEA and PEA and consequently elicit its 
cannabinoid 223 and PPAR-α 236 dependent analgesic and anti-inflammatory effects. 
Pharmacokinetics and pharmacodynamics are generally defined as what the body does 
to the drug and what the drug does to the body respectively.274 Thus the changes in 
the tissue levels of the FAAH substrates is a physiological response to drug 
administration, and therefore a pharmacodynamic parameter. The measurement of the 
FAAH substrates is a useful pharmacodynamic measurement for demonstrating FAAH 
inhibition and establishing mechanism of action.  
 
Previous in vivo studies have measured brain and plasma AEA, OEA and PEA as a 
pharmacodynamic parameter, to demonstrate selectivity for FAAH and to determine 
the degree to which the substrates were increased.225, 227, 273, 275 These studies 
investigated various classes of FAAH inhibitors, and by measuring the FAAH substrates 
they were able to prove that any observed in vivo efficacy seen with each inhibitor was 
in fact due to inhibition of FAAH. Importantly these studies all demonstrated that while 
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FAAH is mostly brain expressed, FAAH inhibition will not only increase AEA, OEA and 
PEA levels in the brain, but also in plasma. This was an important discovery as it 
allows for this approach to be translated from in vivo studies into clinical studies, 
where obviously measuring brain FAAH substrate levels would be impossible. Indeed 
the first clinical trial of the FAAH inhibitor PF-04457845 measured the FAAH substrates 
in plasma as a pharmacodynamic parameter to prove that the drug was in fact 
inhibiting FAAH in humans.184 In this trial blood was collected at various time points 
following oral dosage of the inhibitor. This showed that the inhibitor elevated the 
plasma levels of AEA, OEA and PEA and they remained elevated for the following 7 
days, proving the drug to be a potent FAAH inhibitor. 
 
1.5.3. FAAH substrate assays 
 
For the FAAH substrates to be used as a pharmacodynamic parameter, sensitive and 
selective assays for the quantitation of AEA, OEA and PEA are required. The FAAH 
substrates have weak UV absorption and do not fluoresce.276 Their measurement is 
therefore best performed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS), of which a number of methods have been reported.141, 142, 276-281 The majority 
of these methods have been in human plasma or serum, with a few exceptions looking 
at tissue samples from in vivo studies.141 The FAAH substrates are often measured 
alongside the endocannabinoids,141 and sometimes other related lipid signalling 
molecules.278 The extraction of the FAAH substrates from samples is often by liquid-
liquid extraction, using ethyl acetate/hexane (9:1 v/v) 141 or chloroform/methanol (2:1 
v/v).280 This is often followed by solid phase extraction, evaporation and reconstitution 
to further concentrate the substrates.  
 
Separation of the substrates has mostly been on short C18 columns (50 x 2.1 mm, 1.7 
µm), 142 although there are examples of longer C8 columns (100 x 2.1 mm, 3 µm) 141 
and phenyl columns (50 x 2.1 mm, 5 µm) being used.279 Chromatographic resolution 
of the analytes is not always achieved and does not compromise the analysis.278, 279 As 
positive electrospray is required for the FAAH substrates, the previously reported 
mobile phases have almost all been acetonitrile gradients with 0.1% formic acid to aid 
ionisation. Occasionally ammonium acetate is also added to the mobile phase to act as 
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a buffer.277 Run times for these assays range from 3.5 minutes 277 up to over 20 
minutes.278 In terms of MS/MS, all previously reported methods have ionised the FAAH 
substrates under positive electrospray and monitored the formation of the 62 m/z 
ethanolamine fragment ion.  
 
1.6. Paracetamol 
 
Paracetamol (para-acetylaminophenol, acetaminophen) was first synthesised in 1878 
by Morse and first used in patients in 1887 by von Mering.282 It has since become one 
of the most widely used analgesics.3 A discovery by Högestätt demonstrated that it is 
in part metabolised by FAAH to form the active metabolite AM404.164  
 
 
Figure 1.18. – The multiple pathways of paracetamol metabolism. Paracetamol can be 
conjugated to glucuronide, sulphate, glutathione or arachidonic acid groups. 
 
The majority of paracetamol metabolism occurs in the liver. Between 40–67% of the 
absorbed drug undergoes glucuronidation, 20–46% is sulphated and 5–15% is 
converted to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) before being 
rearranged and conjugated with glutathione (GSH).283, 284 Less than 0.002% of 
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paracetamol is deacetylated in the liver to 4-aminophenol, and then conjugated to 
arachidonic acid via brain expressed FAAH to form AM404 (arachidonoyl phenolamine) 
(Figure 1.18).164, 285  
 
1.6.1. Paracetamol inhibits COX activity 
 
Paracetamol is a weak COX-1 (IC50 = 105 nmol/mL) and COX-2 inhibitor (IC50 = 26 
nmol/mL)76, 286 that blocks prostaglandin synthesis in the brain 287 but not in peripheral 
tissue.288 It does however inhibit PGE2 production in activated macrophages.289  
 
Despite inhibiting COX-1 & 2, paracetamol is ineffective as an anti-inflammatory. This 
is thought to be due to two reasons. Firstly COX-2 is induced in inflammation and as 
paracetamol is only a weak COX-2 inhibitor, prostaglandin synthesis is not significantly 
reduced in inflamed tissue. Secondly for COX to synthesise prostaglandins its active 
site’s tyrosine-385 residue must be oxidised. Paracetamol inhibits COX-1 & COX-2 by 
acting as a reducing agent, preventing the oxidation of this residue and consequently 
blocking prostaglandin synthesis. In inflamed tissue there are high levels of lipid 
hydroperoxides (LHP) that maintain oxidation of the tyrosine residue and keep COX in 
its active state.290 Consequently paracetamol is unable to act as a COX inhibitor in 
inflamed tissue and is therefore rendered ineffective as an anti-inflammatory.  
 
However this explanation of why paracetamol lacks an anti-inflammatory effect has 
been disputed, as in vitro studies with macrophages have shown that paracetamol can 
inhibit COX-2 in both the presence and absence of hydroperoxide.289 This is supported 
by the clinical finding that 1 g of paracetamol administered orally suppresses PGE2 
production in the acute inflammation of peripheral tissue.291 Therefore while evidence 
demonstrates that paracetamol inhibits prostaglandin production, even in inflamed 
peripheral tissue, the reason for its reported lack of an anti-inflammatory effect is still 
not understood. 
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1.6.2. Paracetamol interacts with the endocannabinoid system 
 
Paracetamol lacks affinity for the cannabinoid receptors,292 but its analgesic effect is 
blocked in vivo by selective CB1 antagonists 292, 293 and is abolished in CB1 knock-out 
mice.292 Paracetamol (200 mg/kg p.o.), while analgesic in control mice, fails to exert 
its analgesic effect in FAAH knock-out mice.294 Likewise the FAAH inhibitor URB597 
(0.15 mg/kg i.p.), at a low non-analgesic dose, reverses the analgesic effect of 
paracetamol (300 mg/kg p.o.).292 This dependence of paracetamol on the 
endocannabinoid system is due to its active metabolite AM404.  
 
 
Figure 1.19. – Paracetamol’s effect on endocannabinoid signalling. Paracetamol is 
deacylated to 4-aminophenol and then conjugated to arachidonic acid by FAAH. This forms 
AM404, an AEA reuptake inhibitor that causes a synaptic accumulation of AEA and consequently 
increased activation of the CB1 receptor.  
 
Like paracetamol, AM404 is neither a cannabinoid receptor agonist 295 nor a FAAH 
inhibitor.260 Instead it has an indirect action on the endocannabinoid AEA. The 
inactivation of AEA is a 2-step process, beginning with its reuptake from the synaptic 
cleft into the presynapse, followed by its hydrolysis by intracellular FAAH. Paracetamol 
inhibits both steps of AEA inactivation. Firstly paracetamol reveres FAAH’s normal 
enzyme activity, so that instead of arachidonic acid being hydrolysed from 
ethanolamine, arachidonic acid is rather conjugated to 4-aminophenol, forming 
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AM404.164, 292 Then AM404 interferes with second step by inhibiting AEA reuptake (IC50 
= 5.3 nmol/mL), thus protecting it from deactivation.104 Therefore paracetamol causes 
an increase in extracellular AEA in the synaptic cleft that consequently increases 
cannabinoid receptor activation to produce analgesia (Figure 1.19.).260 
 
An in vivo study investigated the effect of a 300 mg/kg i.p. dose of paracetamol on the 
concentrations of paracetamol, 4-aminophenol and AM404 in the brain, spinal cord, 
blood and liver of rats.164 Paracetamol was present in the liver at a concentration 
comparable to blood (both 3 µmol/g). Paracetamol was deacylated in the liver, 
therefore it was here where the highest concentration of 4-aminophenol occured (30 
nmol/g). 4-aminophenol then transfers to the brain. About a third of the 4-
aminophenol found in the liver was found in the brain (8 nmol/g). FAAH is mostly 
expressed in the brain 102 where there are also high concentrations of arachidonic acid 
(8 µmol/g).180 It is therefore here that the majority of AM404 was synthesised (15 
pmol/g), with low amounts consequently entering the spinal cord (3 pmol/g). Very 
little AM404 was found in blood and liver (< 0.5 pmol/g). 
 
The concentration of AM404 required to induce analgesia is unknown. As already 
stated, while paracetamol (300 mg/kg i.p.) produces cannabinoid receptor-dependent 
analgesia in rats, only low levels of AM404 are produced in the brain (15 pmol/g).164 
Interestingly it has been separately reported that 300 mg/kg paracetamol fails to 
increase brain AEA levels.294 This suggests that AM404 is active at low concentrations. 
In rat models of inflammatory and neuropathic pain AM404 is still analgesic at doses 
as low as 1 mg/kg i.p.296 Therefore paracetamol produces cannabinoid receptor-
dependent analgesia despite only low amounts of AM404 being produced in the CNS 
and no change in AEA levels being detected.  
 
Analgesia from AEA reuptake inhibition is reversed in vivo by CB1 antagonists, but not 
by CB2 antagonists or TRPV1 antagonists.104 AEA reuptake is therefore specific for 
AEA-activation of CB1 receptors. CB1 is expressed centrally in the CNS, CB2 is 
expressed on immune cells and TRPV1 is expressed peripherally on nociceptors. 
Therefore the analgesia produced by AM404 is a central synaptic effect, not a 
peripheral synaptic effect or an immune effect. 
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1.6.3. Paracetamol interacts with serotonin receptors 
 
Serotonin (5-hydroxytryptamine, 5HT) (Figure 1.20.) is a neurotransmitter 
synthesised from L-tryptophan by tryptophan-5-hydroxylase (EC 1.14.16.4). It acts on 
its seven receptors, 5HT1-7. Upon completion of its action 5HT is oxidised by 
monoamine oxidase (EC 1.4.3.4) followed by aldehyde dehydrogenase (EC 1.2.1.3) to 
form its metabolite 5-hydroxyindoleacetic acid (5HIAA).297 Activation of the 5HT 
receptors can be analgesic, for example direct activation of the 5HT1A receptor subtype 
is effective in the treatment of nociceptive pain.298  
 
Figure 1.20. – Structure of 5HT. 5HT is a neurotransmitter integral to the function of 
paracetamol. Production of 5HT is increased by paracetamol and antagonism of 5HT receptors 
reverses paracetamol’s action. 
 
In vivo paracetamol has been shown to increase the levels of 5HT throughout the CNS 
with the exception of the spinal cord.299 The analgesic effect of paracetamol is 5HT 
receptor-dependent, with antagonism of the 5HT1A, 5HT3 and 5HT4 receptors all 
blocking its action.300-302 Interestingly paracetamol lacks affinity for all of the 5HT 
receptors, including 5HT1A, 5HT3 and 5HT4.
303 Therefore paracetamol indirectly 
activates 5HT receptors by increasing 5HT levels in the CNS by an unknown 
mechanism.  
 
This is clinically significant as paracetamol’s action is also reversed in humans with 
5HT3 antagonism, demonstrating that the serotonin system is integral to paracetamol’s 
action.304 Interestingly the analgesic effect of CB1 agonists is also reversed by 
antagonism of the 5HT1A, 5HT3 and 5HT4 receptors.
292 Given that both paracetamol 
and cannabinoid induced analgesia is 5HT receptor-dependent, AM404 could be a 
possible mediator between paracetamol and the 5HT receptor. 
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1.6.4. AM404 interacts with COX, iNOS, TRPV1 and sodium channels 
 
Like paracetamol, AM404 can inhibit prostaglandin synthesis by inhibiting COX-1 (IC50 
= 6.2 nmol/mL) and COX-2 (IC50 = 5.7 nmol/mL).
164 As AM404 synthesis requires 
arachidonic acid, this possibly reduces the amount of arachidonic acid available for 
prostaglandin synthesis.164 Furthermore AM404 can decrease the expression of COX-2 
and iNOS, the synthesising enzyme of nitric oxide.296 AM404 has also been identified 
as a TRPV1 agonist,305 which is interesting as activation of TRPV1 triggers AEA 
synthesis.144 Evidence supports this showing that the analgesic effect of both 
paracetamol and AM404 is abolished in TRPV1 knock-out mice, concluding that AM404 
produces TRPV1 mediated analgesia in the brain.294 Additionally AM404 inhibits pain-
associated voltage-gated Na+ channels (NaV).
306  
 
1.6.5. Pharmacokinetics of intravenous paracetamol in the cerebrospinal fluid 
 
Paracetamol is known to readily cross the blood-brain barrier and consequently 
penetrates rapidly into the cerebrospinal fluid (CSF). CSF is a clear and colourless fluid 
that fills the space around the brain and inside the spinal cord, with its function being 
to keep the brain buoyant and to provide mechanical protection. It flows through the 
brain’s ventricular system regulating its homeostasis and providing chemical 
stability.307 CSF is rich in ions, with millimolar concentrations of Na+, K+, Ca2+, Mg2+ 
and Cl-, and a total volume inside the body of approximately 140 mL.308 It contains low 
levels of protein, low numbers of leukocytes and no erythrocytes.308 Approximately 
60% of CSF is produced and secreted by the choroid plexus, a ventricular structure in 
the brain. The remaining 40% is formed from capillary filtration.307  
 
To enter the CSF a drug must first cross the blood-brain barrier. This barrier consists 
of a highly restrictive endothelial cell network that seals the brain’s capillaries.308 
Molecules that can cross the blood-brain barrier use either transmembrane diffusion, 
specialised transporters, adsorptive endocytosis or extracellular pathways.309 
Transporter proteins are highly expressed on the blood-brain barrier, moving foreign 
molecules away from the brain, while allowing molecules such as O2 and glucose to 
cross.309 Chemically it is large, hydrophilic molecules that are restricted in crossing the 
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blood-brain barrier, explaining why small and hydrophobic molecules of paracetamol 
molecules are capable of penetrating it. The choroid plexus, another component of 
blood-brain barrier,309 consists of permeable endothelial cells. Therefore drugs that 
have managed to cross the blood-brain barrier can readily enter into the CSF.308  
 
Intravenous paracetamol is increasingly being used in post-surgery pain management 
as an alternative to opioids, such as morphine, to avoid the associated adverse effects 
of addiction, tolerance and withdrawal. Recent clinical trials in the treatment of post-
operative pain have demonstrated 1 g intravenous paracetamol to provide comparable 
levels of analgesia to 10 mg intravenous morphine.310-312  
 
The intravenous route of administration for paracetamol is faster acting and more 
efficacious than the oral route, with the peak plasma concentration being reached 
immediately after dosage and with the entire administered dose reaching the systemic 
circulation, hence 100% bioavailability.313 Following a 1 g intravenous dose of 
paracetamol the plasma Cmax is 165 nmol/mL,
314 whereas the same dose orally has a 
lower Cmax of 90 nmol/mL.
315 This difference between the two routes is further 
reflected in the fact that following an intravenous dose the onset of analgesia is 
reported to take approximately 8 minutes, compared to 40 minutes for an oral 
preparation,316 with the maximum analgesic effect not being seen for a further 2 - 3 
hours.317 
 
While the plasma pharmacokinetics of oral paracetamol has been well studied, the CSF 
pharmacokinetics of intravenous paracetamol remains to be determined in adult 
humans. Given that paracetamol is increasingly being dosed intravenously and that 
paracetamol is known to be active in the CNS, this is worth investigating. Previous 
studies in the CSF following intravenous paracetamol have been either in children,318-
320 the elderly 321 or using the pro-drug of paracetamol, propacetamol.322 Of these 
previous clinical trials, only the trial in children was a pharmacokinetics study.320 They 
showed that within 5 minutes of an intravenous injection that paracetamol is 
detectable in the CSF, peaking after 60 minutes and still being present after 5 
hours.320 This rapid penetration into the CSF, fast accumulation and slow clearance is 
possibly responsible for paracetamol’s fast onset and long duration of analgesia.  
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The plasma pharmacokinetics of intravenous paracetamol has only recently been 
comprehensively studied.314 As mentioned earlier following a 1 g dose the Cmax was 
165 nmol/mL, which then cleared from the plasma with a t1/2 of 156 minutes. 
Clearance was determined to be 4.2 mL/min/kg, area under the curve was 5,298 
nmol.min/mL and volume of distribution was 0.9 L/kg.  
 
1.6.6. Paracetamol toxicity 
 
Paracetamol has a good safety profile to the extent that it is even suitable for use in 
neonates 323 and pregnant women.324 The minimum fatal oral dose of paracetamol in 
adult humans is approximately 11 g.325 After an overdose, post-mortem paracetamol 
levels in the blood are reported to be 1 – 2.5 mmol/mL, and in the liver to be 2 
µmol/g.326 Following an overdose the liver's glutathione levels are depleted allowing 
NAPQI to cause damage to hepatocytes that leads to liver damage and potentially liver 
failure.327 N-acetylcysteine is used as the antidote for paracetamol overdose as 
together with glutathione binds to NAPQI and consequently aids in its detoxification.327 
As a precaution paracetamol is often formulated with the amino acid methionine, 
which via cysteine is reduced to glutathione in the liver.328 This addition of methionine 
does not lessen paracetamol’s analgesic effect or alter its pharmacokinetics.328 
 
Chapter 1 
50 
1.7. Aims 
 
The aim of this research is to investigate the analgesic and anti-inflammatory 
pathways that FAAH is involved in. The following areas will be studied: 
 
• The endocannabinoid inactivating enzymes FAAH and MAGL both produce 
arachidonic acid, the precursor to the prostaglandins. The interaction between the 
endocannabinoid and prostaglandin systems will be investigated, focusing on FAAH 
and MAGL as potential sources of arachidonic acid for PGE2 synthesis in activated 
macrophages. 
 
• FAAH inhibitors are currently in development as analgesics. Their analgesic and 
anti-inflammatory effect is dependent on AEA, OEA and PEA. The measurement of 
these lipids as a pharmacodynamic parameter would provide a useful means for 
screening novel FAAH inhibitors to establish their effectiveness at increasing the 
concentration of the FAAH substrates. An assay for the FAAH substrates in brain 
and blood by liquid chromatography-tandem mass spectrometry (LC-MS/MS) will 
be developed and validated. Novel FAAH inhibitors will be investigated in vivo for 
their ability to increase brain and blood AEA, OEA and PEA levels. Furthermore the 
rates of oxidative metabolism and the degree to which each substrate undergoes 
protein binding will be compared. 
 
• The inactivation of AEA is a 2-step process beginning with its reuptake and 
finishing with its hydrolysis via FAAH. Paracetamol interacts with both steps by 
using FAAH to synthesis an AEA reuptake inhibitor, AM404. This active metabolite 
is a conjugate of arachidonic acid and paracetamol. The conjugation of other fatty 
acids to paracetamol via FAAH will be studied here. Furthermore the synthesis of 
AM404 remains to be demonstrated in humans. The metabolism of paracetamol 
into AM404 via FAAH will be investigated in a clinical trial looking at the 
cerebrospinal fluid (CSF) and plasma of patients receiving intravenous paracetamol 
for treatment of post-operative pain. Furthermore the pharmacokinetics of 
paracetamol in the CSF, alongside the effect of paracetamol on the FAAH 
substrates, prostaglandins, leukotrienes and serotonin will also be investigated. 
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CHAPTER 2 
 
 
 
Inhibition of FAAH and MAGL suppresses prostaglandin E2 
synthesis by LPS-stimulated macrophages 
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2.1. Introduction 
 
FAAH and MAGL both produce arachidonic acid, the precursor of the prostaglandins, 
through their hydrolysis of the endocannabinoids AEA and 2-AG. In inflammation 
activated macrophages are a major source of PGE2, which is responsible for multiple 
pro-inflammatory and hyperalgesic effects. It is hypothesised that inhibition of FAAH 
and MAGL in activated macrophages should reduce the levels of arachidonic acid and 
consequently reduce production of PGE2. 
 
RAW264.7, a mouse leukaemic macrophage cell line, is a frequently used macrophage 
cell line,329 that will be used here to study LPS-stimulated PGE2 production. Previously 
LPS-stimulated (10 ng/mL) RAW264.7 macrophages have been shown to have 10-fold 
higher AEA levels and increased expression of FAAH.330 This suggests that with LPS-
stimulation there is an increased metabolism of AEA and possibly an increase in FAAH 
formed arachidonic acid, a potential therapeutic target for inflammatory pain. For 
MAGL, LPS-stimulation of macrophages has been shown to increase 2-AG levels by 
2.4-fold and to down-regulate MAGL activity.331  
 
As both FAAH and MAGL form arachidonic acid in endocannabinoid hydrolysis, it is 
hypothesised that inhibition should indirectly inhibit PGE2 synthesis by LPS-stimulated 
RAW264.7 macrophages. The effect of inhibiting endocannabinoid hydrolysis on LPS-
stimulated PGE2 production by macrophages will be investigated using the FAAH 
inhibitor PF-3845 (IC50 = 0.23 pmol/mL) and the MAGL inhibitor JZL184 (IC50 = 8 
pmol/mL). The effect of FAAH and MAGL inhibition of activated macrophages will be 
determined through the measurement of PGE2, nitric oxide, cell viability and COX-2 
expression. 
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2.2. Materials and methods 
 
2.2.1. Materials 
 
Dulbecco's Modified Eagle's Medium (DMEM), HEPES, phosphate buffered saline (PBS), 
Lipopolysaccharide (from Escherichia coli serotype 0111:B4), JZL184, Sulfanilamide, 
N-1-naphthylenediamine dihydrochloride, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) and protease inhibitor cocktail (containing aminoethyl 
benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin, and aprotinin) were 
from Sigma Aldrich (Poole, UK). Heat inactivated fetal bovine serum (FBS), penicillin 
and streptomycin mixture, lithium dodecyl sulfate (LDS) loading buffer and 4-12% bis-
TRIS gel (1.0 mm x 12 well) were from Invitrogen (Paisley, UK). Orthophosphoric acid 
was from BDH (Poole, UK). PF-3845 was from Cayman (Ann Arbor, Michigan, USA). 
The PGE2 assay was from Cisbio (Bagnols-sur-Ceze, France). The bicinchoninic acid 
(BCA) protein assay and TRIS-buffered saline (TBS) blocking buffer were from Thermo 
Scientific (Runcorn, UK). Mammalian protein extraction buffer, enhanced 
chemiluminescence (ECL) detection reagent and Amersham Hyperfilm ECL were from 
GE Healthcare (Little Chalfont, UK). Immobilon-P transfer membrane was from 
Millipore (Watford, UK). COX-2 polyclonal antibody was from Cambridge Bioscience 
(Cambridge, UK).  
 
2.2.2. Macrophages 
 
RAW264.7 macrophages (American Type Culture Collection, Manassas, Virginia, USA) 
were cultured in DMEM containing 100 U/mL penicillin, 100 µg/mL streptomycin, 24 
mM HEPES (pH 7) and 10% FBS, under standard culture conditions (37oC, 8% CO2 and 
92% air). Cells were seeded into 24-well plates at a density of 2 x 106 cells/well. 
Experiments were performed on confluent cells. Before treatment, non-adherent cells 
were washed away with PBS. Macrophages were activated with LPS (either 10 ng/mL 
or 1 µg/mL). Treatments did not contain FBS. Compounds were dissolved in DMSO, 
with the final DMSO concentration in cell medium not exceeding 0.9%, which was 
shown not to affect cell viability. At the end of experiments medium was collected and 
frozen at -80oC until analysis. 
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2.2.3. Prostaglandin E2 assay 
 
Prostaglandin E2 was quantified using a kit from Cisbio. The PGE2 present in the 
samples competes with d2-labelled PGE2 for binding to an anti-PGE2 cryptate-labelled 
antibody. The assay makes use of Forster’s resonance energy transfer (FRET), a 
mechanism by which energy can be transferred between two fluorophores: a donor 
and an acceptor. Excitation of the donor, which in this assay is cryptate, transfers 
energy to the acceptor, the d2-labelled PGE2, causing an emission of light. When PGE2 
from the sample displaces the d2-labelled PGE2, the proximity between the two is 
increased, which in turn decreases the amount of light emitted. Therefore a high 
concentration of PGE2 will causes a low amount of fluorescence. On completion of each 
experiment media was collected and frozen at -80oC. The assay was used in 
accordance with the kit’s instructions. 10 µL medium was added to 5 µL d2-labelled 
PGE2 and 5 µL anti-PGE2 cryptate-labelled antibody into a 384 well plate, which was 
then left at room temperature over night. An 8-point PGE2 calibration line between 0–
5,000 pg/mL was prepared in the assay diluent and run in triplicate. The plate was 
read using a Berthold Technologies (Harpenden, UK) Mithras LB 940 FRET plate reader 
with FRET being measured and expressed as a ratio of 665 nm and 620 nm. 
 
2.2.4. Nitric oxide assay 
 
Nitric oxide levels were assayed indirectly by measuring its stable and non-volatile 
breakdown product nitrite (NO2
-). NO2
- reacts with sulfanilamide to form a diazonium 
salt, which then couples with N-1-naphthylenediamine dihydrochloride to form a 
chromophore that absorbs at 550 nm. 100 µL Griess reagent (1% w/v sulfanilamide, 
0.1% w/v N-1-naphthylenediamine dihydrochloride and 5% v/v phosphoric acid in 
double distilled H2O) was added to 100 µL of either sample or standard in a 96-well 
plate. A ten-point sodium nitrite calibration line between 0 – 100 nmol/mL was used. 
This was prepared in DMEM to correct for any interference from the colour of DMEM. 
The plate was then read at an absorbance of 550 nm using an Anthos Labtec 
Instruments UV / Vis absorbance plate reader. 
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2.2.5. Cell viability assay 
 
The mitochondrial hydrogenases of living cells cleave dimethyl thiazolyl diphenyl 
tetrazolium (MTT) to form an insoluble purple formazan, an indicator of cell 
viability.332. Cells were aspirated and 0.4 mg/mL MTT dissolved in DMEM was added to 
each well (250 µL/well in a 24 well plate). Plates were incubated for 1 hour at 37oC. 
Wells were aspirated and DMSO was added (250 µL/well). 100 µL from each well was 
transferred into a 96-well plate with UV absorbance being measured at 550 nm. 
 
2.2.6. Western blotting COX-2 
 
Protein was extracted from cells using mammalian protein extraction buffer with 10 
µL/mL protease inhibitor cocktail at 75 µL/well. Protein concentrations were 
determined using the BCA protein assay and then samples were equalised to 2 µg/µL 
protein. 10 µL LDS containing loading buffer was added to 30 µL of sample. Protein 
was denaturised at 100oC for 5 minutes and then cooled to 4oC. 20 µL sample was 
separated by gel electrophoresis (XCell Surelock, Invitrogen) on a 4-12% bis-TRIS gel 
(1.0 mm x 12 well, 10 cm in length), at 200 V for 1 hour. Protein was transferred 
electrophoretically at 30 V for 1.5 hours onto an immobilon-P transfer membrane. 
Membranes were blocked for 1 hour at 4oC with TBS blocking buffer before being 
probed by COX-2 polyclonal antibody (1 µg/mL). Membranes were washed with TTBS 
for 15 minutes before being incubated with anti-rabbit horseradish peroxidise 
conjugated secondary antibody for 1 hour. Blots were visualised using an ECL 
detection reagent, exposed with film to light and developed. 
 
2.2.7. Statistical analysis 
 
Data was analysed by either ANOVA with Tukey’s post-hoc analysis or t-test. Tukey’s 
post-hoc analysis was used as it compares all possible pairs of groups, in a multiple 
group analysis. p < 0.05 was deemed statistically significant. Data are presented as 
mean ± SEM. Statistical analysis was by Prism 3.0 (GraphPad). 
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2.3. Results 
 
2.3.1. Effect of FAAH and MAGL inhibition on the cell viability of LPS-stimulated 
RAW264.7 macrophages 
 
At 10 ng/mL LPS had no effect on cell viability (Figure 2.1. A). At 1 µg/mL LPS 
decreased cell viability by 30% (Figures 2.1. B). JZL184 at concentrations between 
0.01 – 100 nmol/mL did not decrease cell viability, with 100 nmol/mL actually 
increasing viability.  
Control LPS DMSO 0.01 0.1 1 10 100
0
25
50
75
100
125
***
C
el
l v
ia
bi
lit
y
(%
 
o
f u
n
st
im
u
la
te
d 
co
n
tr
o
l)
JZL184 (nmol/mL)
Control LPS DMSO 0.01 0.1 1 10 100
0
25
50
75
100
125
*** *** *** ***
***
C
e
ll 
v
ia
bi
lit
y
(%
 
o
f u
n
st
im
u
la
te
d 
co
n
tr
o
l)
***
JZL184 (nmol/mL)
 
Figure 2.1. – Effect of the MAGL inhibitor JZL184 (0.01 – 100 nmol/mL) on the cell 
viability of RAW264.7 macrophages stimulated with either (A) 10 ng/mL or (B) 1 
µg/mL of LPS. Macrophages were cultured as described in Section 2.2.2. Macrophages were 
incubated for 24 hours after treatment. DMSO treatment was at 0.9% and did not contain LPS. 
Cell viability determined using the MTT assay. Data expressed as mean ± SEM (n = 6 per group). 
Statistical analysis by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 0.001 in comparison with 
unstimulated controls. 
A 
B 
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PF-3845 at concentrations above 10 nmol/mL was cytotoxic (Figure 2.2.), hence this 
inhibitor was only studied at concentrations between 0.01 – 1 nmol/mL. In dimethyl 
sulfoxide (DMSO) PF-3845 is soluble at concentrations up to 44 µmol/mL, while 
JZL184 is soluble at concentrations up to 48 µmol/mL. The highest DMSO 
concentration used was 0.9% for 100 nmol/mL JZL184, which did not affect cell 
viability.  
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Figure 2.2. – Effect of the FAAH inhibitor PF-3845 (0.01 – 100 nmol/mL) on the cell 
viability of RAW264.7 macrophages stimulated with either (A) 10 ng/mL or (B) 1 
µg/mL of LPS. Macrophages were cultured as described in Section 2.2.2. Macrophages were 
incubated for 24 hours after treatment. DMSO treatment was at 0.9% and did not contain LPS. 
Cell viability determined using the MTT assay. Data expressed as mean ± SEM (n = 6 per group). 
Statistical analysis by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 0.001 in comparison with 
unstimulated controls. 
A 
B 
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2.3.2. Effect of FAAH and MAGL inhibition on LPS-induced PGE2 synthesis in RAW264.7 
macrophages 
 
Macrophages were stimulated with 10 ng/mL LPS and treated with increasing 
concentrations of either the FAAH inhibitor PF-3845 or the MAGL inhibitor JZL184 
(Figure 2.3. A).  
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Figure 2.3. – Effect of the FAAH inhibitor PF-3845 (0.01 – 1 nmol/mL) and the MAGL 
inhibitor JZL184 (0.01 – 100 nmol/mL) on the PGE2 production of RAW264.7 
macrophages stimulated with either (A) 10 ng/mL or (B) 1 µg/mL of LPS. Macrophages 
were cultured as described in Section 2.2.2. Macrophages were incubated for 24 hours after 
treatment. PGE2 was quantified in cell media by ELISA. Data expressed as mean ± SEM (n = 6 
per group). Statistical analysis by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 0.001 in 
comparison with LPS-stimulated non-treated controls. 
 
Stimulating macrophages with 10 ng/mL LPS increased PGE2 levels by approximately 
1500 fmol/mL. Both FAAH and MAGL inhibition concentration dependently reduced 
A 
B 
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LPS-stimulated PGE2 synthesis. The EC50, the response halfway between the maximum 
and the baseline, for both inhibitors was approximately 1 nmol/mL. The effect of a 
higher concentration of LPS was investigated with 1 µg/mL being used (Figure 2.3. B). 
At 1 µg/mL, LPS increased PGE2 levels by 6000 fmol/mL. With the exception of 100 
nmol/mL JZL184, no inhibition of PGE2 production was seen. (Figure 2.3.).  
 
2.3.3. Effect of FAAH and MAGL inhibition on LPS-induced nitric oxide synthesis in 
RAW264.7 macrophages 
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Figure 2.4. – Effect of the FAAH inhibitor PF-3845 (0.01 – 1 nmol/mL) and the MAGL 
inhibitor JZL184 (0.01 – 100 nmol/mL) on the NO2
- production of RAW264.7 
macrophages stimulated with either (A) 10 ng/mL or (B) 1 µg/mL of LPS. Macrophages 
were cultured as described in Section 2.2.2. Macrophages were incubated for 24 hours after 
treatment. NO2
- was quantified in cell media using the Griess reagent. Data expressed as mean ± 
SEM (n = 6 per group). Statistical analysis by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 
0.001 in comparison with LPS-stimulated non-treated controls. 
A 
B 
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Stimulating macrophages with 10 ng/mL LPS increased NO2
- concentrations to 30 
nmol/mL (Figure 2.4. A). Only at the highest concentration, 100 nmol/mL, did the 
MAGL inhibitor JZL184 significantly decrease NO2
- concentrations. No effect was seen 
with PF-3845. Stimulating macrophages with 1 µg/mL LPS increased NO2
- 
concentrations to 50 nmol/mL (Figure 2.4. B). Again only at the highest concentration, 
100 nmol/mL, did JZL184 significantly decrease NO2
- concentrations. No effect was 
seen with PF-3845. It was determined whether either PF-3845 or JZL184 would 
interfere with Griess assay. No change in absorbance with the Griess reagent was seen 
with either compound, concluding that neither PF-3845 nor JZL184 interfered with the 
assay. 
 
2.3.4. Effect of MAGL inhibition on LPS-induced COX-2 expression in RAW264.7 
macrophages 
 
It was investigated as to whether JZL184 could decrease COX-2 expression. 10 
nmol/mL JZL184 was not found to alter COX-2 expression in macrophages stimulated 
with 1 µg/mL (Figure 2.5.). As expected COX-2 was not present in unstimulated 
macrophages.35 LPS-stimulation produces a 70 kDa band, corresponding to the 
enzyme.333 
 
 
Figure 2.5. – Effect of JZL184 on LPS-induced COX-2 protein expression in RAW264.7 
macrophages. Macrophages were cultured as described in Section 2.2.2. Macrophages were 
incubated for 24 hours after treatment. The figure shows the results from duplicate experiments. 
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2.4. Discussion 
 
The endocannabinoid and prostaglandin systems are known to interact. Inhibition of 
COX-1 and COX-2 not only reduces PGE2 levels, but also increases levels of the 
endocannabinoids AEA and 2-AG.182, 183 The original aim of this study was to further 
investigate the interaction between endocannabinoid and prostaglandin systems, 
focusing on FAAH and MAGL as sources of arachidonic acid for PGE2 synthesis. A 
previous study demonstrated FAAH inhibition suppressed PGE2 in microglia by using 
the inhibitor URB597.255 Here the more potent and selective inhibitor PF-3845 was 
used for FAAH inhibition and JZL184 was used for MAGL inhibition. 
 
It was investigated as to whether inhibition of FAAH and MAGL could sufficiently lower 
arachidonic acid levels to the extent that prostaglandin production would also be 
reduced. PGE2 production was investigated using RAW264.7 macrophages stimulated 
with LPS. Typically the screening of COX inhibitors for their ability to inhibit PGE2 
production in LPS-stimulated macrophages uses 1 µg/mL LPS, with both NSAIDs and 
cannabinoids inhibiting PGE2 production in this model.116, 286 Here two LPS 
concentrations were used: 10 ng/mL and 1 µg/mL. There is a significant difference in 
expression of COX-2 and the amount of PGE2 produced between these two LPS 
concentrations. The effect of FAAH and MAGL inhibitors were investigated under both 
conditions to determine whether a diminished ability to reduce PGE2 would be seen in 
the presence of higher COX-2 expression. 
 
It was found that the FAAH and MAGL inhibitors PF-3845 and JZL184 concentration-
dependently reduced PGE2 production at 10 ng/mL LPS (Figure 2.3). At this 
concentration of LPS only 1,500 fmol/mL PGE2 was produced despite significant 
expression of COX-2. This suggests that not much arachidonic acid was being liberated 
by phospholipases from the cell membrane. Therefore FAAH and MAGL were able to 
influence arachidonic acid levels and consequently PGE2 production. However this 
effect was dependent on COX-2 expression and PGE2 production. 
 
At 1 µg/mL LPS there was higher expression of COX-2 and a 6,000 fmol/mL release of 
PGE2. This higher concentration of LPS meant that the FAAH and MAGL inhibitors had 
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no effect on PGE2 production. Therefore the phospholipases became a more significant 
source of arachidonic acid. Hence the influence of FAAH and MAGL over arachidonic 
acid levels and PGE2 production was diminished. These findings suggest that under 
certain conditions FAAH and MAGL can control arachidonic acid levels to the extent 
that PGE2 production is influenced. The amount of PGE2 being produced appears to be 
integral to the ability of FAAH and MAGL inhibitors to suppressed PGE2 production. 
 
In addition to PGE2, nitric oxide was also measured indirectly by assaying its stable 
breakdown product nitrite. Nitric oxide was investigated as both LPS and PGE2 
stimulate iNOS expression and NO production.255 Furthermore the FAAH inhibitor 
URB597 has been shown to reduce NO production in activated macrophages.255 It was 
therefore hypothesised that FAAH and MAGL inhibition might reduce LPS-stimulated 
NO production in macrophages, therefore the effect of PF-3845 and JZL184 was 
investigated. JZL184 was the only inhibitor to reduce NO production, an effect that 
was only seen at the highest concentration of 100 nmol/mL (Figure 2.4.). Therefore no 
correlation between FAAH and MAGL inhibition on NO levels were found. 
 
Previously cannabinoids have been demonstrated to inhibit the production of PGE2,116 
interleukin-2,334 interleukin-6,116 TNF-α,335 and nitric oxide 336 in macrophages. 
Activation of the cannabinoid receptors therefore clearly influences macrophage 
activity. Therefore the observed decreases in PGE2 presented here may possibly be 
mediated by the cannabinoid receptors. However a recent study that showed the FAAH 
inhibitor URB597 to inhibit PGE2 production in microglia,255 demonstrated that CB1 
and CB2 antagonists did not block this effect. Therefore it was concluded that this 
activity was independent of the cannabinoid receptors.  
 
While FAAH and MAGL inhibition increases AEA and 2-AG levels respectively, it is 
unlikely that the observed effect on macrophage PGE2 production presented in this 
chapter is mediated by the cannabinoid receptors. This is supported by a study that 
demonstrated that an anti-oedema effect mediated by FAAH was not reversible by 
cannabinoid antagonism.337 This is the first in vivo evidence of an anti-inflammatory 
effect that despite being mediated by FAAH was independent of the cannabinoid 
receptors, suggesting that this was due to FAAH’s suppression of PGE2 production. 
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Following from this it would be interesting to see whether in vivo FAAH and MAGL 
inhibition can reduce prostaglandin production in tissue, and whether cannabinoid 
receptor antagonists can block prostaglandin production. 
 
The direct effect of AEA and 2-AG on PGE2 production by LPS-stimulated macrophages 
has not been previously investigated due to AEA and 2-AG being analogues of 
arachidonic acid, and hence susceptible to metabolism by COX.116 As this present 
study investigated induced COX-2 expression alongside FAAH inhibition, it is possible 
that COX derived metabolites of AEA were formed. Unlike the cannabinoids, the COX 
derived AEA metabolite PGE2-ethanolamide does not have an anti-inflammatory effect 
on activated macrophages.116 The evidence from this study therefore does not support 
the involvement of PGE2-ethanolamide in the action of FAAH inhibitors. 
 
While PGE2 was investigated here, FAAH and MAGL may have control of a wider range 
of lipids involved in inflammation, such as leukotriene and thromboxane. Recently it 
was demonstrated that MAGL regulates a network of lipids in tumour cells including 
fatty acids, fatty acid glycerols and PGE2.338 Having demonstrated here that FAAH and 
MAGL can inhibit PGE2 production, it was investigated as to the same effect could be 
seen with LTB4. A previous study demonstrated that LTB4 could be produced by 
RAW264.7 macrophages when stimulated with the calcium ionophore (10 µM 
A23187).339 An unsuccessful attempt was made to reproduce this observation as a 
model for investigating the effect of FAAH and MAGL inhibitors of LTB4. This was 
supported by a report demonstrating only a transient production of leukotrienes 
following stimulation.340 JZL184 was recently shown to inhibit 2-AG induced 
biosynthesis of LTB4 in human neutrophils.341 Therefore human neutrophils would be 
an appropriate technique for determining whether FAAH inhibition can also suppress 
LTB4 biosynthesis. 
 
Further work is required to elucidate the relationship between arachidonic acid release 
and LPS-stimulation. Ideally this should look at increasing amounts of LPS and 
different periods of stimulation. To accomplish this an arachidonic acid assay would be 
required, of which LC-MS/MS methods have been reported.342 The majority of the 
arachidonic acid used in PGE2 synthesis is released by cPLA2.18 Even still MAGL 
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appears to have significant control over arachidonic acid levels, as MAGL inhibition 
reduces unesterified arachidonic acid in the brain by 50%.218 It is important that the 
relative contributions of FAAH, MAGL and phospholipase A2 to arachidonic acid levels 
are determined under both physiological and pathological conditions. 
 
The finding that the ability of FAAH and MAGL to inhibit PGE2 production is LPS 
dependent suggests that FAAH and MAGL are more likely to influence physiological 
PGE2 production, when COX-2 is not induced, than in inflammatory production, when 
COX-2 is induced. Further investigation would be required in vivo to determine 
whether there is any physiological relevance to this finding. Inhibition of FAAH and 
MAGL is known to be anti-inflammatory and effective in the treatment of inflammatory 
pain in vivo. For example FAAH inhibition has previously been shown to reduce 
peripheral inflammation in mice.226 Whether this effect is in part due to a suppression 
of PGE2 needs to be investigated. An ideal future experiment would be to repeat such 
a study, investigating the effect of a dose-response of a FAAH inhibitor on PGE2 
concentrations. 
 
The substrates of FAAH and MAGL have multiple analgesic and anti-inflammatory 
properties. It is therefore possible that the reduction in PGE2 seen here with FAAH and 
MAGL inhibition is in part due to the increased concentrations of their substrates. 
Therefore it would be worth determining the effects of OEA, PEA, 2-oleoyl glycerol (2-
OG) and 2-palmitoyl glycerol (2-PG) on LPS-stimulated macrophages to further 
investigate this. 
 
LPS stimulation of macrophages has been shown to increase AEA levels, induce FAAH 
expression,330 increase 2-AG levels and down regulate MAGL expression.331 The 
development of FAAH and MAGL assays in macrophages was attempted here using 
fluorogenic substrates, but with little success. Future studies could achieve this by 
using a recently reported assay that measures FAAH leukocyte activity by monitoring 
the hydrolysis of a deuterated AEA analogue with LC-MS/MS.343 Based on this method 
a similar MAGAL assay using deuterated 2-AG could be easily adapted for this purpose. 
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2.4.1. Limitations of the present study 
 
This study has several limitations. Firstly similar to previous studies,35 PGE2 was 
measured directly in the cell medium without extraction. The PGE2 assay was carried 
out in accordance with the manufactures (Cisbio) instructions, which states that the 
assay is suitable for use with cell culture medium. However there are examples of 
other studies using C18 cartridges to extract prostaglandins from cell medium.344 The 
benefit of such cleaner extracts is less interaction between the other components of 
the cell medium with the assay. PGE2 was measured using a kit, which although 
validated by the manufacturer, was not independently validated. In this present study 
cells were cultured with cell medium containing FBS, with treatments not containing 
FBS. While LPS still managed to stimulate production of PGE2 and NO, in hindsight FBS 
should have been included in treatments as previous studies have shown serum 
proteins to be potentiate LPS activation of macrophages.345, 346 
 
The western blotting of COX-2 was part of a pilot study to investigate the effect of the 
FAAH and MAGL inhibitors on COX-2 expression. While protein in samples were 
equalised to 2 µg/µL no loading controls, such as β-actin or tubulin, were used. JZL184 
was investigated at 10 nmol/mL on macrophages stimulated with 1 µg/mL LPS. Under 
these same conditions no effect is seen on PGE2 levels. Therefore in the future the 
experiment should be reproduced instead using 10 ng/mL LPS. Furthermore like 
JZL184, the effect of PF-3845 on COX-2 expression should be investigated.255 
 
While PF-3845 and JZL184 have both been developed for the treatment of 
inflammatory pain, there are no reports as to whether they have any off-target 
selectivity for the COX enzymes. To conclusively rule out that the effects of PF-3845 
and JZL184 on PGE2 are not due to off-target inhibition of COX, these inhibitors should 
be assayed for their binding affinity to pure COX-1 and COX-2 proteins. 
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2.4.2. Summary 
 
In summary, previously it has been shown that URB597 reduces PGE2 in microglia.255 
Here for the first time it has been shown that the more selective FAAH inhibitor PF-
3845 and the MAGL inhibitor JZL184 inhibits 10 ng/mL LPS-stimulated PGE2 
production in macrophages, but not at the 100-fold higher concentration of 1 mg/mL. 
To allow for a fuller understanding of the interaction between the endocannabinoid 
system and the prostaglandin system in macrophages, LPS stimulation now needs to 
be correlated with FAAH and MAGL activity, FAAH and MAGL expression, arachidonic 
acid levels and PGE2 levels. Furthermore whether there is an in vivo effect on PGE2 
levels by FAAH and MAGL inhibitors needs to be investigated. 
 
 
Chapter 3 
67 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
 
FAAH substrates as a pharmacodynamic response in an 
in vivo model of inflammatory pain 
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3.1. Introduction 
 
The measurement of the FAAH substrates AEA, OEA and PEA is a useful 
pharmacodynamic parameter for demonstrating FAAH inhibition and thus proving the 
mechanism of action for potential inhibitors. The studies presented here will 
investigate the pharmacodynamic effects of the irreversible covalent inhibitors, 
URB597 and PF-04457845, alongside three other reversible non-covalent inhibitors, 
referred to here as NC1, NC2 and NC3 and the COX inhibitor celecoxib. NC1, NC2 and 
NC3 are novel and uncharacterised non-covalent inhibitors of FAAH. Additionally the 
COX-2 inhibitor, celecoxib, will be used to investigate whether FAAH substrates would 
be affected by other analgesics.  
 
To accomplish this, firstly an LC-MS/MS assay for the measurement of AEA, OEA and 
PEA in both rat brain and whole blood will be developed and validated. Freund’s 
complete adjuvant (FCA)-induced hypersensitivity will be used as a model of 
inflammation in rats, with weight bearing being used to determine analgesia. FCA is an 
oil emulsion of dead Mycobacterium tuberculosis that is injected into the knee to 
induce a stable and treatable thermal hyperalgesic pain.347, 348 The brain and blood 
FAAH substrate levels and FAAH activity will be investigated before and after FCA to 
determine whether they are changed with inflammation. Furthermore measuring 
reversal of hypersensitivity will determine whether FAAH substrate levels and FAAH 
activity are changed with analgesia. It is assumed that a change in the enzyme’s 
activity should be reflected by a change in its substrates. The benefit of measuring 
both the enzyme’s activity and substrates is that it will provide a comprehensive 
picture of whether this is always the case. 
 
The accumulation of AEA, OEA and PEA as a result of FAAH inhibition should subject 
the substrates to increased amounts of non-FAAH-mediated metabolism. As already 
discussed in Section 1.2.4. the oxidative metabolites of AEA have not been identified in 
vivo under normal physiological conditions. The oxidative metabolism of the other 
FAAH substrates, OEA and PEA, is yet to be investigated and is possibly more likely to 
be a physiological occurrence due to their higher endogenous concentrations. Using 
liver microsomes it will be determined as to whether OEA and PEA can undergo 
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oxidative metabolism by liver microsomes. The rate of oxidation for AEA, OEA and PEA 
by liver microsomes will be compared. 
 
FAAH is highly expressed in brain and liver, therefore FAAH inhibition will increase the 
levels of protein bound AEA, OEA and PEA in these tissues. To further understand 
FAAH inhibition it is therefore important that the protein binding of these lipids is 
investigated. Lipids strongly and reversibly bind to non-specific proteins,349 and 
therefore exist as bound and unbound fractions, with only unbound lipid signalling 
molecules being available to activate their receptors and be oxidised. Therefore it is 
important that intrinsic clearance values be corrected for binding to microsomal 
protein.350 Protein binding of AEA, OEA and PEA to microsomal protein will be 
determined, with also binding to brain protein being investigated. 
 
Together these studies will investigate the utility of the AEA, OEA and PEA as 
indicators of FAAH inhibition. They will be evaluated on how readily detectable they are 
analytically, how abundant they are in tissue samples, the extent to which FAAH 
inhibition increases their concentration, how closely brain levels correlate with blood 
levels, the extent at which they undergo oxidative metabolism and the degree to which 
they bind to protein. 
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3.2. Materials and methods 
 
3.2.1. Materials 
 
FAAH inhibitors were synthesised by chemists at GSK. AEA, OEA, PEA and PEA-d4 
were from Cayman Chemicals (Ann Arbor, Michigan, USA). PEA-d4 contains four 
deuterium atoms, two at the 7-position and two at the 8-position. All analytes were 
stored in ethanol at -80oC. URB597 was from Cayman Chemicals and stored as a solid 
at -20oC. Far UV/gradient quality acetonitrile was from Romil Chemicals (Cambridge, 
UK). Analytical reagent grade formic acid was from BDH (Poole, UK). Analytical 
reagent grade absolute ethanol was from Fisher Scientific (Loughborough, UK). TRIS-
HCl, TRIS-base, HEPES, EDTA, Glycerol and Triton X-100 were from Sigma Aldrich 
(Poole, UK). Sprague Dawley rat liver microsomes were from Xenotech LLC (Kansas, 
USA). Microsomes were mixed gender pools prepared at 20 mg/mL in 50 mM sodium 
phosphate buffer (pH 7.4). The 96-well equilibrium dialysis block and dialysis 
membranes were from HTDialysis LLC (Connecticut, USA). 
 
3.2.2. FCA-induced hypersensitivity 
 
Male Random hooded rats (Charles River Laboratories, Kent, UK) were kept on a 12 
hour light/dark cycle with ad libitum access to food and water. They were fed a 5LF2 
diet (LabDiet, UK). Rats used in the studies were typically between 9 - 10 weeks old 
and 200 – 220 g in weight.  
 
Inflammation was induced by injection of 100 µL 1 mg/mL FCA into the left hind paw. 
Weight bearing on the left hind paw was measured before and after FCA to determine 
FCA-induced hypersensitivity, and then measured after the drug to determine % 
reversal of FCA-induced hypersensitivity. Rats were culled under CO2 followed by 
cervical dislocation 1 hour after drug administration. Rat brains were frozen on 
collection in liquid nitrogen. Whole rat blood was collected into EDTA tubes from the 
rat tail vein for serial studies and using cardiac puncture once rats had been culled. 
Samples were stored at -80oC until analysis. All animal studies were ethically reviewed 
and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the 
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GSK Policy on the Care, Welfare and Treatment of Laboratory Animals. The above work 
was performed by technicians at GSK. 
 
3.2.3. Drug administration 
 
URB597 was formulated as 2 mg/mL in 2% DMSO, 65% PEG-400 and 33% H2O. NC1, 
NC2, NC3 and celecoxib were prepared in methyl cellulose. PF-04457845 was prepared 
in 5% dimethylacetamide (DMA) with 95% cyclodextrin, URB597 was administered at 
10 mg/kg as an intraperitoneal (i.p.) injection. NC1 and NC2 were both administered 
at 10 mg/kg i.p. PF-04457845 was administered at 3 mg/kg i.p. NC3 was administered 
at 3, 10 and 30 mg/kg i.p. Celecoxib was administered at 10 mg/kg i.p. The above 
work was performed by technicians at GSK. 
 
3.2.4. Sample preparation 
 
Left brain hemisect was collected for FAAH substrate measurements, while the right 
brain hemisect was collected for a separate FAAH activity assay. An aqueous buffer 
(pH 7.4, 125 mM TRIS, 0.4 mM HEPES, 1 mM EDTA, 0.2% v/v Glycerol, 0.02% v/v 
Triton X-100 and 10 µM URB597) was added at 2 mL per gram of brain tissue and 
homogenised using an Ultra-turrax handheld high speed disperser. 100 µL 
homogenate was extracted and protein precipitated with 300 µL acetonitrile containing 
100 ng/mL internal standard, PEA-d4. Samples were vortex mixed and centrifuged for 
15 minutes at 1,500 g. 50 µL supernatant was transferred into a 96-well plate and 
diluted with 50 µL H2O using a Tecan liquid handling robot (Reading, UK). 
 
Upon collection 50 µL blood was immediately deproteinated by addition of 150 µL 
acetonitrile containing 100 ng/mL PEA-d4 as an internal standard. Samples were 
frozen on dry ice and stored at -80oC until analysis. The precipitated blood was allowed 
to thaw, then vortex mixed and centrifuged for 15 minutes at 1,500 g. 50 µL 
supernatant was transferred into a 96-well plate and diluted with 50 µL H2O using a 
Tecan liquid handling robot. 
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3.2.5. FAAH substrate assay by LC-MS/MS 
 
LC-MS/MS analysis was performed on a Waters Acquity system with a Quattro Premier 
tandem mass spectrometer. A 5 µL injection was made onto a Waters Acquity BEH 
phenyl column (2.1 x 50 mm, 1.7 µm) maintained at 50oC. Gradient elution was 
between mobile phase A (95% H2O, 5% acetonitrile, 0.1% formic acid) and B (95% 
acetonitrile, 5% H2O, 0.1% formic acid). At 0.1% formic acid the mobile phase was pH 
2.6. The gradient ran from 20% B, increasing linearly to 90% over 2 minutes at a flow 
rate of 0.5 mL/min. This was held until 2.2 minutes, then returned to 20% and allowed 
to re-equilibrate. The total runtime was 2.5 minutes. Analytes were quantified by 
tandem mass spectrometry with positive electrospray ionisation. Multiple reaction 
monitoring (MRM) was performed with the [M + H]+ selected for each analyte, 
monitoring the transitions 348  62 m/z for AEA, 326  62 m/z for OEA, 300  62 
m/z for PEA and 304  62 m/z for PEA-d4. The optimised parameters for monitoring 
these transitions are shown in Table 3.1. 
 
Table 3.1. – The selected precursor and product m/z values for each analyte with their 
respective dwell times, cone voltages and collision energy voltages used for their 
identification and quantification by LC-MS/MS.  
 Precursor 
(m/z) 
Product  
(m/z) 
Dwell 
(s) 
Cone voltage 
(V) 
Collision energy 
(V) 
AEA 348.4 62.0 0.12 22 16 
OEA 326.3 62.0 0.12 28 22 
PEA 300.1 62.0 0.12 22 16 
PEA-d4 304.5 62.0 0.12 22 16 
Where m/z is the mass-to-charge ratio, s is seconds and V is voltage. 
 
For the calibration line, standards of AEA, OEA and PEA were prepared at 12 
concentrations from 4 pmol/g – 20,000 pmol/g in control brain tissue homogenate and 
1 pmol/mL – 6,500 pmol/mL in control whole blood (Figure 3.10.). Standards were 
prepared using a Tecan liquid handling robot. 10 µL each standard was spiked into 100 
µL brain homogenate, 5 µL was spiked into 50 µL blood. Blanks were made using H2O 
instead of analyte standard and total blanks were precipitated using acetonitrile 
without the internal standard. Due to high endogenous levels of OEA and PEA in the 
brain the calibration lines do not intercept the y-axis at zero. 
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3.2.6. FAAH activity assay 
 
FAAH activity was assayed using a previously reported method.351 Brain homogenates 
and blood were incubated for 10 minutes at 37oC in the presence of 2 µM [3H]-AEA. 
FAAH hydrolyses this substrate into radiolabeled ethanolamine and unlabeled 
arachidonic acid. The unhydrolysed [3H]-AEA and arachidonic acid were removed by 
differential absorption to activated charcoal. The remaining radiolabeled ethanolamine 
was measured by liquid scintillation counting. Brain and blood from untreated rats was 
assumed to have 100% FAAH activity. FAAH activity was expressed as a percentage of 
this control group. The above work was performed by technicians at GSK. 
 
3.2.7. Intrinsic clearance assay 
 
Oxidation of the FAAH substrates will be investigated using the standard approach, 
which is the use of liver microsomes to assay intrinsic clearance.350 Drug metabolising 
enzymes are abundant in the liver. Microsomes are isolated from the liver by 
centrifuging liver homogenate centrifuged at 9,000 g for 20 minutes.352 At 9,000 g 
cells and large organelles sediment out of solution leaving cytochrome P450, other 
soluble enzymes and fragments of endoplasmic reticulum. The microsomes are then 
isolated by ultracentrifugation at 100,000 g for 1 hour.352 This process selectively 
concentrates intracellular enzymes, such as cytochrome P450.352  
 
An automated Packard MultiPROBE II HT EX system (West Drayton, UK) was used for 
the determining intrinsic clearance. A 0.5 mg/mL suspension of microsomes was 
prepared in PBS and incubated at 37OC for 10 minutes. The compound of interest was 
added to 300 µL of the suspension to give a final concentration of 0.5 µM. A co-factor 
solution was used to initiate the cytochrome P450 enzymes. 80 µL of the co-factor 
solution was added, which contained 7.8 mg/mL glucose-6-phosphate, 1.7 mg/mL 
NADP and 6 U/mL glucose-6-phosphate dehydrogenase (EC 1.1.1.49) in 2% sodium 
bicarbonate buffer (pH 7.4). Samples of 25 µL were removed at 0, 3, 6, 9, 12, 15, 18, 
24 and 30 minutes, and the proteins precipitated with 200 µL acetonitrile containing 
the 100 ng/mL of the internal standard PEA-d4. The sample extracts were then 
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centrifuged for 15 minutes at 1,500 g. 150 µL supernatant was extracted and then 
diluted with 150 µL H2O. The clearance (CLi) was calculated as: 
 
CLi= k x 1/I x SF 
 
where k is the rate constant, I is the compound concentration and SF is the scaling 
factor. CLi is expressed as mg/min/g of wet liver tissue. The scaling factor was used to 
predict the clearance in vivo from the clearance observed in the microsomes. For rat to 
human this is accepted as being 52.5.353-355  
 
Cytochrome P450 activity requires cofactors, which were added to the liver microsome 
suspension. Microsomes without co-factors were also prepared to investigate non-
cytochrome P450 activity. The percentage of the compound cleared without co-factors 
compared to that with co-factors was calculated and is referred to here as no-cofactor 
loss. A value near 0% suggests the compound was mostly metabolised by cytochrome 
P450, while a value near 100% means that the compound was highly metabolised via 
non-cytochrome P450 pathways. The experimental validity was determined by two 
compounds, namely 7-ethoxycoumarin and dextromethorphan, which were used as 
positive controls. Both are metabolised by a range of cytochrome P450 isoforms and 
therefore are useful probes to determine whether the enzymes are active or not.356, 357 
FAAH substrates were measured by LC-MS/MS according to Section 3.2.5. Clearance 
was calculated using the peak area ratio of analyte to internal standard, therefore 
calibration was not required. 
 
3.2.8. Protein binding assay 
 
The standard assay for protein binding is equilibrium dialysis.358 A dialysis membrane 
is used to separate two compartments. The compound and the matrix to be 
investigated are placed on one side, with an appropriate buffer placed on the other. 
The unbound fraction of the compound is therefore free to diffuse across the 
membrane. At equilibrium the unbound compound will be at the same concentration in 
either compartment. But as protein bound compounds are unable to permeate the 
membrane they will not enter the buffer compartment. Hence the total concentration 
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will be higher in the matrix compartment. The concentration of unbound compound in 
the buffer compartment divided by the concentration of the bound and unbound 
compound in the matrix compartment gives the percentage protein binding.  
 
While Random hooded rats were used in the in vivo studies, liver microsomes from this 
strain were not commercially available. Sprague Dawley rat brain and liver microsomes 
were used instead for the investigation of protein binding.  
 
Dialysis membrane strips, obtained from HTDialysis LLC, were soaked for 1 hour in 
H2O and then left in 20% ethanol / 80% H2O until required for use. The 96-well 
equilibrium dialysis block was assembled with each well in the 96-well plate being 
separated into two compartments by the dialysis membrane. Brains were homogenised 
with PBS at 2mL per gram of tissue. Microsome suspensions were prepared at 0.5 
mg/mL in 50 mM PBS (pH 7.4). AEA, OEA and PEA were added separately to the brain 
homogenate at a final concentration of 10 µM. AEA, OEA and PEA were added 
separately to the microsomes at a final concentration of 0.3 µM. 100 µL PBS was 
added to the buffer compartment of the membrane and to the other side, the matrix 
compartment, 100 µL of the incubation mixture was added, either the microsomes or 
brain homogenate. The plate was sealed with an adhesive strip to prevent evaporation. 
The block was placed on a shaker inside an incubator cabinet set at 37oC. Brain 
homogenates were incubated for 5 hours and microsomes for 20 hours. 
 
As the analysis of the samples was by LC-MS/MS it was essential to ensure that all 
samples had a similar matrix composition and final volume to prevent matrix effects. 
For the microsomes, after incubation 50 µL from the matrix compartment was 
precipitated with 200 µL acetonitrile and then 50 µL PBS was added. From the buffer 
compartment, 50 µL was precipitated with 200 µL acetonitrile and then 50 µL control 
microsome suspension was added. For brain, 50 µL of the matrix compartment was 
precipitated with 200 µL acetonitrile and then 100 µL PBS was added. From the PBS 
compartment 50 µL was precipitated with 200 µL acetonitrile and then 100 µL control 
brain homogenate was added. PEA-d4 was used as the internal standard and was 
present in the acetonitrile at 100 ng/mL. Samples were centrifuged for 15 minutes at 
1,500 g. The supernatant was removed and diluted 1:1 with H2O before analysis.  
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FAAH substrates were measured by LC-MS/MS according to Section 3.2.5. percentage 
protein binding was calculated using the peak area ratio of analyte to internal 
standard, therefore calibration was not required. The percentage of the unbound 
compound was taken as the amount of unbound compound in the buffer compartment 
divided by the amount of bound and unbound compound in the matrix compartment. 
Subtracting this percentage from 100 then gave the percentage of the protein bound 
compound. 
 
3.2.9. Statistical analysis 
 
Data was analysed by either ANOVA with Tukey’s post-hoc analysis or t-test. Tukey’s 
post-hoc analysis was used as it compares all possible pairs of groups, in a multiple 
group analysis. p < 0.05 was deemed statistically significant. Data are presented as 
mean ± SEM. Statistical analysis was by Prism 3.0 (GraphPad). 
Chapter 3 
77 
3.3. Results 
 
3.3.1. FAAH substrate assay - optimisation 
 
The MS/MS conditions were optimised for maximum formation and detection of 
product ions by direct infusion of 100 ng/mL standard solutions. The FAAH substrates 
positively ionised under electrospray ionisation and formed a prominent 62 m/z ion 
when fragmented, corresponding to ethanolamine (Figures 3.1. – 3.4.).  
 
 
Figure 3.1. – Product ion mass spectrum and corresponding structure for AEA (348.4  
62.0 m/z) following collision induced dissociation. Site of fragmentation is identified on the 
figure. MS/MS conditions are per Table 3.1. 
 
 
Figure 3.2. – Product ion mass spectrum and corresponding structure for OEA (326.3  
62.0 m/z) following collision induced dissociation. Site of fragmentation is identified on the 
figure. MS/MS conditions are per Table 3.1. 
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Figure 3.3. – Product ion mass spectrum and corresponding structure for PEA (300.1  
62.0 m/z) following collision induced dissociation. Site of fragmentation is identified on the 
figure. MS/MS conditions are per Table 3.1. 
 
 
Figure 3.4. – Product ion mass spectrum and corresponding structure for PEA-d4 (304.5 
 62.0 m/z) following collision induced dissociation. Site of fragmentation is identified on 
the figure. MS/MS conditions are per Table 3.1. 
 
The analytes each lost a hydroxyl group, hence the presence of a fragment 17 m/z 
less than the precursor ion in each spectra. The cone voltage, collision energy and 
dwell times obtained from the optimisation process are shown in Table 3.1. 
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A phenyl column was used as the substrates were highly retained on the C18 columns, 
which was not suited for the desired fast run times. Formic acid was used in the mobile 
phase to promote ionisation. A fast gradient was required so that the method could be 
high throughput. The three analytes and internal standard were not 
chromatographically resolved (Figure 3.5. and 3.6.), but as ion suppression was within 
the acceptable ±20% limit this did not need to be dealt with (Table 3.2.). 
 
 
Figure 3.5. – Representative chromatograms obtained by LC-MS/MS showing 
endogenous AEA (A), OEA (B), PEA (C) and the internal standard PEA-d4 (D) in rat 
brain. Brain was extracted and analysed as described in Section 3.2.4. and Section 3.2.5. 
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Figure 3.6. – Representative chromatograms obtained by LC-MS/MS showing 
endogenous AEA (A), OEA (B), PEA (C) and the internal standard PEA-d4 (D) in rat 
blood. Blood was extracted and analysed as described in Section 3.2.4. and Section 3.2.5. 
 
As AEA, OEA and PEA are enzyme substrates it was important that FAAH activity was 
stopped as early in the sample preparation process as possible, to minimise analyte 
loss. On collection brains were frozen in liquid nitrogen and stored at -80oC. While still 
frozen, brains were homogenised, then immediately protein precipitated with 
acetonitrile and centrifuged before extraction of the supernatant. Blood on collection 
was immediately protein precipitated with acetonitrile and stored at -80oC until 
analysis without any prior centrifugation.  
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FAAH is predominantly expressed in the brain. For the preparation of brain tissue the 
use of the FAAH inhibitor URB597 was investigated. The principle being that inhibiting 
the enzyme responsible for the degradation of the analytes would minimise analyte 
loss. A comparison was made between calibration lines prepared from brains 
homogenised with and without 10 µM URB597. The homogenates were then extracted 
in the same way as previously described. This was to observe the effect of URB597 on 
FAAH activity in the presence of its substrates at a range of concentrations. The 
presence of URB597 further reduced enzyme activity and thus improved recovery of 
each analyte (Figure 3.7.). 
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Figure 3.7. – Effect of URB597 on AEA stability in brain homogenate. Calibrations lines 
were prepared in brain homogenates either in the absence (open circles) or presence of 10 µM 
URB597 (filled circles). Samples were extracted and analysed as described in Section 3.2.4. and 
Section 3.2.5. 
 
3.3.2. FAAH substrate assay - validation 
 
The method was validated following the FDA approved guidance and principles of 
validation (Table 3.2.).359 The linearity was good, with all calibration lines having R2 
values above 0.99 (Figure 3.8). The limit of quantification (LOQ) was taken as the 
concentration at which the signal:noise ratio = 10. All analytes demonstrated a LOD of 
2 pmol/g wet weight brain and 0.3 pmol/g blood, and a LOQ of 7 pmol/g wet weight 
brain and 0.9 pmol/mL blood. All samples contained levels of AEA, OEA and PEA above 
the LOQ. 
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Figure 3.8. – AEA, OEA and PEA calibration lines prepared in (A) rat brain and (B) whole 
blood. Samples were extracted and analysed as described in Section 3.2.4. and Section 3.2.5. 
 
For brain and blood the extraction repeatability was calculated for 10 different extracts 
(Table 3.2.). The intra-injection repeatability was calculated for the same extract 
injected onto the column 10 times. The high variation seen with AEA in blood is most 
likely due to its lower endogenous levels and shorter biological half life compared to 
OEA and PEA.221, 360 The higher variation in blood than brain for the 3 substrates is 
most likely due to the endogenous levels being lower in this tissue. 
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Table 3.2. – Summary of validation parameters for AEA, OEA and PEA in brain and blood 
by LC-MS/MS 
 AEA OEA PEA 
Brain    
LOD (pmol/g) 2 2 2 
LOQ (pmol/g) 7 7 7 
Extraction repeatability 8% 6% 8% 
Injection repeatability 6% 2% 3% 
Recovery 94 ± 7% 93 ± 8% 92 ± 4% 
Ion suppression -10 ± 1% -13 ± 3% -15 ± 2% 
    
Blood    
LOD (pmol/mL) 0.3 0.3 0.3 
LOQ (pmol/mL) 0.9 0.9 0.9 
Extraction repeatability 32% 12% 4% 
Injection repeatability 28% 10% 6% 
Recovery 103 ± 6% 101 ± 7% 102 ± 11% 
Ion suppression 9 ± 1% 7 ± 1% 7 ± 2% 
LOD and LOQ defined as signal:ratio = 3 and 10 respectively. For extraction repeatability, 
samples were repeatedly extracted, assayed and expressed as the coefficient of variation (n=10). 
For intra-injection repeatability, a single extracted sample was repeatedly assayed and expressed 
as the coefficient of variation (n=10). Concentrations of 100 ng/mL were used for each analyte. 
Values were calculated using peak areas and expressed as the mean percentage ± SD (n = 6). 
Samples were extracted and analysed as described in Section 3.2.4. and Section 3.2.5. Recovery 
and ion suppression were determined using peak areas. Concentrations of 50 ng/mL were used 
for each analyte. Values expressed as the mean percentage ± SD (n = 6). Samples were 
extracted and analysed as described in Section 3.2.4. and Section 3.2.5. 
 
Recovery and ion suppression were determined for AEA, OEA and PEA in both brain 
and blood (Table 3.2.). For recovery, brain and blood was spiked with 50 ng/mL of the 
analytes and then extracted. The peak area was compared to that of brain and blood 
extracted first and then spiked with the analyte. Both groups were corrected for 
endogenous background levels and expressed as a percentage. As long as the 
extraction method is reproducible, recovery need not be near 100%, ideally being 
within a ± 20% limit. For ion suppression, a comparison was made between brain and 
blood that was extracted and then spiked with 50 ng/mL of the analytes, to that of a 
50 ng/mL solution of the analytes. Again endogenous levels were corrected for and the 
result was expressed as a percentage. Ion suppression values should also be within a 
± 20% limit, with the values being well within this limit. 
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Brain homogenate was spiked at 100 ng/mL with either AEA, OEA or PEA. Samples 
were then stored on ice for different periods of time before being extracted and 
analysed. No significant degradation was observed over the first five hours (Figure 
3.9.). In reality brain samples were extracted immediately after homogenisation. The 
long term stability of samples was not tested as samples were not stored long term. 
Samples were analysed within a couple of days of collection.  
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Figure 3.9. – Stability of analytes in brain homogenate. 100µL brain homogenates were 
spiked with either 100 ng/mL AEA, OEA or PEA and stored on ice over the time course. Samples 
were extracted and analysed as described in Section 3.2.4. and Section 3.2.5. Data expressed as 
mean ± SD (n = 3). 
 
Brains were homogenised in a buffer containing the non-ionic surfactant Triton X-100, 
which at a low concentration will solubilise membrane proteins to help maintain their 
native state structure.361 This treatment was required for the FAAH activity assay. To 
confirm the utility of this solution in the sample preparation stage, it was investigated 
as to whether the buffer would cause any matrix effects. Calibration lines were 
prepared from brain homogenates treated with either H2O or in this buffer. No 
difference was seen in the calibration line’s gradient and linearity for either treatment, 
proving that this was a suitable buffer. 
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3.3.3. Effect of URB597 on brain and blood FAAH substrate levels in an in vivo 
inflammatory pain model 
 
Rats injected with FCA showed a reduced weight distribution on the inflamed paw by 
90 ± 10% (Figure 3.10.).  
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Figure 3.10. – Reversal of FCA-induced hypersensitivity by URB597 in rats. Rats (n = 18) 
were injected with FCA and left for 24 hours. Within each group naïve (n = 6), vehicle (n = 6) or 
URB597 (10 mg/kg i.p.) (n = 6) treatments were given. Weight bearing on the left hind paw was 
determined and expressed as % reversal of FCA-induced hypersensitivity. Data expressed as 
mean ± SEM. Statistical analysis was by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 0.001 
in comparison with naïve and vehicle treatments. 
 
FCA did not change FAAH activity (Figure 3.11. A) or FAAH substrate levels in the brain 
(Figure 3.12.). However it did reduce FAAH activity in the blood by 40% (Figure 3.11 
B), despite blood FAAH substrates being unchanged (Figure 3.13). At 10 mg/kg, 
URB597 reversed the FCA-induced hypersensitivity by 80 ± 15% (Figure 3.10.), 
indicating that URB597 was analgesic. FAAH activity was significantly inhibited in both 
brain and blood by URB597 (Figure 3.11.). URB597 significantly increased the brain 
and blood FAAH substrate levels in comparison to naïve and vehicle treatments 
(Figures 3.12 & 3.13). This effect was seen in both the control and FCA groups. 
 
In comparison between the FCA vehicle and FCA URB597 treatments the concentration 
of brain PEA increased the most (2700 ± 380 pmol/g), followed by OEA (1830 ± 220 
pmol/g) then AEA (70 ± 16 pmol/g). In the blood, OEA increased the most (105 ± 20 
pmol/mL), followed by PEA (50 ± 6.6 pmol/mL), then AEA (4 ± 0.6 pmol/mL). 
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Figure 3.11. – Percentage FAAH activity in (A) brain and (B) blood of rats with or 
without FCA, either untreated (naïve), treated with vehicle or treated with the FAAH 
inhibitor URB597. Rats were either untreated (n = 18) or injected with FCA (n = 18), then left 
for 24 hours. Within each group naïve (n = 6), vehicle (n = 6) or URB597 (10 mg/kg i.p.) (n = 6) 
treatments were given as per Section 3.2.6. Brain and blood was collected 1 hour after 
treatment. % FAAH activity was determined. Data expressed as mean ± SEM. Statistical analysis 
was by ANOVA with Tukey’s post-hoc analysis. ** = p ≤ 0.01 and *** = p ≤ 0.001. Comparisons 
made between naïve and URB597 treatments. Other comparisons depicted on figures. 
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Figure 3.12. – Brain levels of AEA (A), OEA (B) and PEA (C) in rats without (control) or 
with FCA that were either untreated (naïve), treated with vehicle or treated with the 
FAAH inhibitor URB597. Rats were either untreated (n = 18) or injected with FCA (n = 18), 
then left for 24 hours. Within each group naïve (n = 6), vehicle (n = 6) or URB597 (10 mg/kg 
i.p.) (n = 6) treatments were given. Brain was collected 1 hour after treatment. Samples were 
extracted and analysed as described in Section 3.2.4. and Section 3.2.5. Data expressed as mean 
± SEM. Statistical analysis was by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 0.001 in 
comparison with the URB597 treatment group to the naïve and vehicle treatments. 
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The vehicle had no effect on hypersensitivity or FAAH activity. While in brain the 
vehicle had no effect on FAAH substrate levels, there was interestingly a significant 
increase in blood PEA levels in both the control and FCA groups (Figure 3.13. C).  
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Figure 3.13. – Blood levels of AEA (A), OEA (B) and PEA (C) in rats untreated (naïve), 
treated with vehicle or treated with the FAAH inhibitor URB597. Rats were either 
untreated (n = 18) or injected with FCA (n = 18), then left for 24 hours. Within each group naïve 
(n = 6), vehicle (n = 6) or URB597 (10 mg/kg i.p.) (n = 6) treatments were given. Blood was 
collected 1 hour after treatment. Samples were extracted and analysed as described in Section 
3.2.4. and Section 3.2.5. Data expressed as mean ± SEM. Statistical analysis by ANOVA with 
Tukey’s post-hoc analysis. ** = p ≤ 0.01 and *** = p ≤ 0.001 in comparison with the URB597 
treatment group to the naïve and vehicle groups. 
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For the FCA group treated with URB597 blood was collected before and after FCA, and 
after dosage of URB597. No difference was seen before and after FCA. AEA, OEA and 
PEA were significantly increased after URB597 (Figure 3.14.). 
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Figure 3.14. – Blood levels of AEA (A), OEA (B) and PEA (C) in rats before and after FCA 
injection, and then after treatment with the FAAH inhibitor URB597. Blood was collected 
from rats (n = 6) before injection of FCA, 24 hours after the injection, URB597 (10 mg/kg i.p.) 
was dosed and blood was collected again 1 hour later. Samples were extracted and analysed as 
described in Section 3.2.4. and Section 3.2.5. Data expressed as mean ± SEM. Statistical analysis 
by paired two-tailed t-test. *** = p ≤ 0.001 in comparison with both the before FCA group. 
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3.3.4. Effect of the PF-04457845 and two non-covalent inhibitors, NC1 and NC2, on 
brain and blood FAAH substrate levels in an in vivo inflammatory pain model 
 
The two non-covalent FAAH inhibitors, NC1 (10 mg/kg i.p.) and NC2 (10 mg/kg i.p.) 
did not increase FAAH substrate levels in either brain or blood, with the exception of a 
small increase in blood OEA levels by NC2 (Figure 3.15. & 3.16.).  
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Figure 3.15. – Brain levels of AEA (A), OEA (B) and PEA (C) in rats treated with either 
the non-covalent FAAH inhibitors, NC1 or NC2, or the covalent FAAH inhibitor  
PF-04457845. Rats were injected with FCA and 24 hours later treated with either an inhibitor or 
its vehicle. NC1 (10 mg/kg i.p.) and NC2 (10 mg/kg i.p.) were dosed with the vehicle methyl 
cellulose (MC). PF-04457845 (3 mg/kg i.p.) was dosed with the vehicle 5% DMA and 95% 
cyclodextrin. Brain was collected 1 hour after dosage. Samples were extracted and analysed as 
described in Section 3.2.4. and Section 3.2.5. Data expressed as mean ± SEM (n = 5 per group). 
Statistical analysis by ANOVA with Tukey’s post-hoc analysis. *** = p ≤ 0.001 in comparison to 
their corresponding vehicle groups. 
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The covalent FAAH inhibitor PF-04457845 (3 mg/kg i.p.) significantly increased brain 
OEA (310 ± 110 pmol/g) and PEA (710 ± 220 pmol/g) levels, and blood AEA (3.3 ± 
0.7 pmol/mL), OEA (14 ± 3 pmol/mL) and PEA (18 ± 4 pmol/mL) levels. Despite these 
increases brain AEA levels were unchanged by inhibition. 
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Figure 3.16. – Blood levels of AEA (A), OEA (B) and PEA (C) in rats treated with either 
the non-covalent FAAH inhibitors, NC1 or NC2, or the covalent FAAH inhibitor PF-
04457845. Rats were injected with FCA and 24 hours later treated with either an inhibitor or its 
vehicle. NC1 (10 mg/kg i.p.) and NC2 (10 mg/kg i.p.) were dosed with the vehicle methyl 
cellulose (MC). PF-04457845 (3 mg/kg i.p.) was dosed with the vehicle 5% DMA and 95% 
cyclodextrin. Blood was collected 1 hour after dosage. Samples were extracted and analysed as 
described in Section 3.2.4. and Section 3.2.5. Data expressed as mean ± SEM (n = 5 per group). 
Statistical analysis by ANOVA with Tukey’s post-hoc analysis. * = p≤ 0.05 and *** = p ≤ 0.001 
in comparison to their corresponding vehicle groups. 
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3.3.5. Dose response of the non-covalent FAAH inhibitor, NC3, on brain and blood 
FAAH substrate levels in an in vivo inflammatory pain model 
 
NC3, a non-covalent FAAH inhibitor that lacks the ability to cross the blood-brain 
barrier, failed to increase any of the brain FAAH substrate levels at doses 3 – 30 
mg/kg (Figure 3.17. & 3.18.). A minor exception was that in blood low increases of 
OEA (16 ± 7 pmol/mL) and PEA (13 ± 8 pmol/mL) were seen at the highest dose, 30 
mg/kg. 
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Figure 3.17. – Dose response of a non-covalent FAAH inhibitor, NC3, on rat brain levels 
of AEA (A), OEA (B) and PEA (C). Rats were injected with FCA and 24 hours later treated with 
either the inhibitor NC3 (3, 10 or 30 mg/kg) or its vehicle methyl cellulose (MC). Brain was 
collected 1 hour after dosage. Samples were extracted and analysed as described in Section 
3.2.4. and Section 3.2.5. Data expressed as mean ± SEM (n = 6 per group). Statistical analysis 
by ANOVA with Tukey’s post-hoc analysis.  
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Figure 3.18. – Dose response of a non-covalent FAAH inhibitor, NC3, on rat blood levels 
of AEA (A), OEA (B) and PEA (C). Rats were injected with FCA and 24 hours later treated with 
either the inhibitor NC3 (3, 10 or 30 mg/kg) or its vehicle, methyl cellulose (MC). Brain was 
collected 1 hour after dosage. Samples were extracted and analysed as described in Section 
3.2.4. and Section 3.2.5. Data expressed as mean ± SEM (n = 6 per group). Statistical analysis 
by ANOVA with Tukey’s post-hoc analysis. * = p≤ 0.05 and *** = p ≤ 0.001 in comparison with 
the vehicle group. 
 
3.3.6. Effect of the COX-2 inhibitor, celecoxib, on brain and blood FAAH substrate 
levels in an in vivo inflammatory pain model 
 
Celecoxib is a selective COX-2 inhibitor (IC50 = 40 pmol/mL) that functions as an 
analgesic and anti-inflammatory through its inhibition of prostaglandin synthesis.362 
The selective COX-2 inhibitor, celecoxib, was used to investigate whether the FAAH 
substrates would be affected by an analgesic that worked independent of FAAH. 
A 
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C 
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Celecoxib (10 mg/kg i.p.), failed to increase brain or blood AEA, OEA or PEA levels 
(Figure 3.19.). 
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Figure 3.19. – Brain (A) and blood (B) levels of AEA, OEA and PEA in rats treated with 
and without celecoxib. Rats (n=12) were injected with FCA and 24 hours later treated with 
either celecoxib (10 mg/kg i.p.) (n=6) or its vehicle methyl cellulose (n=6). Brain and blood was 
collected 1 hour after treatment. Samples were extracted and analysed as described in Section 
3.2.4. and Section 3.2.5. Data expressed as mean ± SEM (n = 6 per group). Statistical analysis 
by ANOVA with Tukey’s post-hoc analysis. 
 
3.3.7. Oxidative metabolism of the FAAH substrates in liver microsomes 
 
The oxidative metabolism of the FAAH substrates was investigated using liver 
microsomes. The preparation of liver microsomes selectively concentrates cytosolic 
intracellular enzymes, therefore the membrane bound FAAH protein should be absent. 
However as FAAH is highly expressed in liver it was necessary to initially investigate 
FAAH activity in liver microsomes. Microsomes were incubated with 0.5 µM URB597 for 
15 minutes before either AEA, OEA or PEA was added. The rate of metabolism of the 
FAAH substrates by the liver microsomes was identical to those without URB597 
(Figure 3.20.), demonstrating that the liver microsomes lacked FAAH activity. 
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Figure 3.20. – Oxidative metabolism of AEA (A), OEA (B) and PEA (C) by liver 
microsomes with and without URB597. AEA, OEA and PEA (0.5 µM) were added separately to 
0.5 mg/mL liver microsome suspensions with (squares) and without URB597 (0.5 µM) (circles) 
and incubated at 37OC over a 30 minute time course. Reactions were stopped by protein 
precipitation. FAAH substrates were not quantitated, with the peak area ratio to the internal 
standard instead being used. Intrinsic clearance was assayed as per Section 3.2.7. 
 
Having demonstrated that FAAH does not contribute to the substrate metabolism in 
liver microsomes, the intrinsic clearance of AEA, OEA and PEA was investigated. No co-
factor loss, t1/2 (half life), intrinsic clearance (CLi) and the rate constant (k) were all 
determined. AEA was more readily metabolised by non-FAAH enzymes than OEA and 
PEA, as demonstrated by its short t1/2 and fast clearance (Figure 3.21.). High no co-
factor losses were seen for each substrate, indicating that non-cytochrome P450 
metabolism was also occurring.  
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No co-factor loss: 83%  t1/2: 5:16 
CLi: 10.0 mL/min/g liver  k: 0.09 
 
Figure 3.21. – Kinetics of the oxidative metabolism of AEA (A), OEA (B) and PEA (C) by 
rat liver microsomes. AEA, OEA and PEA (0.5 µM) were added separately to 0.5 mg/mL liver 
microsome suspensions and incubated at 37OC over a 30 minute time course. Reactions were 
stopped by protein precipitation. FAAH substrates were not quantitated, with the peak area ratio 
to the internal standard instead being used. Data expressed as mean ± SD (n = 3). Where no co-
factor loss is the amount oxidised by non-cytochrome P450 pathways, t1/2 is half-life, CLi is 
intrinsic clearance and k is the rate constant. Intrinsic clearance was assayed as per Section 
3.2.7. 
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3.3.8. Protein binding of the FAAH substrates in brain and liver microsomes 
 
The protein binding of the FAAH substrates to brain homogenate and liver microsomes 
was investigated using equilibrium dialysis. OEA and PEA underwent significantly more 
protein binding than AEA in brain (Figure 3.22.). In liver microsomes PEA underwent 
significantly more protein binding than AEA. In both brain and liver microsomes there 
was no significant difference between the protein binding of OEA and PEA. Intrinsic 
clearance values were corrected for protein binding by taking the percentage unbound 
fraction and dividing the intrinsic clearance by this value (Table 3.3.). In brain, AEA is 
considerably less bound to protein than the other two FAAH substrates and is thus 
more available for intrinsic clearance. In microsomes, all three substrates have low 
binding. 
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Figure 3.22. – Protein binding of AEA, OEA and PEA in rat brain and liver microsomes. 
AEA, OEA and PEA (0.3 µM) were added separately to suspensions of either brain or liver 
microsomes on one side of a microdialysis membrane, and left to equilibrate and incubate at 37oC 
(5 hours for brain, 20 hours for microsomes). Samples were collected from both sides of the 
membrane and analysed. Protein binding was expressed as the percentage that is protein bound. 
Data expressed as mean ± SD (n = 6). Statistical analysis by ANOVA with Tukey’s post-hoc 
analysis. * = p≤ 0.05 and *** = p ≤ 0.001 in comparison with AEA. 
 
Table 3.3. – Rat liver microsomal intrinsic clearance (mL/min/g liver) of FAAH 
substrates corrected for protein binding. 
 AEA OEA PEA 
Intrinsic clearance 57.2 27.4 10.0 
    
Corrected intrinsic clearance 336.5 171.2 83.3 
Intrinsic clearance values were corrected for protein binding by dividing the intrinsic clearance by 
the percentage unbound fraction. 
Chapter 3 
98 
3.4. Discussion 
 
3.4.1. FAAH substrate assay 
 
An analytical method for the measurement of AEA, OEA and PEA in brain and whole 
blood was established. Like previous methods,141 the FAAH substrates ionised well 
under positive electrospray forming a prominent 62 m/z ethanolamine ion (Figures 
3.1. – 3.4.). Despite the majority of the previously reported methods using C18 
columns, here a phenyl column was employed. The substrates were less retained, 
allowing for fast run times (Figures 3.5. & 3.6.). The fastest AEA assay currently 
reported method has a 3.5 minute run time, with no resolution of the 3 substrates.277 
The faster gradient used here had a run time of just 2.5 minutes, with likewise all 3 
substrates co-eluting. Previous methods have also lacked resolution of the analytes, 
with analysis not being compromised.278, 279 Likewise the lack of resolution in this 
assay did not compromise analysis, with ion suppression being within ± 15% (Table 
3.2.) and low limits of quantitation (7 pmol/g in brain and 0.9 pmol/mL in blood for 
each analyte) demonstrating good sensitivity. This is small improvement of an earlier 
method that had a LOQ of 10 pmol/g.141 The fast run time made the assay high 
throughput, with 24 samples being run an hour. 
 
The previously reported methods extracted the FAAH substrates using a combination 
of liquid-liquid and solid phase extraction. Here deproteination by acetonitrile was 
investigated. Recoveries were high, within ± 10% (Table 3.2.). It was found that 
concentrating the samples was not a requirement as the concentrations of AEA, OEA 
and PEA were well above the LOQ. Therefore protein precipitation by acetonitrile was 
an appropriate technique that contributed to the assay being high throughput. 
 
To ensure analyte stability a novel approach was employed. The FAAH inhibitor, 
URB597, was used in the sample preparation. The addition of URB597 ensured that 
there FAAH activity was stopped in sample preparation. This was demonstrated to 
significantly increase the stability of the analytes (Figure 3.7.). As non-covalent FAAH 
inhibitors will readily detach from the enzyme, the addition of URB597 in the sample 
preparation was an important step. 
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Validation of the method showed good sensitivity, good linearity, analyte stability, no 
matrix effects, no ion suppression, good recoveries and repeatability, all 
demonstrating the method to be robust. This assay was used to measure the FAAH 
substrates in brain and blood from in vivo studies of inflammatory pain, and also in in 
vitro studies of intrinsic clearance and protein binding. 
 
3.4.2. Effect of FAAH inhibitors on brain and blood FAAH substrate levels in an in vivo 
inflammatory pain model 
 
The measurement of AEA, OEA and PEA in tissue samples is increasingly being used as 
a pharmacodynamic parameter to assess the ability of FAAH inhibitors to increase 
substrate levels.225, 227, 273, 275 The approach was even used to investigate the first 
FAAH inhibitor to enter clinical trials, PF-04457845.184 Typically these studies have 
measured AEA, OEA and PEA. Although one study additionally measured 2-AG, to 
demonstrate that this endocannabinoid was not affected by FAAH inhibition.227 
Furthermore another study measured linoleoyl ethanolamide (LEA), a more recently 
identified substrate of FAAH.184 
 
Here FAAH inhibitors were screened for their ability to increase AEA, OEA and PEA 
levels in the brain and blood from a FCA-induced hypersensitivity rat model of 
inflammatory pain. In addition to causing hypersensitivity, FCA decreased FAAH 
activity in the blood (Figure 3.11. B), while no change was seen in the FAAH substrate 
levels (Figure 3.13.). Decreased FAAH activity would normally equate to higher 
substrate levels and analgesia, which is obviously not the effect of pro-inflammatory 
FCA. It therefore appears that FAAH activity, FAAH substrate levels and cannabinoid 
receptor-mediated analgesia cannot always be correlated. The fact that FAAH 
substrate levels are not changed with inflammatory pain adds to their utility, as it 
shows that this will not be an interfering factor. 
 
The first inhibitor to be investigated in this study was the well characterised FAAH 
inhibitor URB597, which in accordance with reported results,267 returned weight 
distribution to normal (Figure 3.10.), inhibited FAAH activity (Figure 3.11.) and 
increased AEA, OEA and PEA levels (Figures 3.12. – 3.14.). Blood substrate levels 
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correlated well with brain substrate levels, FAAH activity and analgesia. The implication 
of this is useful clinically as it demonstrates that blood FAAH substrates levels are an 
easily accessible indicator of brain FAAH activity. This in vivo observation was 
translated to humans in the following chapter, where FAAH activity following 
paracetamol was investigated by measuring plasma FAAH substrate levels. 
 
The drug vehicle used for URB597 (2% DMSO, 65% PEG-400 and 33% H2O) 
significantly increased blood PEA levels (Figure 3.13. C) indicating that this was a 
peripheral not central response. However FAAH activity and weight distribution were 
not changed. Therefore FAAH substrate levels again did not correlate with FAAH 
activity and analgesia. Similarly the substrate levels seen with the vehicle DMA were 
significantly higher than those seen with the other vehicle methyl cellulose (Figure 
3.15.) Consequent studies accounted for this difference by comparing substrate 
increases between drug vehicle and drug dose groups, an approach also used in 
previously reported studies.225 
 
The initial investigation of the substrates using the inhibitor URB597 provided 
important information for future experimental design. Blood was no longer collected 
before and after FCA as no change in substrate levels were seen. Blood was no longer 
taken before and after drug dose, as comparisons were instead made between groups 
dosed with the vehicle. As there was little difference between the FCA and control 
groups, only FCA pain models were subsequently used. Finally as a difference between 
naïve and vehicle levels was seen, future studies accounted for this by not using naïve 
groups and instead evaluated FAAH inhibitors on the concentration difference between 
the drug vehicle and the dose groups.  
 
Various FAAH inhibitors were screened for their ability to increase substrate levels, 
with dose responses and CNS penetration being investigated (Table 3.4.). Both 
covalent inhibitors, URB597 and PF-04457845, significantly increased FAAH substrate 
levels. In comparison the non-covalent inhibitors and the COX-2 inhibitor celecoxib 
failed to increase AEA, OEA and PEA levels. Like the FAAH inhibitors, celecoxib is also 
beneficial in the treatment of inflammatory pain. It was used here to demonstrate the 
specificity of measuring AEA, OEA and PEA as indicator of analgesia via FAAH than via 
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COX. None of the investigated inhibitors were capable of elevating substrate levels 
beyond that of URB597.  
 
Table 3.4. – The difference in concentration between vehicle and dose groups for 
various FAAH inhibitors in brain and blood 
 AEA OEA PEA 
 Brain 
(pmol/g) 
Blood 
(pmol/mL) 
Brain 
(pmol/g) 
Blood 
(pmol/mL) 
Brain 
(pmol/g) 
Blood 
(pmol/mL) 
URB597 
(10 mg/kg) 
70 4 1831 106 2698 52 
PF-04457845 
(3 mg/kg) 
0 3.3 310 14 710 18 
NC1 
(10 mg/kg) 
2 0.7 -73 3 -334 1 
NC2 
(10 mg/kg) 
13 0.2 136 5 63 5 
NC3 
(10 mg/kg) 
-5 2 -56 7.3 -90 10 
Celecoxib 
(10 mg/kg) 
-1 0 -46 3 -99 3 
Red values indicate non-significant concentration differences as determined by ANOVA with 
Tukey’s post-hoc analysis. 
 
Significant differences in the FAAH substrate levels were seen in the control groups 
between experiments. For example the variations in the control groups for brain OEA 
levels ranged from 500 – 1300 pmol/g (Figure 3.15. B & 3.12. B),. The baseline levels 
of brain OEA have previously been reported as approximately 200 pmol/mL 
respectively.225 Therefore higher concentrations than previously reported have been 
shown here. Quality controls would have ruled out whether that these variations were 
due to analytical variation, although unfortunately they were not used. The FAAH 
substrates in rats have been shown to be influenced by diurnal variation, with 
substrate concentrations increasing up to 6-fold in the presence of darkness.363 This is 
a possible explanation for the variation in control levels seen between the 
experiments. To overcome the observed variation inhibitors were compared on the 
concentration difference between vehicle and dose groups, thus cancelling out the 
variation in baseline levels.  
 
In summary, both covalent and non-covalent FAAH inhibitors were screened for their 
ability to increase brain and blood levels of AEA, OEA and PEA. Significant FAAH 
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substrate increases were seen with covalent inhibitors, whereas no change in substrate 
levels was observed for non-covalent inhibitors. 
 
3.4.3. Oxidative metabolism and protein binding of AEA, OEA and PEA 
 
Oxidative metabolites of AEA have been identified in vitro using high AEA 
concentrations incubated on either pure enzymes or liver microsomes.177 These 
metabolites have not yet been shown to be produced physiologically under normal 
conditions,179 but have been identified in FAAH knock outs injected with AEA.181 The 
synthesis of such metabolites is only likely to be in low concentrations in tissue where 
there are high AEA levels and high expression of its oxidising enzymes. Such 
conditions are a possibility following FAAH inhibition in inflamed tissue, and are 
therefore worth investigating. 
 
Here it was shown that AEA undergoes a faster rate of oxidative metabolism by liver 
microsomes and significantly less binding to brain protein than OEA and PEA (Figure 
3.21. & 3.22.). This is the first demonstration of OEA and PEA undergoing oxidative 
non-FAAH metabolism. The no co-factor losses indicate that some of this metabolism is 
via cytochrome P450, while the majority is via other oxidising enzymes present in the 
liver microsomes. 
 
Cytochrome P450 metabolises AEA to 5,6-, 8,9-, 11,12-, and 14,15-
epoxyeicosatrienoic acid ethanolamide (EET-EA), of which 5,6-EET-EA is the most 
potent CB2 agonist.364 The oxidative metabolites of OEA and PEA need to be 
determined so that it can be investigated as to whether they too have any 
pharmacological action. This data provides the first evidence that that OEA and PEA 
can be metabolised by enzymes other than FAAH, possibly cytochrome P450. To 
extend the understanding of their clearance the isoforms responsible would need to be 
determined. As oleic acid is hydroxylated by the cytochrome P450 isoform 2E1,365 this 
isoform could possibly also oxidise OEA. A useful addition to this study would have 
been the measurement of the oxidative metabolites alongside the substrates over the 
time course. This would have shown the simultaneous metabolism of the substrates 
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and formation of metabolites, allowing for the most abundant metabolites to be 
identified. 
 
Table 3.5. – Chemical properties of the FAAH substrates alongside their rates of 
intrinsic clearance in liver microsomes. 
 Molecular 
weight 
Number of carbons in 
fatty acid chain 
Number of double bonds 
in fatty acid chain 
Intrinsic clearance 
(mL/min/g liver) 
AEA 347.5 20 4 336.5 
     
OEA 325.5 18 1 171.2 
     
PEA 299.5 16 0 83.3 
 
The properties that give AEA its low protein binding probably are probably also making 
it susceptible to oxidative metabolism. Table 3.5. compares the molecular weights, 
carbon length and saturation of the FAAH substrates to the intrinsic clearance, 
suggesting that fatty acid length and saturation influence the metabolic stability of the 
FAAH substrates. 
 
The physiological relevance of these findings is unknown. As discussed earlier the 
oxidative metabolites of arachidonic acids are all well characterised, while the oxidative 
metabolites of AEA are yet to be detected in vivo under normal physiological 
conditions. The concentration of arachidonic acid in the brain is 8 µmol/g compared to 
AEA being 13 – 32 pmol/g.141, 180 Therefore any production of such AEA metabolites 
will only be in low amounts, and may not be of any pharmacological relevance. Given 
their low concentrations very sensitive assays would be required for their detection.  
 
Interestingly the clinical trial of the FAAH inhibitor PF-04457845 showed that following 
dosage the plasma levels of AEA, OEA and PEA levels returned to normal 5 days before 
FAAH activity returned to normal,184 demonstrating their metabolism despite no FAAH 
activity Therefore when FAAH is inhibited in humans there are possibly alternative 
enzymatic pathways available for the metabolism of these accumulated substrates. 
This clinical trial did not show any difference in the rates that these substrates were 
being cleared, suggesting that the finding here that OEA and PEA undergo more 
protein binding and less oxidative metabolism than AEA is not physiologically relevant. 
In conclusion, non-FAAH metabolism of FAAH substrates probably occurs 
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physiologically when FAAH is inhibited, specifically in tissues where there is high 
expression of oxidising enzymes, such as in the liver and inflamed tissue. However the 
differences in rates of oxidative metabolism and protein binding are not likely to be 
physiologically relevant. 
 
3.4.4. Summary 
 
The FAAH substrates AEA, OEA and PEA were measured as a pharmacodynamic 
parameter to evaluate various FAAH inhibitors in an in vivo model of inflammatory 
pain. These studies showed that the blood substrate levels correlate well with brain 
FAAH activity and brain AEA levels. Therefore measuring these substrates in blood is a 
useful indicator of what is happening in the brain. Covalent FAAH inhibitors performed 
much better than non-covalent FAAH inhibitors, due to their irreversible inhibition of 
the enzyme and therefore longer pharmacodynamics. Following this the oxidative 
metabolism and protein binding of these substrates was investigated. OEA was the 
most abundant substrate in brain and blood, however PEA can be measured with the 
most sensitivity by LC-MS/MS, it increases the most with FAAH inhibition, it undergoes 
the least oxidative metabolism and it binds the most to protein. Therefore PEA is 
probably the optimum substrate to measure peripherally in plasma as an indicator of 
FAAH activity centrally. In the following chapter the plasma FAAH substrates levels will 
be measured to investigate paracetamol’s affect on FAAH. 
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CHAPTER 4 
 
 
 
Pharmacokinetics and metabolism of intravenous 
paracetamol in the human cerebrospinal fluid and its 
conjugation to fatty acids via FAAH 
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4.1. Introduction 
 
The endocannabinoids AEA is inactivated in a 2-step process, beginning with reuptake 
into the cell then followed by hydrolysis by FAAH. Paracetamol interferes with both 
steps,164, 292 firstly using FAAH to conjugate paracetamol with arachidonic acid, forming 
AM404. AM404 then inhibits AEA reuptake, blocking its entry into the cell and 
protecting it from inactivation.104 As a result there is an extracellular accumulation of 
AEA in the synaptic cleft, increasing activation of the cannabinoid receptors and 
producing analgesia.260 
 
Figure 4.1. – Structures of AM404, the oleic acid and palmitic acid derivatives of 
paracetamol. AM404 is a conjugate of arachidonic acid and 4-aminophenol that is produced in 
vivo in paracetamol metabolism. The oleic acid and palmitic acid conjugates of paracetamol are 
yet to be identified as paracetamol metabolites.  
 
Given that an arachidonic acid conjugate of paracetamol can be formed by FAAH, it is 
feasible that paracetamol metabolism also forms oleic acid and palmitic acid 
derivatives (Figure 4.1.). The first study to show AM404 synthesis by FAAH did so by 
incubating 4-aminophenol with rat brain homogenate. It was demonstrated that rat 
brain homogenates (in 10 mM TRIS buffer containing 1 mM EDTA at 5-10 mL/g of wet 
tissue), incubated at 37oC for 60 minutes with paracetamol (1 µmol/mL) synthesised 
AM404 (14 pmol/g wet tissue).164 A higher yield of AM404 (250 pmol/g) was obtained 
when paracetamol was replaced with 10 nmol/mL of the intermediate 4-aminophenol. 
Amounts were further increased 6-fold with 100 nmol/mL arachidonic acid. This 
synthesis of AM404 was demonstrated to be FAAH-dependent, with the FAAH inhibitor 
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phenylmethylsulfonyl fluoride (PMSF) preventing its formation.164 Using this previously 
reported technique it will be investigated as to whether other fatty acids can be used 
by FAAH to form novel paracetamol metabolites. Based on their hypothesised 
structures the fragmentation and optimal mass spectrometry conditions for these 
potential metabolites will be extrapolated from those obtained for AM404. Finally then 
the synthesis of potential metabolites will be investigated in brain homogenate 
incubated with 4-aminophenol and either oleic or palmitic acid to determine whether 
these theorised metabolites are actually formed. The inhibitor URB597 will be used to 
show if formation of metabolites is via FAAH. 
 
Following this initial study a clinical trial will be undertaken to comprehensively 
investigate paracetamol’s pharmacokinetics, metabolism and mechanism of action in 
both CSF and plasma following intravenous administration. The pharmacokinetics of 
paracetamol has yet to be studied in the CSF of adult humans. Paracetamol will be 
measured in both the CSF and plasma, allowing for its pharmacokinetic parameters to 
be derived and for the CSF:plasma ratio to be investigated. Alongside paracetamol, its 
metabolites will also be measured, namely its two major metabolites, paracetamol 
glucuronide and paracetamol sulphate, and its minor active metabolite, AM404. 
Currently AM404 has only been investigated in vivo and is yet to be identified as an 
actual metabolite in humans. As FAAH is predominantly expressed in the brain,102 
AM404 should mostly be synthesised there,164, 292 making the CSF the ideal body fluid 
to investigate AM404 formation in humans. 
 
Finally the various endogenous mediators thought to be integral to the mechanism of 
action of paracetamol will also be measured. For COX, both PGE2 and LTB4 will be 
measured, the hypothesis being that COX inhibition should decrease PGE2 levels, 
consequently increasing the amount of arachidonic acid available for LTB4 production. 
Paracetamol’s active metabolite, AM404, is an AEA reuptake inhibitor formed via FAAH. 
To study the interaction with the endocannabinoid system AEA will be measured, 
alongside the other FAAH substrates OEA and PEA. Furthermore paracetamol is known 
to increase 5HT levels in the CNS and for its analgesia to be blocked by 5HT receptor 
antagonists. Therefore to investigate this interaction 5HT will also be measured. 
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4.2. Materials and methods 
 
4.2.1. Materials 
 
AM404, AEA, OEA, PEA, PEA-d4, arachidonic acid and URB597 were from Cayman 
Chemicals (Ann Arbor, Michigan, USA). Paracetamol, paracetamol glucuronide, 
paracetamol sulphate, 3-aminophenol, 4-aminophenol, indomethacin, phosphate 
buffered saline, oleic acid, palmitic acid, serotonin, 5-hydroxyindoleacetic acid and 
tryptophan were from Sigma Aldrich (Poole, UK). Ammonium acetate, potassium 
phosphate and EDTA were from VWR (Lutterworth, UK). Analytical grade methanol, 
acetonitrile, H2O and formic acid were from Fisher Scientific (Loughborough, UK).  
 
4.2.2. Formation and detection of FAAH formed paracetamol metabolites in rat brain 
homogenate 
 
Brain homogenate was prepared from both male and female Random hooded rat 
brains. Brains were homogenised in a buffer containing 125 mM TRIS, 0.4 mM HEPES, 
1 mM EDTA, 0.2% v/v Glycerol and 0.02% v/v Triton X-100 (pH 7.4), which was 
added to brain at 2 mL per gram of wet tissue using an Ultra-turrax handheld high 
speed disperser. 
 
Experiments were carried out in 100 µL aliquots of homogenate incubated at 37oC. 
Reactions were started by adding 1 mM 4-aminophenol. Brain homogenates were 
supplemented with 1 mM of either arachidonic acid, oleic acid or palmitic acid. To stop 
the reaction 100 µL brain homogenate was extracted with 300 µL acetonitrile 
containing 100 ng/mL internal standard, PEA-d4. Samples were vortex mixed and 
centrifuged for 15 minutes at 1,500 g. 50 µL supernatant was transferred into a 96-
well plate and diluted with 50 µL H2O. 
 
LC-MS/MS analysis was performed on a Waters Acquity system attached to a Quattro 
Premier tandem mass spectrometer. The separation was on a Waters Acquity BEH 
Phenyl column (2.1 x 50 mm, 1.7 µm) maintained at 50oC. Gradient elution was 
between mobile phase A (95% H2O, 5% acetonitrile, 0.1% formic acid) and B (95% 
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acetonitrile, 5% H2O, 0.1% formic acid). The gradient ran from 20% B, increasing 
linearly to 90% over 4 minutes at a flow rate of 0.5 mL/min. This was held until 4.5 
minutes, then returned to 20% and allowed to re-equilibrate. The total runtime was 5 
minutes. A 5 µL injection was used. Analytes were quantified by tandem mass 
spectrometry with positive electrospray ionisation. The analytes were detected by 
monitoring the transitions 396  110 m/z for AM404, 374  110 m/z for the oleic acid 
conjugate, 348  110 m/z for the palmitic acid conjugate and 304  62 m/z for the 
internal standard PEA-d4. For all analytes a dwell time of 0.15 seconds, a cone voltage 
of 22 V and a collision energy of 22 V were used. 
 
4.2.3. Patients 
 
The clinical trial was approved by the National Research Ethics Service (East London 
REC 1) and the REC reference number for this study is 10/H0703/80. The ethics 
protocol, ethic approval and MHRA (Medicines and Healthcare products Regulatory 
Agency) approval are included in the Appendix. The study was designed and carried 
out in conjunction with the Pain and Anaesthesia Research Centre at St Bartholomew's 
Hospital, London. 
 
The criteria for recruitment were that patients were between 18 – 80 years old and 
had no known blood clotting abnormalities. 30 patients were recruited from whom full 
written informed consent was obtained. Each patient underwent elective urological 
surgery under spinal anaesthesia, receiving intravenous paracetamol as a routine part 
of their treatment for post-operative pain. In their participation in this trial no 
additional risks to the patient were foreseen. The intravenous paracetamol preparation 
was obtained from Fresenius Kabi (Cheshire, UK). Paracetamol was formulated with 
H2O, cysteine and mannitol. 30 patients received 1 g paracetamol (6.6 mmoles) 
intravenously as a single bolus dose. The clinical aspect to this study was carried out 
by an anaesthetist. 
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4.2.4. Sample collection 
 
The 30 patients were randomised into 3 groups to determine at what time their CSF 
and blood was to be collected. 5 mL of CSF and 10 mL of blood was then collected 
from each patient post dose at one of the three following time points: 15, 30 and 120 
minutes. Blood was collected between 2 - 8 minutes after the CSF. CSF was collected 
prior to the administration of the anaesthetic into EDTA blood vacutainers containing 
17.9 mg of the non-selective COX inhibitor indomethacin, so that after the addition of 
5 mL CSF the final concentration of indomethacin was 10 µM. Blood was collected into 
EDTA blood vacutainers containing 35.8 mg indomethacin, so that after the addition of 
10 mL blood the final concentration was 10 µM. The purpose of indomethacin was to 
prevent further formation of prostaglandins after collection, thus ruling out any 
interference with the PGE2 assay. CSF and blood was centrifuged at 1,400 g at 4oC for 
15 minutes using a MSE Mistral 3000i. CSF and plasma samples were frozen and 
stored at -20oC until analysis.  
 
4.2.5. Protein assay 
 
CSF protein concentrations were determined by a bicinchoninic acid (BCA) assay kit 
(Thermo Scientific, Runcorn, UK) that was used according to the manufacturer’s 
instructions. 
 
4.2.6. Paracetamol assay 
 
For CSF 100µL was diluted with 100 µL mobile phase containing the internal standard. 
For plasma 100 µL was precipitated with 300 µL methanol containing the internal 
standard. 20 µg/mL 3-aminophenol was used as an internal standard as suggested by 
a previously reported assay.366 Samples were centrifuged at 13,000 g for 10 minutes 
using a Heraeus Biofuge 15. 100 µL supernatant was diluted with 100 µL mobile 
phase.  
 
Sample extracts were injected (20 µL for CSF and 10 µL for plasma) and separated on 
a Thermo Scientific C18 column (100 x 4.6mm, 5µm). For CSF, the column was eluted 
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with 50 mM ammonium acetate (pH 5.5) with 1 mM EDTA and 5% methanol using a 
Jasco PU-980 pumping at 1 mL/min. For plasma, 50 mM potassium dihydrogen 
phosphate (pH 6.5) with 1 mM EDTA and 5% methanol was used as the mobile phase. 
Analytes were detected by a Jasco UV-975 UV detector set at a wavelength of 242 nm, 
the same wavelength used in a previously reported assay.366 Jasco Chrompass was 
used for control of system operation and data collection. A 6-point calibration line was 
run between 0 µg/mL – 250 µg/mL for paracetamol and between 0 µg/mL – 100 
µg/mL for paracetamol glucuronide and paracetamol sulphate. The standards used in 
the calibration line were prepared as µg/mL solutions. After quantitation the 
determined sample concentrations were converted to nmol/mL. For CSF the calibration 
line was prepared in PBS, for plasma it was prepared in blank plasma. All CSF samples 
were run on the same day, as were the plasma samples.  
 
4.2.7. AM404 and FAAH substrate assay 
 
For CSF 100 µL of sample was diluted with 100 µL H2O. For plasma 100 µL of sample 
was precipitated with 300 µL acetonitrile containing 100 ng/mL internal standard PEA-
d4. Samples were centrifuged at 13,000 g for 10 minutes using a Heraeus Biofuge 15, 
followed by dilution of 100 µL supernatant with 100 µL H2O. 
 
LC-MS/MS analysis was performed on a Thermo Scientific Accela system attached to a 
Thermo Scientific TSQ Vantage mass spectrometer. The separation was on a Waters 
Acquity BEH phenyl column (2.1 x 50mm, 1.7µm) maintained at 50oC. 10 µL of sample 
was injected onto the column. Gradient elution was between mobile phase A (95% 
H2O, 5% methanol, 0.1% formic acid) and B (95% methanol, 5% H2O, 0.1% formic 
acid). The gradient ran from 5% B, increasing linearly to 95% over 3 minutes at a flow 
rate of 0.5 mL/min. This was held until 5 minutes, then returned to 5% and allowed to 
re-equilibrate. AM404, AEA, OEA and PEA were detected under positive electrospray 
ionisation followed by the monitoring MRM transitions in Table 4.1. 
 
The collision gas was argon, spray voltage was 3500 V, vaporiser temperature was 
300oC, sheath gas pressure was 60 psi, capillary temperature was 270oC, collision cell 
pressure was 1.5 mTorr and no declustering voltage was applied.  
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Table 4.1. – The selected precursor and product m/z values for AM404 and the FAAH 
substrates with their dwell and collision energy used for their identification and 
quantification by LC-MS/MS. 
 Precursor (m/z) Product (m/z) Dwell (s) Collision energy (V) 
AM404 396.3 110.2 0.10 19 
AEA 348.3 62.2 0.10 16 
OEA 326.4 62.2 0.10 16 
PEA 300.3 62.2 0.10 15 
PEA-d4 303.4 62.2 0.10 15 
Where m/z is the mass-to-charge ratio, s is seconds and V is voltage. 
 
A 6-point calibration line 0 ng/mL – 300 ng/mL was prepared, in either blank CSF or 
blank plasma. Calibration lines were prepared for both CSF and plasma. For CSF, 
concentrations were determined by external standard quantitation. An internal 
standard was not used due to the insolubility of lipids in aqueous solutions. For 
plasma, quantitation was by peak area ratio of analyte to the internal standard PEA-
d4. 
 
4.2.8. Prostaglandin E2 assay 
 
PGE2 was extracted from CSF and plasma in accordance to a previously reported 
method 367 that has since been further optimised.288, 368 C18 cartridges (Waters, 
Elstree, UK) were conditioned with 4 mL ethanol then 4 mL H2O. 1 mL of either CSF or 
plasma was applied to the cartridge, which was then washed with 4 mL H2O followed 
by 4 mL 15% methanol in H2O (adjusted to pH 3 with HCl). PGE2 was eluted with 2 mL 
ethyl acetate, which was evaporated using a speed vac and then reconstituted in 200 
µL sodium phosphate buffer (pH 7) with 1% casein for analysis. PGE2 was measured 
using a Cisbio kit (Bagnols-sur-Ceze, France) in accordance with the manufacturer’s 
instructions (see Section 2.2.3.). An 8-point calibration line was run in triplicate from 0 
pg/mL – 5000 pg/mL PGE2. The plate was read using a Berthold Technologies 
(Harpenden, UK) Mithras LB 940 FRET plate reader with FRET being measured and 
expressed as a ratio of 665 nm and 620 nm. The determined final concentrations were 
corrected to account for the sample preparation concentrating the sample 5-fold. 
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4.2.9. Leukotriene B4 assay 
 
CSF and plasma was extracted in the same way as for PGE2. LTB4 was quantified 
using a kit obtained from Cisbio (Bagnols-sur-Ceze, France), which uses the same 
principle as the PGE2 assay. The LTB4 present in the samples competes with XL665-
labelled LTB4 for binding to an anti-LTB4 cryptate-labelled antibody. The fluorescent 
signal is inversely proportional to analyte concentration with the more LTB4 in the 
sample the lower the fluorescent signal. An 11-point calibration line was run in 
triplicate from 0 – 5 µg/mL LTB4. All sample concentrations fell within the range of the 
calibration line. The plate was read using a Berthold Technologies (Harpenden, UK) 
Mithras LB 940 FRET plate reader with FRET being measured and expressed as a ratio 
of 665 nm and 620 nm. The determined final concentrations were corrected to account 
for the sample preparation concentrating the sample 5-fold. 
 
4.2.10. 5HT assay 
 
CSF was diluted 1:1 with 100 mM ammonium acetate (pH 5.5) containing 1 mM EDTA. 
50 µL was injected and separated on a Thermo Scientific C18 column (100 x 4.6mm, 
5µm) eluted with 100 mM ammonium acetate (pH 5.5) with 1 mM EDTA and 6% 
methanol, by a Jasco PU-980 pumping at 1 mL/min. 5HT, tryptophan and 5HIAA were 
monitored using a Jasco FP-920 fluorescent detector at excitation: 290nm and 
emission: 335nm. Jasco Chrompass was used for control of system operation and data 
collection. An 8-point calibration line was run between 0 µmol/mL – 100 µmol/mL.  
 
4.2.11. Pharmacokinetic calculations 
 
Pharmacokinetic parameters were determined using standard equations.369 Transfer in 
and out of the CSF was assumed to be by passive diffusion and that the absorption 
into the CSF was thus by an exponential process. CSF concentration-time curves of 
paracetamol were fitted to a simple pharmacokinetic model to describe its absorption 
into the CSF. Cmax, tmax and t1/2 were derived directly from the graph, where cmax is the 
highest observed drug concentration, tmax is the time at which the cmax is reached and 
t1/2 is the time at which the drug concentration is half that of the cmax. As a delay was 
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expected in paracetamol’s penetration into the CSF following administration due to its 
crossing of the blood-brain barrier, an initial time lag parameter (tlag) was incorporated 
into the model to account for this. The following pharmacokinetic model was used: 
)1(
)(
0
laga ttk
t eCC
−−
−=
 
where Ct is the paracetamol concentration in the CSF at time t, C0 is the extrapolated 
initial paracetamol concentration at time tlag, ka is the rate constant of paracetamol 
absorption into the CSF and tlag is the time lapse between administration and first 
appearance of paracetamol in the CSF.  
 
Plasma concentration-time curves of paracetamol were fitted to an exponential model 
using the following equation: 
t
t eCC
.
0.
λ−
=  
where Ct is the paracetamol concentration in the plasma at time t, C0 is the 
extrapolated initial paracetamol concentration at time t0 and λ is the rate constant. 
Cmax, tmax and t1/2 were derived directly from the graph.  
 
Area under the curve (AUC), the measure of the drug’s plasma exposure over a time 
period, was calculated using the following equation: 
λ
0
0
C
AUC =
∞−
 
where AUC0-∞ is the AUC extrapolated to infinity, C0 is the extrapolated initial 
paracetamol concentration at t0 in nmol/mL and λ is the rate constant, which in this 
case is the exponential function derived from exponential model fitted to the graph to 
describe the pharmacokinetics. 
 
Plasma clearance (CL), the measure of drug removal from plasma, was calculated 
using the following equation: 
∞−
=
0AUC
Dose
CL  
where dose is the amount of drug administered in moles and AUC0-∞ is the AUC 
extrapolated to infinity. 
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Volume of distribution (VD), the apparent volume of body fluid at which the drug 
distributes itself in at equilibrium, was calculated using the following equation: 
λ
CL
VD =  
where CL is clearance and λ is the rate constant. 
 
Pharmacokinetic parameters were calculated in Microsoft Excel 2003. Concentration-
time curves were fitted using the Excel Solver tool, with R2 being used to express 
correlation. 
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4.3. Results 
 
4.3.1. Detection of fatty acid paracetamol conjugates in brain homogenate 
 
As oleic acid and palmitic acid conjugates of paracetamol were not available, their 
structures, their precursor and product ions and their optimal MS/MS conditions and 
liquid chromatography were all deduced using knowledge of the structure and 
chemistry of AM404 as explained below. 
 
AM404 has a molecular weight of 395.5 and is comprised of arachidonic acid, which 
has a molecular weight of 304.5 and 4-aminophenol, which has a molecular weight of 
109.1. To get to the final weight of 395.5, arachidonic acid loses an –OH- ion (17 m/z) 
and 4-aminophenol loses a –H+ ion (1 m/z), in a condensation reaction forming H2O. 
 
Arachidonic acid  +  4-aminophenol   AM404 
304.5 -17  + 109 -1   = 395.5 
 
Following this it can be assumed that as oleic acid and palmitic acid have molecular 
weights of 282.5 and 256.6, that the molecular weights of their conjugates are 373.5 
and 347.5 respectively. 
 
Oleic acid   +  4-aminophenol  Oleic acid conjugate 
282.5 -17  + 109 -1  = 373.5 
 
Palmitic acid   +  4-aminophenol  Palmitic acid conjugate 
256.6 -17  + 109 -1  = 347.6 
 
From these calculations the molecular weights of oleic acid and palmitic acid 
conjugates of paracetamol were determined to be 373.5 and 347.6 respectively. The 
optimal MS/MS conditions for these compounds were extrapolated from those of 
AM404 (Table 4.2.). Under direct-infusion positive electrospray ionisation, AM404’s 
precursor ion was 396.262 m/z, which formed a 109.931 m/z fragment corresponding 
to 4-aminophenol (Figure 4.2.). It was assumed that the other conjugates would also 
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form this same fragment ion, therefore the product ion, dwell time, cone voltage and 
collision energy were kept the same. 
 
 
Figure 4.2. - Product ion mass spectrum and corresponding structure for AM404 (396.3 
 109.9 m/z) following collision induced dissociation by positive electrospray 
ionisation and fragmentation by MS/MS. Site of fragmentation is identified on the figure. 
MS/MS conditions described in Table 4.2. 
 
Table 4.2. – The precursor and product m/z value for AM404 and extrapolated values 
for the oleic acid conjugate and palmitic acid conjugate of 4-aminophenol with the 
dwell and collision energy used for their identification and quantification by LC-MS/MS. 
 Precursor 
(m/z) 
Product  
(m/z) 
Dwell 
(s) 
Cone voltage 
(V) 
Collision energy 
(V) 
AM404 396.262 109.931 0.15 22 22 
      
Oleic acid conjugate 374.262 109.931 0.15 22 22 
      
Palmitic acid conjugate 348.262 109.931 0.15 22 22 
Where m/z is the mass-to-charge ratio, s is seconds and V is voltage. 
 
Given that AM404 is essentially a structural analogue of AEA the same LC conditions 
detailed in Section 3.2.5. were used. The gradient time was extended from 2.5 
minutes to 5 minutes, which is more suitable for metabolite profiling. To determine if 
there were endogenous compounds that shared the same MRM transitions as AM404 
and the hypothesised fatty acid conjugates of paracetamol control rat brain 
homogenate was analysed. Rat brains were homogenised as described in Section 
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3.2.4. With the exception of the oleic acid conjugate where a few minor peaks were 
detected, no other peaks were found at the other MRM transitions (Figure 4.3.). The 
LC conditions were therefore suitable for the detection of these compounds. 
 
 
 
 
 
Figure 4.3. – LC-MS/MS chromatograms of control rat brain demonstrating that (A) 
AM404, (B) oleic acid conjugated paracetamol and (C) palmitic acid conjugated 
paracetamol are not endogenous. Samples were analysed using the methodology described in 
Section 4.2.2. 
 
Brain homogenates were prepared for analysis by deproteination with acetonitrile. 100 
µL rat brain homogenate was extracted with 300 µL acetonitrile containing 100 ng/mL 
internal standard, PEA-d4. To ensure that this was a suitable approach, recovery and 
ion suppression of AM404 was investigated. Recovery was 109 ± 4% and ion 
suppression was 18 ± 6%. Recovery and ion suppression were well within a ± 20% 
limit, concluding that this approach was well suited for these analytes. 
 
C 
B A 
Chapter 4 
119 
4.3.2. Formation of fatty acid paracetamol conjugates by FAAH in rat brain 
homogenate 
 
It was initially verified as to whether AM404 could be synthesized ex vivo in rat brain 
homogenates as previously reported.164 Homogenates were incubated at 37oC with 1 
µmol/mL 4-aminophenol and 1 µmol/mL arachidonic acid, with formation of AM404 
being investigated after 60 minutes (Figure 4.4.). A peak at 3.13 minutes at the 396.2 
-> 109.9 m/z MRM transition confirmed the formation of AM404. URB597 prevented 
AM404 formation, proving FAAH-dependent synthesis. 
 
 
 
 
Figure 4.4. – LC-MS/MS chromatograms demonstrating arachidonic acid conjugation to 
4-aminophenol in rat brain homogenates at (A) 0 minutes, (B) 60 minutes and at (C) 
60 minutes in the presence of URB597. Reactions were started with the addition of 4-
aminophenol (1 µmol/mL). Brain homogenates were supplemented with arachidonic acid (1 
µmol/mL). For the URB597 (100 nmol/mL) treated homogenates the inhibitor was added to the 
buffer before control brain was homogenised, so that FAAH was already inactive when 4-
aminophenol was added. Reactions were stopped by addition of acetonitrile. Samples were 
analysed using the methodology described in Section 4.2.2., with the 396.3  109.9 m/z 
transition being monitored for AM404. 
A 
B 
C 
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Having demonstrated the synthesis of AM404 in brain tissue homogenate, the 
conjugation of other fatty acids to paracetamol was investigated (Figures 4.5. and 
4.6.). Brain homogenates were incubated at 37oC with 1 µmol/mL 4-aminophenol and 
either 1 µmol/mL oleic acid or palmitic acid. Peaks appeared at 3.11 minutes for the 
oleic acid conjugate and at 3.00 minutes for the palmitic acid conjugate. URB597 
prevented formation, proving a FAAH-dependent route of synthesis. 
 
 
 
 
Figure 4.5. – LC-MS/MS chromatograms demonstrating oleic acid conjugation to 4-
aminophenol in rat brain homogenates at (A) 0 minutes, (B) 60 minutes and at 60 
minutes in the presence of (C) URB597. Reactions was started with the addition of 4-
aminophenol (1 µmol/mL). Brain homogenates were supplemented with oleic acid (1 µmol/mL). 
For the URB597 (100 nmol/mL) treated homogenates the inhibitor was added to the buffer before 
control brain was homogenised, so that FAAH was already inactive when 4-aminophenol was 
added. Reactions were stopped by addition of acetonitrile. Samples were analysed using the 
methodology described in Section 4.2.2., with the 374.3  109.9 m/z transition being monitored 
for the oleic acid paracetamol conjugate. 
B 
C 
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Figure 4.6. – LC-MS/MS chromatograms demonstrating palmitic acid conjugation to 4-
aminophenol in rat brain homogenates at (A) 0 minutes, (B) 60 minutes and at 60 
minutes in the presence of (C) URB597. Reactions were started with the addition of 4-
aminophenol (1 µmol/mL). Brain homogenates were supplemented with palmitic acid (1 
µmol/mL). For the URB597 (100 nmol/mL) treated homogenates the inhibitor was added to the 
buffer before control brain was homogenised, so that FAAH was inactive when 4-aminophenol was 
added. Reactions were stopped by addition of acetonitrile. Samples were analysed using the 
methodology described in Section 4.2.2., with the 348.3  109.9 m/z transition being monitored 
for the palmitic acid paracetamol conjugate. 
 
The formation of these conjugates, as well as AM404, was monitored over the course 
of an hour (Figure 4.7.). URB597 was used to demonstrate whether the formation of 
these conjugates was FAAH-dependent. The syntheses of the conjugates were all time-
dependent. AM404 synthesis appeared to peak after 30 minutes. The synthesis of the 
oleic acid conjugate peaked at 40 minutes and then for an unknown reason depleted. 
No conjugates could be detected in homogenate incubated with URB597, concluding 
that their formation was FAAH-dependent. This study showed for the first time that as 
well as arachidonic acid, FAAH can also conjugate oleic acid and palmitic acid to 4-
aminophenol. 
B 
C 
A 
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Figure 4.7. – Time course of the conjugation of (A) arachidonic acid, (B) oleic acid and 
(C) palmitic acid to paracetamol in rat brain homogenates. The presence of 4-aminophenol 
(10 µM) caused time-dependent production of fatty acid conjugates of paracetamol in brain 
homogenates (filled circles) (n = 3). No conjugates were detected in brain homogenate treated 
with the FAAH inhibitor URB597 (100 µM) (open circles) (n = 3). Samples were analysed using 
the methodology described in Section 4.2.2. Data are presented as mean ± SD. 
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4.3.3. Collection of human CSF and plasma samples 
 
The clinical trial lasted 71 days. 30 patients were recruited, 2 of which self-
administered paracetamol within 24 hours of participating in the study and were 
consequently excluded. Of the remaining 28 patients only 2 were female, and were 
also excluded for uniformity. The 26 remaining patients were all adult males between 
34 - 78 years of age, with an average age of 65 ± 12. Their weights ranged from 52 – 
125 kg, with the average of 83 ± 18 kg. Patients were split into 3 groups, with the 
collection of CSF and blood being either 15, 30 or 120 minutes post paracetamol dose. 
Given the inevitable unpredictability of operating theatre schedules precise timing was 
not possible. Instead of fitting in three discrete groups, the data was continuous with 
the time of CSF collection following paracetamol ranging from 10 – 206 minutes and 
for blood ranging from 15 – 211 minutes.  
 
4.3.4. Measurement of total protein in CSF 
 
The average protein concentration in CSF was determined by the bicinchoninic acid 
assay to be 701 ± 103 µg/mL (n = 26). The low amount of protein present in CSF 
meant that it could simply be diluted 1:1 with an appropriate buffer to be ready for 
analysis.  
 
4.3.5. Preliminary investigation of a single method for quantitation of paracetamol and 
its major and minor metabolites 
 
It was initially investigated as to whether paracetamol, paracetamol glucuronide, 
paracetamol sulphate and AM404 could all be assayed by a single method. MS/MS 
readily ionised and fragmented AM404 under positive electrospray. However 
paracetamol and paracetamol sulphate were only weakly ionisable under positive 
electrospray and the glucuronide could only be ionised under negative electrospray. 
Following this LC-UV was investigated as an alternative analytical approach, making 
use of the UV absorbance of paracetamol’s aminophenol group. Given its 
hydrophobicity, AM404 eluted after paracetamol. However there was not adequate 
sensitivity, with the LOD for AM404 being 43 nmol/mL. Separate methodologies were 
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therefore required, with paracetamol and its major metabolites being measured by LC-
UV (Section 4.2.6.) and its minor metabolite AM404 being measured by LC-MS/MS 
(Section 4.2.7.). 
 
4.3.6. Paracetamol assay by LC-UV - optimisation 
 
Different mobile phases were used for the analysis of CSF and plasma. Endogenous 
components in CSF eluted near paracetamol glucuronide (Figure 4.8.). These were 
resolved with 50 mM ammonium acetate (pH 5.5) as opposed to the 50 mM potassium 
phosphate buffer (pH 6.5) used for plasma. The paracetamol glucuronide peak in the 
plasma appears to be two unresolved peaks (Figure 4.9.). Comparison of spiked 
plasma with control plasma showed that this was in fact paracetamol glucuronide.  
 
 
Figure 4.8. – Overlayed LC-UV chromatograms of an extracted CSF sample (red) and a 
standard (black) showing paracetamol and its metabolites. Peaks were identified by 
comparison of an extracted CSF sample post 1 g i.v. paracetamol with a standard of 83 µg/mL 
paracetamol, 33 µg/mL paracetamol glucuronide and 33 µg/mL paracetamol sulphate prepared in 
PBS run using the methodology as described in Section 4.2.6. The internal standard, 3-
aminophenol, is present in both at 20 µg/mL. 
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Figure 4.9. – Overlayed LC-UV chromatograms of an extracted plasma sample (red) and 
a standard (black) showing paracetamol and its metabolites. Peaks were identified by 
comparing an extracted CSF sample post 1 g i.v. paracetamol with a standard of 100 µg/mL 
paracetamol, 83 µg/mL paracetamol glucuronide and 83 µg/mL paracetamol sulphate prepared in 
control run using the methodology as described in Section 4.2.6. The internal standard, 3-
aminophenol, is present in both at 20 µg/mL. 
 
4.3.7. Paracetamol assay - validation 
 
The measurement of paracetamol and its major metabolites was by LC-UV with 
separation being on a C18 column. Before analysing clinical samples the assay for 
paracetamol and its major metabolites was validated (Table 4.3.) following the FDA 
approved guidance and principles of validation.359 
 
The linearity was very good, with all calibration lines having R2 values above 0.99 
(Figure 4.10.). The limit of detection (LOD) and limit of quantification (LOQ) were 
taken as the concentration at which the signal:noise ratio was 3 for LOD and 10 for 
LOQ. With the exception of paracetamol sulphate in some CSF samples, all 
concentrations were above the LOQ.  
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Figure 4.10. – Calibration lines for paracetamol, paracetamol glucuronide and 
paracetamol sulphate prepared in (A) PBS and in (B) plasma measured by LC-UV. 
Standards were analysed using the methodology as described in Section 4.2.6. 
 
The intra-injection repeatability of the described method was determined. This was 
expressed as the coefficient of variation and was below 2% for all analytes. Inter-
assay reproducibility was not investigated as all samples were analysed on the same 
day. Recovery was calculated by comparing samples spiked with standards so that the 
final concentration was 100 µg/mL for paracetamol and 83 µg/mL for it metabolites. 
Recovery was expressed as a percentage. Recoveries fell within a ± 10% range (n = 
4). Validation of the method proved that it was robust enough for the analysis of the 
clinical samples. 
 
A 
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Table 4.3. – Summary of validation parameters for paracetamol, paracetamol 
glucuronide and paracetamol sulphate assay by LC-UV. 
 Paracetamol Paracetamol 
Glucuronide 
Paracetamol 
Sulphate 
3-aminophenol  
 
CSF     
LOD 54 pmol/mL 2 pmol/mL 9 pmol/mL  
LOQ 180 pmol/mL 6 pmol/mL 30 pmol/mL  
Intra-injection 
repeatability 
0.5% 0.6% 0.6% 0.6% 
Recovery 99 ± 0.1% 93 ± 1% 103 ± 0.5%  
     
Plasma     
LOD 0.2 nmol/mL 0.9 nmol/mL 1.2 nmol/mL  
LOQ 0.6 nmol/mL 2.4 nmol/mL 3.9 nmol/mL  
Intra-injection 
repeatability 
0.9% 1.1% 1.2% 1.9% 
Recovery 92 ± 1% 87 ± 1% 93 ± 2%  
LOD and LOQ defined as signal:ratio = 3 and 10 respectively. For intra-injection repeatability, a 
single extracted sample was repeatedly assayed and expressed as the coefficient of variation 
(n=10). Recovery expressed as the mean percentage ± SD (n = 6). Values were calculated using 
peak areas. Concentrations were 100 µg/mL for paracetamol, and 83 µg/mL for paracetamol 
glucuronide and paracetamol sulphate. Samples were extracted and analysed as described in 
Section 4.2.6. 
 
4.3.8. AM404 and FAAH substrate assay - validation 
 
The measurement of AM404 and the FAAH substrates was by LC-MS/MS with 
separation on a phenyl column (Figure 4.11.). The assay for AM404, AEA, OEA and 
PEA was based on the FAAH substrate assay described in Section 3.2.5. and the 
AM404 assay described in Section 4.2.2.  
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Figure 4.11. – Typical LC-MS/MS chromatograms of AM404 in CSF post 1 g intravenous 
(A) paracetamol, (B) 75 pmol/mL AM404 standard prepared in blank CSF and (C) blank 
CSF. Blank CSF was collected from a patient not dosed with paracetamol. Samples were analysed 
using the methodology described in Section 4.2.7. with the 396.3  110.2 m/z transition being 
monitored for AM404. 
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The assay was validated before use (Table 4.4.) following the FDA approved guidance 
and principles of validation.359 Linearity was good, with all calibration lines having R2 
values above 0.97 (Figure 4.12.). The limit of detection (LOD) and limit of 
quantification (LOQ) were taken as the concentration at which the signal:noise ratio 
was 3 for LOD and 10 for LOQ.  
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Figure 4.12. – Calibration lines of AM404 in (A) CSF and (B) plasma. Standards were 
prepared in either control CSF or plasma, and were analysed using the methodology described in 
Section 4.2.7. with the 396.3  110.2 m/z transition being monitored for AM404. 
 
The intra-injection repeatability of the described method was determined. This was 
expressed as the coefficient of variation and was below 10% for all analytes. Inter-
assay reproducibility was not investigated as all samples were analysed on the same 
day. Recovery was calculated by comparing a CSF sample spiked with standards so 
that the final concentration was 100 ng/mL. Recovery was expressed as a percentage. 
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In the case of the FAAH substrates endogenous amounts were corrected for. 
Recoveries fell within a ± 10% range (n = 4). Validation of the method proved that it 
was robust enough for the analysis of the clinical samples. 
 
Table 4.4. – Summary of validation parameters for the AM404 and FAAH substrate 
assay by LC-MS/MS 
 AM404 AEA OEA PEA PEA-d4 (IS) 
CSF      
LOD 0.1 pmol/mL  0.2 pmol/mL  0.7 pmol/mL  0.4 pmol/mL   
LOQ 0.5 pmol/mL 0.5 pmol/mL 2.3 pmol/mL 1.3 pmol/mL  
Intra-injection 
repeatability 
4% 4% 8% 4% 8% 
Recovery 95 ± 8% 93 ± 9% 93 ± 7% 91± 9%  
      
Plasma      
LOD 1.6 pmol/mL  2.0 pmol/mL  2.7 pmol/mL  2.0 pmol/mL   
LOQ 5.0 pmol/mL 7.0 pmol/mL 9.0 pmol/mL 7.0 pmol/mL  
Intra-injection 
repeatability 
9% 9% 2% 4% 7% 
Recovery 101 ± 5% 100± 6% 101± 5% 91± 5%  
LOD and LOQ defined as signal:ratio = 3 and 10 respectively. For intra-injection repeatability, a 
single extracted sample was repeatedly assayed and expressed as the coefficient of variation 
(n=10). Recovery expressed as the mean percentage ± SD (n = 4). Values were calculated using 
peak areas. Concentrations of 100 ng/mL were used for each analyte. Samples were extracted 
and analysed as described in Section 4.2.7. 
 
4.3.9. 5HT assay - validation 
 
The measurement of 5HT, its precursor and its metabolite, was by LC-fluorescence 
with separation on a C18 column. The assay for 5HT, 5HIAA and tryptophan was 
validated before use (Table 4.5.) following the FDA approved guidance and principles 
of validation.359 The 3 analytes were all chromatographically resolved (Figure 4.13.). 
Linearity was very good, with all calibration lines having R2 values above 0.99 (Figure 
4.14.). The limit of detection (LOD) and limit of quantification (LOQ) were taken as the 
concentration at which the signal:noise ratio was 3 for LOD and 10 for LOQ. All 
determined concentrations were above the LOQ. The intra-injection repeatability of the 
described method was determined. This was expressed as the coefficient of variation 
and was below 5% for all analytes. Inter-assay reproducibility was not investigated as 
all samples were analysed on the same day. Recovery was calculated by comparing a 
spiked sample with a standard, correcting for endogenous amounts and then 
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expressing the final value as a percentage. Recoveries fell within a ± 10% range (n = 
6). Validation of the method proved that it was robust enough for the analysis of the 
clinical samples. 
 
 
Figure 4.13. – A typical LC-fluorescence chromatogram of a CSF sample post 1 g 
intravenous paracetamol showing 5HIAA, 5HT and tryptophan. Samples were analysed 
using the methodology as described in Section 4.2.10. 
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Figure 4.14. – Calibration line of 5HIAA, 5HT and TRP prepared in H2O. Standards were 
analysed using the methodology as described in Section 4.2.10. 
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Table 4.5. – Summary of validation parameters for the 5HT assay by LC-fluorescence 
 5HT 5HIAA Tryptophan 
LOD 0.01 nmol/mL 0.03 nmol/mL 0.15 nmol/mL 
LOQ 0.04 nmol/mL 0.1 nmol/mL 0.5 nmol/mL 
Intra-injection 
repeatability 
2% 3% 1% 
Recovery 96 ± 8% 103 ± 7% 106 ± 5% 
LOD and LOQ defined as signal:ratio = 3 and 10 respectively. For intra-injection repeatability, a 
single extracted sample was repeatedly assayed and expressed as the coefficient of variation 
(n=10). Recovery expressed as the mean percentage ± SD (n = 4). Values were calculated using 
peak areas. Concentrations of 5 nmol/mL were used for each analyte. Samples were extracted 
and analysed as described in Section 4.2.10. 
 
4.3.10. Pharmacokinetics of paracetamol in the cerebrospinal fluid and plasma 
following intravenous administration 
 
Following intravenous administration paracetamol was detectable in the CSF as soon 
as 10 minutes at 5 nmol/mL and increased over time (Figure 4.15.). No clearance of 
paracetamol from the CSF was observed over the time course. Therefore the 
pharmacokinetic model fitted to the CSF data could only be used to describe 
absorption. The model showed a significant trend in the accumulation of paracetamol 
in the CSF (R2 = 0.73). The tlag was 5 minutes. After 120 minutes the CSF paracetamol 
concentration appeared to plateau with a Cmax of 76 nmol/mL. The time taken to 
accumulate to half this concentration, 38 nmol/mL, was approximately 43 minutes. 
The time course was not long enough to observe clearance of paracetamol from the 
CSF therefore the t1/2 after the Cmax could not be calculated. For this same reason CL 
and AUC could also not be calculated. VD was determined to be 87 L, this was then 
corrected for the average patient body weight (83 kg), to give a volume of distribution 
of 1.05 L/kg (Table 4.6.). 
 
The plasma pharmacokinetics of paracetamol was described using an exponential fit 
with a trend seen in its plasma clearance over time (R2 = 0.61). The peak plasma 
concentration of paracetamol was immediately following intravenous administration. 
Extrapolating back to t0 determined the Cmax to be 377 nmol/mL. This then decreased 
over the time course with a t1/2 of 100 minutes. AUC0-∞ was calculated to be 53,818 
nmol.min/mL, CL was 122 mL/min and VD was 17.5 L. VD was then corrected for the 
average patient body weight (83 kg), to give a volume of distribution of 0.2 L/kg. At 
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the end of the time course the concentration of paracetamol was approximately 100 
nmol/mL. The CSF:plasma ratio of paracetamol was shown to increase linearly over 
the time course peaking at 0.6 (R2 = 0.85). 
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Figure 4.15. – Time courses of paracetamol in (A) CSF, (B) plasma and (C) the 
CSF:plasma ratio from 26 patients receiving a 1 g intravenous dose of paracetamol. 
Samples were analysed using the methodology described in Section 4.2.6. Data shown are 
combined from 26 patients. The pharmacokinetic models described in Section 4.2.11. were fitted 
to the CSF and plasma data. For the CSF:plasma ratio a linear regression was used.
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Table 4.6. – Summary of pharmacokinetic parameters for paracetamol in CSF and 
plasma from patients receiving a 1 g intravenous dose of paracetamol. 
 CSF Plasma 
C0 (nmol/mL) 5 377 
Cmax (nmol/mL) 76 377 
tmax (min) 200 0 
t1/2 (min) before Cmax  43 - 
t1/2 (min) after Cmax - 100 
AUC (nmol.min/mL) - 53,818 
CL (mL/min) - 122 
VD (L) 87 17.5 
Corrected VD (L/kg) 1.05 0.2 
C0 = concentration at time zero, Cmax = maximum concentration, tmax = time of Cmax, t1/2 = time at 
which concentration is half Cmax, AUC = area under plasma concentration-time curve, CL = 
plasma clearance, VD = volume of distribution, VD was then corrected for average patient 
bodyweight. All parameters were calculated using the formula described in Section 4.2.11. 
 
4.3.11. Metabolism of paracetamol to paracetamol glucuronide, paracetamol sulphate 
and AM404 in the cerebrospinal fluid and plasma following intravenous administration 
 
Paracetamol glucuronide was detectable in the CSF after 10 minutes at a concentration 
of 1.3 nmol/mL, while the sulphate was first detectable after 15 minutes at 0.1 
nmol/mL (Figure 4.16 and 4.17.). Paracetamol glucuronide was identified in all CSF 
and plasma samples. Paracetamol sulphate was identified in all plasma samples, but 
was absent from 9 of the 26 CSF samples. Logarithmic models were fitted to the data 
sets but no trend was seen with concentrations over time for either the glucuronide (R2 
= 0.08) or the sulphate (R2 = 0.11). No pharmacokinetic parameters could be derived 
from these data sets. 
 
The glucuronide and sulphate metabolites were at a much higher concentration in the 
plasma and appeared to accumulate over time. Again logarithmic models were fitted to 
the data sets but no trend was seen with their concentrations over time for either the 
glucuronide (R2 = 0.13) or the sulphate (R2 = 0.09). No pharmacokinetic parameters 
could be derived from this data set. The CSF:plasma ratio for the glucuronide 
metabolite appears to decrease logarithmically with time (R2 = 0.48), whereas no 
trend was seen with the ratio for the sulphate metabolite (R2 = 0.23).  
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Figure 4.16. – Time courses of paracetamol glucuronide in (A) CSF, (B) plasma and (C) 
the CSF:plasma ratio from 26 patients receiving a 1 g intravenous dose of paracetamol. 
Samples were analysed using the methodology described in Section 4.2.6. Data shown are 
combined from 26 patients. Logarithmic curves were fitted to the three data sets. 
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Figure 4.17. – Time courses of paracetamol sulphate in (A) CSF, (B) plasma and (C) the 
CSF:plasma ratio from 26 patients receiving a 1 g intravenous dose of paracetamol. 
Samples were analysed using the methodology described in Section 4.2.6. Data shown are 
combined from 26 patients. Logarithmic curves were fitted to the three data sets. Red points 
represent values at or below the limit of quantification. 
 
A 
B 
C 
Chapter 4 
137 
Each compound was expressed as a percentage of the total combined molar 
concentrations of paracetamol, glucuronide and sulphate (Figure 4.18. and 4.19.). 
With the exception of the first few minutes, paracetamol was the predominant of the 3 
compounds in the CSF over the time course. 
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Figure 4.18. – Time course of (A) paracetamol, (B) paracetamol glucuronide and (C) 
paracetamol sulphate concentrations expressed as a percentage of their combined 
molar concentrations in CSF. Data shown are the combined values from 26 patients. Red 
points represent values at or below the limit of quantification. Logarithmic curves were fitted to 
the three data sets. 
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Like CSF, paracetamol is again the dominant of the 3 compounds in plasma (Figure 
4.19.). However the percentage paracetamol does not stay near 100% like in the CSF, 
but instead decreases to 60% as the other two metabolites are formed. 
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Figure 4.19. – Time course of (A) paracetamol, (B) paracetamol glucuronide and (C) 
paracetamol sulphate concentrations expressed as a total of their combined molar 
concentrations in plasma. Data shown are the combined values from 26 patients. Logarithmic 
curves were fitted to the three data sets. 
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The CSF:plasma ratio was calculated for the combined molar concentrations of the 
paracetamol, glucuronide and sulphate (Figure 4.20.). This value increased 
logarithmically over the time course (R2 = 0.78). 
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Figure 4.20. – Time course of the CSF:plasma ratio for the sum of the paracetamol, 
paracetamol glucuronide and paracetamol sulphate concentrations. Data shown are the 
combined values from 26 patients. The sum of the paracetamol, paracetamol glucuronide and 
paracetamol sulphate concentrations were determined for both CSF and plasma and then 
expressed as the CSF:plasma ratio. A logarithmic curve was fitted to the data set. 
 
Following intravenous administration of paracetamol, AM404 was detectable in the CSF 
after just 10 minutes at 5 nmol/mL. AM404 was detected in 17 of the 26 CSF samples. 
With the exception of one sample, AM404 ranged between 5 - 40 pmol/mL and was 
not changed with time (Figure 4.21.).  
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Figure 4.21. – Time course of the AM404 concentration in CSF from patients receiving a 
1 g intravenous dose of paracetamol. CSF was analysed using the methodology described in 
Section 4.2.7. Data shown are the combined concentrations from 26 patients. Red points 
represent values at or below the limit of quantification. No regression model could be fitted to this 
data set. 
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AM404 was detected in 7 of the 26 plasma samples, with only 3 being above the limit 
of quantification ( >5 pmol/mL). 
 
4.3.12. Formation of oleic and palmitic acid derived metabolites of paracetamol in CSF 
following intravenous administration 
 
Having demonstrated that FAAH is capable of conjugating oleic acid and palmitic acid 
to 4-aminophenol, it was investigated as to whether, like AM404, these potentially 
novel metabolites of paracetamol could be formed in humans. As oleic acid and 
palmitic acid conjugates of paracetamol are not commercially available a compromise 
was required.  
 
A precursor ion scan was used to determine the precursor ions that form the 110.2 
m/z product ion corresponding to 4-aminophenol. For the oleic acid conjugate, product 
ions between 373.741 – 374.941 m/z were scanned, while for the palmitic acid 
conjugate, product ions between 347.741 – 348.941 m/z was scanned.  
 
Chromatograms from CSF where AM404 was high and low were compared (Figure 
4.22. and 4.23.). The assumption being that if significant amounts of AM404 could be 
formed then so could these other metabolites. Due to the number of endogenous 
peaks present in each chromatogram it was not possible to identify which peaks, if 
any, corresponded to the predicted metabolites.  
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Figure 4.22. – LC-MS/MS chromatograms from the precursor ion scan (373.741 – 
374.941 m/z  110.2) for the oleic acid conjugate in CSF when AM404 was (A) high 
and (B) low. 
 
 
Figure 4.23. – LC-MS/MS chromatograms from the precursor ion scan (347.741 – 
348.941 m/z  110.2) for the palmitic acid conjugate in CSF when AM404 was (A) high 
and (B) low. 
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4.3.13. FAAH substrate levels in the CSF and plasma following intravenous 
administration 
 
The effect of paracetamol on FAAH was investigated by measuring the FAAH 
substrates. AEA could not be detected in either the CSF or plasma. OEA and PEA were 
only detected in plasma. No correlation over the time course was found with either 
plasma OEA or PEA levels (Figure 4.24). 
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Figure 4.24. – Time courses of the OEA (A) and PEA (B) concentration in plasma from 
26 patients receiving a 1 g intravenous dose of paracetamol. Samples were analysed using 
the methodology described in Section 4.2.7. Data shown are the combined concentrations from 
26 patients. No regression model could be fitted to this data set. 
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4.3.14. Prostaglandin E2 levels in the CSF and plasma following intravenous 
administration 
 
The effect of paracetamol on COX was investigated by measuring PGE2. The results 
from the analysis showed no change in PGE2 with time in both CSF and plasma (Figure 
4.25.).  
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Figure 4.25. – Time courses of PGE2 levels in the (A) CSF and (B) plasma from 26 
patients receiving a 1 g intravenous dose of paracetamol. Samples were analysed using the 
methodology described in Section 4.2.8. Data shown are the combined concentrations from 26 
patients. No regression models could be fitted to these data sets. 
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4.3.15. Leukotriene B4 levels in the CSF and plasma following intravenous 
administration 
 
The effect of paracetamol on LTB4 was investigated. The results from the analysis 
showed no change in LTB4 with time in both CSF and plasma (Figure 4.26.). 
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Figure 4.26. – Time courses of LTB4 levels in the (A) CSF and (B) plasma from 26 
patients receiving a 1 g intravenous dose of paracetamol. Samples were analysed using the 
methodology described in Section 4.2.9. Data shown are the combined concentrations from 26 
patients. No regression models could be fitted to these data sets. 
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4.3.16. 5HT levels in the CSF and plasma following intravenous administration 
 
The effect of paracetamol on 5HT, its precursor and metabolite, was investigated. No 
changes in 5HT or tryptophan levels were found in the CSF (Figure 4.27.). Only some 
samples contained detectable concentrations of 5HIAA. 
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Figure 4.27. – Time courses of (A) 5HT and (B) tryptophan levels in the CSF from 26 
patients receiving a 1 g intravenous dose of paracetamol. Samples were analysed using the 
methodology described in Section 4.2.10. Data shown are the combined concentrations from 26 
patients. No regression models could be fitted to these data sets. 
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4.4. Discussion 
 
4.4.1. Conjugation of fatty acids to paracetamol via FAAH in brain homogenates 
 
Two novel metabolites of paracetamol were hypothesised and shown to form through 
conjugation of oleic acid and palmitic acid to 4-aminophenol via FAAH in rat brain 
homogenate (Figure 4.1.). These two molecules are absent in control brain tissue, but 
are present in brain homogenates incubated with 4-aminophenol and either oleic acid 
or palmitic acid (Figures 4.5. & 4.6.). They are formed time-dependently and their 
formation is prevented by the FAAH inhibitor URB597. The metabolites have different 
retention times and molecular weights, but each form the same 110 m/z fragment, 
corresponding to 4-aminophenol. Therefore these compounds have different molecular 
weights and hydrophobicities, but share the same 4-aminophenol group and same 
FAAH-dependent route of synthesis as AM404. 
 
Whether formation of these two metabolites actually occurs under physiological 
conditions in humans is yet to be determined. Of the three fatty acids arachidonic acid, 
oleic acid and palmitic acid, the most abundant in the human brain is palmitic acid (20 
µmol/g), followed by oleic acid (17 µmol/g) and then arachidonic acid (8 µmol/g).180 It 
seems likely then that following deacylation of paracetamol in the liver, that more 4-
aminophenol would be converted to the oleic and palmitic metabolites by FAAH than to 
the arachidonic metabolite, AM404. 
 
Further work requires the chemical synthesis and purification of these two metabolites 
so that quantification can be performed using optimal MS/MS conditions. It cannot be 
assumed that the lower response values for the oleic acid and palmitic acid is due to 
less formation of these metabolites, as the method of their detection was not 
optimised for their structures but instead derived from those of AM404. 
 
Inhibiting FAAH reverses the effect of paracetamol suggesting an important role for 
FAAH formed metabolites. It has already been established that AM404 is integral to 
paracetamol’s analgesic action. Now it is important that the activity of the two novel 
metabolites described here also be characterised. AM404 has been shown to relieve 
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pain in in vivo models of nociception, inflammatory pain and neuropathic pain.296 The 
effects of these novel paracetamol metabolites should also be investigated in such in 
vivo models to determine whether they too are analgesic and anti-inflammatory.  
 
Possible routes of biological action for these two metabolites can be hypothesised 
through comparison with the structurally similar lipids OEA and PEA and also to 
AM404. The main action of AM404 is the inhibition of AEA uptake. This ability is due to 
AM404 being a structural analogue of AEA, sharing an arachidonic acid side chain. As 
OEA and PEA are not transported in this same fashion, it is unlikely that oleic acid and 
palmitic acid conjugates of paracetamol will inhibit this same transporter. It also 
seems unlikely that the metabolites would have affinity for the cannabinoid receptors 
as AM404 lacks affinity and so do OEA and PEA. Therefore any effect is likely to be 
independent of the endocannabinoid system. 
 
Two possible biological targets for these metabolites are GPR55 and PPAR-α. GPR55, 
the putative third cannabinoid receptor, is activated by AEA, OEA and PEA. It is 
possible then that the two paracetamol metabolites may also activate it. Likewise, 
AM404 may also have affinity for this receptor. Furthermore OEA and PEA are PPAR-α 
agonists. Although a connection between paracetamol and PPAR is yet to be 
demonstrated, the novel metabolites may be possible activators of this receptor. Of 
course all this depends on whether they reach pharmacologically active concentrations.  
 
Interestingly it is paracetamol’s hydroxyl group that is sulphated and glucuronidated 
and its acetyl group that is conjugated with arachidonic acid. It is therefore possible 
that AM404 sulphate and AM404 glucuronide are also formed during paracetamol 
metabolism. It is also possible that other fatty acid derivatives could be formed from 
fatty acids such as stearic acid and linoleic acid. Furthermore the arachidonic acid side 
chain of AM404 may also be oxidised, like AEA, by COX, LOX and cytochrome P450. 
These theoretical metabolites would all need to be investigated in future work. 
However given the low concentrations of AM404 found here in the CSF, it is unlikely 
that AM404 glucuronide and AM404 sulphate would be detected. 
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In summary, the present findings provide the first evidence that FAAH can conjugate 
oleic acid and palmitic acid to small molecules, and that by this mechanism two 
potential metabolites of paracetamol can be formed. Typically the aim of drug 
metabolism is to decrease lipophilicity to allow for clearance, with water soluble 
molecules, such as glutathione and glucuronic acid, being attached to increase 
solubility. Interestingly in this example FAAH does the opposite and increases the 
lipophilicity of paracetamol by attaching fatty acids to it. 
 
In vivo AM404 has been shown to be formed mostly in the brain and spinal cord and to 
a lesser extent in liver and blood.164 It is feasible that if the oleic acid and palmitic acid 
metabolites are formed in humans that they would be detectable in CSF and blood 
post intravenous paracetamol dose. One aspect of the subsequent clinical trial was to 
investigate whether these two novel metabolites are formed. 
 
4.4.2. Pharmacokinetics of paracetamol in human cerebrospinal fluid and plasma 
 
The three aims of the clinical trial were to study paracetamol’s pharmacokinetics, 
metabolism and mechanism of action. Patients were intravenously administered with 1 
g paracetamol, with single samples of CSF and blood being collected afterwards. Only 
a single CSF sample per patient could be collected due to the clinical limitation of 
collecting multiple CSF samples from each patient. The average volume of CSF in 
humans is 140 mL,308 thus the 5 mL collected per patient here is approximately 3.5% 
of the total volume. Data obtained from each patient was combined into single 
concentration-time plots, where CSF pharmacokinetic parameters were then derived 
(Table 4.7.). 
 
Paracetamol was shown to rapidly enter the CSF and was detectable within the first 10 
minutes (Figure 4.15.). Over the time course it accumulated, peaking at 76 nmol/mL 
towards the end of the time course. The time taken to reach half Cmax was 43 minutes, 
with the Cmax being reach at approximately 200 minutes. The t1/2 after the Cmax could 
not be determined as no clearance was observed over the 200 minutes (Table 4.7.). 
There paracetamol reached and maintained a high concentration, that lasted for 
several hours following its administration. 
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Table 4.7. – Comparison of the CSF paracetamol pharmacokinetics from this study with 
data from a previous study in children. 
 This study Kumpulainen et al. 314 
Patient age 35 – 79 years 3 months – 12 years 
Dose 1000 mg i.v. 15 mg/kg mg i.v. 
C0 (nmol/mL) 5 10 
cmax (nmol/mL) 76 120 
tmax (min) 200 60 
t1/2 (min) before Cmax  43 30 
t1/2 (min) after Cmax - 110 
C0 = concentration at time zero, Cmax = maximum concentration, tmax = time of Cmax, t1/2 = time at 
which concentration is half Cmax. 
 
Currently only a single study on the pharmacokinetics of intravenous paracetamol in 
the CSF has been reported, with a 15 mg/kg dose being investigated in children.320 15 
mg/kg is an approximately equivalent dose to 1 g in an adult human. Due to the 
significant difference in patient age little comparison can be drawn between the studies 
(Table 4.7.). The study in children showed that within 5 minutes paracetamol was 
detectable at 10 nmol/mL and accumulated over time to 120 nmol/mL. Interestingly 
the clinical trial in children and the clinical trial reported here both showed paracetamol 
to be present in the CSF within minutes of administration in the low nmol/mL range. 
However a significant difference between the two studies is that here no clearance of 
paracetamol from the CSF was observed over the 200 minute time course, while in the 
other study paracetamol clearance from CSF began as soon as 60 minutes. 
 
In the plasma paracetamol reached a Cmax of 377 nmol/mL immediately following its 
administration (Figure 4.15.). The t1/2 was reached after 100 minutes. After 200 
minutes paracetamol was still presented in the plasma at a concentration of 
approximately 100 nmol/mL. The plasma pharmacokinetics of paracetamol has been 
well studied following oral administration.315 The pharmacokinetics of intravenous 
administered paracetamol is less well investigated, although it has recently been 
comprehensively studied (Table 4.8.).314 This previous study showed that the Cmax 
following 1 g intravenous paracetamol was 165 nmol/mL, which is a lot lower than the 
377 nmol/mL presented here. This was reportedly cleared from the plasma with a t1/2 
of 156 minutes, which is a lot slower than the 100 minutes presented here. 
Furthermore the AUC, CL and VD values differed significantly from those reported here. 
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Therefore the results from the clinical trial presented here are not consistent with 
previously reported intravenous pharmacokinetics. The reason for this difference is 
unknown.  
 
Table 4.8. – Comparison of the plasma paracetamol pharmacokinetics from this study 
with data from previous intravenous and oral studies. 
 This study Liukas et al. 314 Hinz et al. 315 
Dose 1000 mg i.v. 1000 mg i.v. 1000 mg p.o. 
cmax (nmol/mL) 377 165 105 
t1/2 (min) 100 156 268 
tmax (min) 0 0 75 
AUC (mg.h/mL) 138 48 63 * 
CL (mL/min) 122 349 - 
VD (L/kg) 0.2 0.9 - 
Cmax = maximum concentration, t1/2 = time at which concentration is half Cmax, tmax = time of Cmax, 
AUC = area under plasma concentration-time curve, CL = plasma clearance, VD = volume of 
distribution, VD was then corrected for bodyweight. * = recalculated values from original units. 
 
As expected the Cmax of 1000 mg oral paracetamol (105 nmol/mL) is a lot lower than 
the same dose given intravenously (377 nmol/mL). Interestingly in the clinical trial 
presented here paracetamol was still above 100 nmol/mL in the plasma at the end of 
the time course. Therefore it takes approximately 200 minutes for the plasma 
paracetamol level following an intravenous dose to fall to that of the Cmax of an oral 
dose.  
 
In summary, the results presented here demonstrate that paracetamol rapidly enters 
the CSF where it accumulates over several hours. However significant differences 
between this study and previous studies in terms of plasma pharmacokinetics were 
seen. A potential reason for this is that concentration-time plots were produced from 
combined data from 26 patients. 
 
4.4.3. Metabolism of paracetamol in human cerebrospinal fluid and plasma 
 
The second aim of the clinical trial was to study the metabolism of paracetamol. The 
majority of intravenous paracetamol is known to be cleared as the unmetabolised drug 
and its major metabolites in the urine.370 Previous studies of intravenous paracetamol 
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have not measured the paracetamol glucuronide and paracetamol sulphate, either in 
CSF or plasma. Here the metabolism of paracetamol into its two major metabolites, 
paracetamol glucuronide and paracetamol sulphate, as well as its minor metabolite 
AM404, was investigated in the CSF and plasma. 
 
The major metabolites were detectable in the CSF as soon as 10 minutes post 
intravenous administration (Figures 4.16. & 4.17.). Their concentrations ranged from 1 
- 15 nmol/mL for paracetamol glucuronide and from 0.1 – 1.7 nmol/mL for 
paracetamol sulphate, with the higher concentrations being seen at the beginning of 
the time course. No trend in their concentration over time was found, and no 
pharmacokinetic model could be applied. This is the first time that paracetamol 
glucuronide and paracetamol sulphate have been found in human CSF. The blood-brain 
barrier should be impermeable to large and hydrophilic compounds.309 By an unknown 
mechanism low concentrations of these large and charged molecules either managed 
to cross the blood-brain barrier and consequently enter the CSF, or were actually 
synthesised somewhere within the CNS. The latter seems unlikely given the low 
amount of protein in the CSF and that the majority of drug metabolism occurs in the 
liver. A previously reported study looking at the pharmacokinetics of intravenous 
morphine in the CSF found morphine-6-glucuronide.371 Therefore the presence of 
glucuronidated drug metabolites in the CSF is known, but the reason behind their 
presence here is poorly understood and requires further investigation. 
 
Similar to the CSF, no trend between concentration and time could be seen in the 
plasma for either metabolite and thus standard pharmacokinetic models could not be 
applied. Their concentrations ranged from 10 - 160 nmol/mL for paracetamol 
glucuronide and 10 – 80 nmol/mL for paracetamol sulphate. These concentrations are 
comparable to previously reported concentrations following 1 g intravenous 
paracetamol, where paracetamol glucuronide peaked at 60 nmol/mL after 240 
minutes, with paracetamol sulphate peaking much later after 120 minutes at 30 
nmol/mL.314 Their study demonstrated a clear trend in the accumulation and clearance 
of the paracetamol metabolites, and also included pharmacokinetic parameters of the 
metabolites. In contrast this present study showed no trend in the concentration-time 
plots of the metabolites and therefore no pharmacokinetic parameters could be 
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derived. This is most likely because data was used from multiple patients to construct 
single concentration-time plots. Therefore the expected variation between patients, 
such as weight (which ranged from 52 – 125 kg), made it difficult for any trend to be 
observed. 
 
Of the paracetamol metabolites it was paracetamol glucuronide that is the most 
concentrated. In the CSF 5 - 20% of paracetamol was glucuronidated compared to 
only 1 - 4% being sulphated (Figure 4.18.). This was also seen the in plasma, with 
between 20 - 40% of paracetamol being glucuronidated and 5 - 20% being sulphated 
(Figure 4.19.). In summary, the major metabolites of paracetamol, its glucuronide and 
sulphate, are mostly formed within the plasma and as shown here for the first time are 
also present in the CSF, arriving rapidly. 
 
4.4.4. Metabolism of paracetamol to AM404 and other fatty acid conjugates 
 
The results from this study showed for the first time that AM404, the FAAH-formed 
active metabolite of paracetamol and AEA reuptake inhibitor, is formed in humans and 
is present in both the CSF (17 of 26 patients) and plasma (3 of 26 patients). AM404 
concentrations ranged from 5 – 40 pmol/mL in the CSF (Figure 4.21.). 
 
FAAH is mostly expressed in the brain.102 AM404 should therefore mostly be formed in 
the brain, with a small amount crossing into the CSF. This is supported by an in vivo 
study that demonstrates that the majority of AM404 produced following paracetamol 
administration is found in the brain and to a lesser extent in the spinal cord, with 
negligible concentrations being found in the plasma.164 This explains why in the clinical 
trial described here AM404 was found in the CSF, with only a couple of samples 
containing detectable amounts of AM404. The concentration of AM404 is reported to 
be 15-fold higher in the brain than in the spinal cord levels.164 Therefore while low 
levels of AM404 were found here in the CSF, significantly higher levels of this 
metabolite should be found in the brain, but such a study is not possible in humans. 
 
The dose of paracetamol used in this clinical trial was 1 g, which is equivalent to 6.6 
mmoles. The total volume of CSF in the adult human body is on average 140 mL.308 
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Assuming all patients had a CSF volume of 140 mL, then the peak paracetamol CSF 
concentration of 60 nmol/mL seen in this present study is equivalent to a peak mass of 
approximately 8.4 µmoles. Therefore around 0.13% of the dosed paracetamol 
molecules accumulate in the CSF, whereas only 0.004% accumulates as the 
glucuronide and 0.0002% as the sulphate. Even less, approximately 0.0001%, was 
found in the CSF as AM404.  
 
It is difficult to conclude whether the low amounts of AM404 formed in the human CNS 
are of any pharmacological relevance. The carrier protein responsible for AEA reuptake 
that AM404 inhibits, the FAAH-like anandamide transporter (FLAT), has only recently 
been identified.104 AM404 inhibits this protein’s reuptake of AEA with an IC50 of 5.3 
nmol/mL. This is obviously 1000-fold higher than the concentrations found in the CSF, 
but AEA reuptake occurs in neurons of the brain where AM404 levels should be 
significantly higher. 
 
AM404 was found to be present in the CSF at a similar concentration (5 – 40 pmol/mL) 
to the endogenous opioid β-endorphin (12 pmol/mL).372 The other major endogenous 
opioid, met-enkephalin, is present at an even lower concentration of 79 fmol/mL.373 
This demonstrates that the endorphins, enkephalins and potentially AM404, can still be 
potent mediators of pain perception even at low concentrations. Therefore while 
AM404 may be present in the CSF at the pmol/mL range, it does not mean it is 
pharmacologically inactive. 
 
The definitive study to determine whether AM404 reaches a pharmacological relevant 
concentration and consequently produces analgesia via the cannabinoid receptors in 
humans would be by using antagonists. The 5HT receptors were demonstrated to be 
integral to paracetamol’s action in humans in a simple study that investigated the pain 
threshold of subjects receiving paracetamol compared to subjects receiving 
paracetamol and the 5HT3 receptor antagonist tropisetron.
301 Repeating the same 
study, but replacing tropisetron with a cannabinoid receptor antagonist such as 
rimonabant, would demonstrate whether paracetamol’s analgesia is cannabinoid 
receptor-dependent. Unfortunately cannabinoid receptor antagonists, including 
rimonabant, reportedly cause severe depression and have now been withdrawn.374 
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Although a few of the CSF samples and most of the plasma samples did not have 
detectable amounts of AM404, it does not mean they were not present. Due to their 
low concentration the assay used may have lacked the required sensitivity. A future 
refinement of the analytical method may be required to concentrate the samples via 
SPE, for added sensitivity. However this would need to be balanced with the fact that 
only small volumes of CSF can be collected.  
 
It was demonstrated in Section 4.3.2. that FAAH can conjugate other fatty acids to 4-
aminophenol. While the arachidonic acid derived metabolite of paracetamol, AM404, 
was shown here to be formed in humans, it cannot be concluded from this study 
whether the oleic acid or palmitic acid derived metabolites are also formed. Given the 
fact that human brain contains 20 µmol/g palmitic acid, 17 µmol/g oleic acid and 8 
µmol/g arachidonic acid,180 it is possible that more of these novel metabolites should 
be formed than AM404. The analytical approach used here was not successful at 
finding these metabolites (Figure 4.22. & 4.23.). To determine whether these 
metabolites are actually formed an optimised analytical method to be developed, 
which would require the chemical synthesis of the two hypothesised metabolites.  
 
In summary, the formation of AM404 by humans was demonstrated and detected in 
CSF following intravenous paracetamol. As the mechanism of paracetamol is known to 
be dependent on the cannabinoid receptors in vivo, the finding that humans produce 
AM404 supports this although further investigations would be required to definitively 
prove this. The other oleic acid and palmitic acid conjugates of paracetamol could not 
be detected using the methodology used here. 
 
4.4.5. The transfer of paracetamol and its metabolites into the CSF 
 
The CSF:plasma ratio of paracetamol increased linearly over the time course (Figure 
4.15. C). After 200 minutes the ratio was 0.6, indicating that at this point there was 
more than half the amount of paracetamol in the CSF than in the plasma. This is in 
contrast to a previous study looking at intravenous paracetamol in the CSF of children, 
which showed twice as much paracetamol in the CSF than in the plasma after 300 
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minutes.320 The most likely explanation for this observation is the anatomical 
differences between children and adults.  
 
The CSF:plasma ratio is influenced by the simultaneous accumulation of paracetamol 
in the CSF and its metabolism and clearance from the plasma. Due to these dynamics, 
equilibrium between the two compartments should not occur. However a 1:1 
concentration ratio between the two compartments may occur, but would only be 
transient. The CSF:plasma ratio was also calculated for the combined molar 
concentrations of paracetamol and the glucuronide and sulphate metabolites (Figure 
4.20.). This was to rule out the role of metabolism in increasing the CSF:plasma ratio, 
as the paracetamol moiety was investigated as opposed to just paracetamol. This 
demonstrated that the paracetamol moiety, whether unconjugated or conjugated, 
transfers into the CSF by a logarithmic process (R2 = 0.78). The process by which this 
occurs begins to plateau towards the end of the 200 minute time course. Therefore 
while the CSF:plasma ratio of paracetamol alone appears to show that transfer into the 
CSF is a linear process, combining the molar concentrations of paracetamol and its 
metabolites reveals that it follows a more logarithmic transfer mechanism. 
 
In summary, paracetamol is known to be active in the CNS. This is supported by its 
rapid transfer into the CSF. There is still much to be investigated concerning the 
mechanism by which paracetamol enters the CSF, specifically related to how its 
metabolites manage to be transferred there. 
 
4.4.6. Paracetamol’s effect on endogenous pathways 
 
The third aim of the clinical trial was to comprehensively study the mechanism of 
action of paracetamol following intravenous administration. Paracetamol is known to 
inhibit COX and to interact with both the endocannabinoid and serotonin systems. To 
study these interactions various endogenous mediators associated with paracetamol 
were measured in both the CSF and plasma. 
 
Paracetamol is a weak inhibitor of COX-1 and COX-2. It has been reported that the 
IC50 of paracetamol in human whole blood for inhibiting COX-1 is 105 nmol/mL and at 
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COX-2 is 26 nmol/mL.315 This same study showed that 1 g oral paracetamol results in 
a Cmax of 105 nmol/mL and therefore is high enough to significantly inhibit COX-2, but 
not COX-1.315 In this present study the Cmax of 1 g intravenous paracetamol was 377 
nmol/mL in plasma. Therefore the drug was present at a pharmacologically relevant 
concentration for the inhibition of both COX-1 and COX-2 activity over the entire time 
course. In the CSF paracetamol reached a concentration of 76 nmol/mL, which may be 
pharmacologically relevant due to COX-2 being expressed in the spinal cord.66 PGE2 
levels in the brain 287, 288 and spinal cord 375 have previously been shown in in vivo 
studies to be decreased by paracetamol.  
 
Given the pharmacologically relevant concentrations of paracetamol, it was 
hypothesised that inhibition of PGE2 synthesis should be observed in plasma. If such 
inhibition of PGE2 synthesis were to occur then there may also be increased 
arachidonic acid present for the synthesis of LTB4 via LOX. However no change in 
PGE2 or LTB4 was observed in both CSF and plasma over the time course (Figures 
4.25. & 4.26.). As no change was seen in PGE2, it is understandable as to why no 
change was also seen with LTB4. These results were supported by a similar previous 
study that showed orally administered paracetamol did not effect PGE2 levels in 
human plasma.376 Interestingly an in vivo study showed that paracetamol (200 mg/kg) 
was analgesic in rats without reducing brain PGE2 levels.294 Therefore there is 
evidence to support a lack of PGE2 inhibition by paracetamol it certain tissues. It 
should be noted that an in vivo study showed spinal cord injury triggered PGE2 
production in the CSF of rats.377 Whether lumbar puncture also causes PGE2 
production is not known, but it may be an issue here. 
 
The determined concentrations of PGE2 and LTB4 were mostly similar to the known 
endogenous levels of these mediators. In the CSF, PGE2 levels were predominantly 
between 4 – 9 fmol/mL and LTB4 levels were mostly between 30 – 150 fmol/mL. 
These concentrations were similar to previously reported human CSF control levels of 
PGE2 (17 – 43 fmol/mL) 378 and LTB4 (60 – 180 fmol/mL).379 In the plasma, PGE2 
levels were mostly between 140 – 430 fmol/mL, and LTB4 levels were mostly between 
1200 – 2400 fmol/mL. While the PGE2 concentration was similar to previously reported 
control levels in human plasma (100 - 130 fmol/mL),380 the LTB4 concentrations were 
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higher than previously reported levels (60 - 80 fmol/mL).381 The reason for this 
discrepancy is unclear. 
 
The presence of AM404 in human CSF following intravenous paracetamol supports the 
role of the endocannabinoid system in paracetamol’s action. As paracetamol’s active 
metabolite, AM404, is an AEA reuptake inhibitor, it was hypothesised that paracetamol 
may have an affect on AEA levels, particularly in the CSF. Previously reported studies 
assaying AEA by LC-MS/MS showed that the normal concentration of AEA in human 
CSF is between 5 - 9 fmol/ml 382 and between 0.3 – 1.5 pmol/mL in plasma.142 In this 
present study the LC-MS/MS assay lacked adequate sensitivity for the detection of 
AEA. As previous studies concentrated the samples by SPE before analysis, it is likely 
that the samples required pre-concentrating to be detectable. However an in vivo 
study previously showed that paracetamol at a dose of 300 mg/kg was analgesic 
without increasing brain AEA levels.294 Therefore even with adequate sensitivity a 
change in AEA levels may not have been seen. 
 
Furthermore it was hypothesised that as FAAH is required for AM404 synthesis that 
paracetamol may change OEA and PEA levels. In Chapter 3 it was demonstrated that 
in vivo blood OEA and PEA correlated well with brain AEA and brain FAAH activity. 
Previous studies have shown that FAAH substrates are present in the CSF at the 
fmol/mL level.382-384 The LC-MS/MS method used here had inadequate sensitivity for 
their quantitation. There was however adequate sensitivity to quantitate OEA and PEA 
in plasma, however no change in their concentrations over the time course was 
observed (Figure 4.24.). 
 
Paracetamol’s analgesic action is partly dependent on its indirect activation of 5HT 
receptors,300 which it achieves by increasing 5HT concentrations in certain regions of 
the CNS.299 The analgesic effect of paracetamol has been shown to be blocked in 
humans by 5HT antagonists.304 5HT, its precursor tryptophan and its metabolite 5HIAA 
are all naturally fluorescent and were measured in the CSF using a previously reported 
method.385 Plasma was not assayed as 5HT has a different role in blood, being stored 
in platelets and released in clots to act as a vasoconstrictor (narrowing of the blood 
vessels).386 Despite the apparent dependence of paracetamol on the 5HT receptors, no 
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change was seen with either 5HT or its precursor tryptophan (Figure 4.27.). This is not 
surprising as paracetamol does not change in vivo spinal cord 5HT levels.299 The 
endogenous concentration of 5HT in normal human CSF has been reported to be 
between 0.3 – 1.3 nmol/mL.387 Similar concentrations were therefore seen here, with 
5HT levels being shown to range between 0.3 – 0.5 nmol/mL. 
 
As already discussed, the results from the paracetamol pharmacokinetics study 
showed that over time the concentration of paracetamol increased in the CSF and 
decreased in the plasma. Therefore it appears that in the presence of 
increasing/decreasing concentrations of paracetamol that PGE2, LTB4, OEA, PEA and 
5HT were not affected in CSF or plasma. These findings are supported by previously 
discussed in vivo studies that also showed no change in brain PGE2, brain AEA or 
spinal cord 5HT levels following paracetamol administration. 
 
Despite no changes in PGE2, LTB4, OEA, PEA and 5HT being reported here, it cannot 
be concluded that these endogenous mediators are not integral to the action of 
paracetamol. The data from this study is unpaired in that samples were only taken 
from one time point per patient. No comparison before and after paracetamol dosage 
was made. An ideal trial would take CSF before paracetamol administration, so that 
baseline readings of each endogenous mediator could be made, and then at multiple 
time points afterwards. This would demonstrate whether paracetamol altered the 
concentrations of these mediators in each patient. However sampling at multiple time 
points may potentially cause the patient harm and additional stress and discomfort, 
and therefore would not be seen as ethical.  
 
4.4.7. Summary 
 
Paracetamol’s pharmacokinetics, metabolism and mechanism of action were studied in 
human CSF and plasma following intravenous administration. The data from this study 
was from 26 male patients of different ages, weights, heights and with various 
disorders. Despite this a clear trend was seen in paracetamol’s accumulation in CSF 
and clearance from plasma over time. Its major metabolites, paracetamol glucuronide 
and paracetamol sulphate, were all found to be present in the CSF, and for the first 
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time the FAAH formed metabolite AM404 was shown to be produced by humans 
following paracetamol administration. Oleic acid and palmitic acid derivatives of 
paracetamol, while being shown here to be produced by FAAH in rat brain 
homogenates, were not detected in CSF. Furthermore the levels of the endogenous 
mediators PGE2, LTB4, AEA, OEA, PEA and 5HT were not shown to be changed by 
paracetamol over the time course.  
 
The limitations of this study are that it was only a small study (n = 26). Drug dose was 
not weight adjusted. As the patient’s weights ranged from 52 – 125 kg the 1 g dose 
effectively ranged from 8 - 20 mg/kg. No clearance of paracetamol was observed over 
the time course and therefore any future studies should ideally be performed over a 
longer duration to investigate clearance from the CSF. AM404 was only detected in 17 
of the 26 patients. This is probably not because it was absent, but because the assay 
was not sensitive enough to quantitate samples with AM404 concentrations lower than 
0.5 pmol/mL. This is also the case for AEA, which was measured to see whether its 
reuptake inhibitor AM404 would change its levels. AEA is known to be present in the 
CSF at the fmol/mL level. Therefore a more sensitive assay would be required for 
quantitation. PGE2 and 5HT are both known to be important endogenous mediators of 
paracetamol’s action. A possible reason as to why no change was seen in their 
concentration is due to the experimental design. Taking a CSF sample before and after 
paracetamol would therefore allow for comparisons to be made to a baseline level. A 
change in their concentration is more likely to be detected using this approach, but 
would potentially cause more discomfort to the patient. Additionally trauma to the 
spinal cord would cause a release of PGE2 and impair its measurement. 
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5.1. Overview 
 
The research presented here has explored several areas of FAAH and its role in 
analgesia and inflammation. FAAH was studied in cultured activated macrophages 
(Chapter 2), in an in vivo model of inflammatory pain (Chapter 3) and in human 
cerebrospinal fluid during a clinical trial (Chapter 4). These investigations concluded in 
several novel findings as detailed below. 
 
1. FAAH and MAGL are known to produce arachidonic acid in the hydrolysis of the 
endocannabinoids. It was investigated here as to whether these enzymes could 
influence production of prostaglandins, which are oxidative metabolites of 
arachidonic formed via COX. It was shown that inhibition of either FAAH or MAGL 
reduced PGE2 production in activated macrophages (Chapter 2). 
 
2. Measurement of the FAAH substrates are increasingly being used as a 
pharmacodynamic parameter in the development of novel FAAH inhibitors. 
Covalent FAAH inhibitors were shown to produce significant increases in AEA, OEA 
and PEA, while such an effect was not seen with non-covalent inhibitors. Blood 
OEA and PEA levels were found to be indicative of brain FAAH activity and brain 
AEA concentrations (Chapter 3). 
 
3. FAAH is already known to be capable of conjugating arachidonic acid to small 
molecules, such as 4-aminophenol, ethanolamine and dopamine. Here FAAH was 
demonstrated for the first time to also be capable of conjugating oleic acid and 
palmitic acid to small molecules (Chapter 4). 
 
4. The active metabolite of paracetamol, AM404, is a conjugate of arachidonic and 4-
aminophenol that is synthesised by FAAH. FAAH was shown for the first time to 
also form novel oleic acid and palmitic acid conjugates of paracetamol (Chapter 4). 
 
5. The action of paracetamol has been demonstrated to be dependent on the 
endocannabinoid system. AM404, an inhibitor of AEA reuptake, is thought to 
mediate this action. This FAAH formed active metabolite has only previously been 
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investigated in vivo and has not been identified in humans. For the first time 
AM404 was shown here to be synthesised by humans and be detectable in the 
cerebrospinal fluid of patients receiving intravenous paracetamol (Chapter 4). This 
offers the first evidence of paracetamol interacting with the endocannabinoid 
system in humans. 
 
6. The pharmacokinetics of paracetamol in the plasma following oral administration 
has been well studied. However paracetamol’s pharmacokinetics in the CSF 
following intravenous administration is not known. As paracetamol is increasingly 
been administered intravenously and as the analgesic is known to be active in the 
CNS, this was worth investigating. For the first time the pharmacokinetics of 
intravenous paracetamol in the CSF of adult humans was determined, with 
paracetamol being detectable in the CSF within 10 minutes and still being present 
after 3 hours (Chapter 4). 
 
7. Paracetamol has two major metabolites, paracetamol glucuronide and paracetamol 
sulphate. These metabolites are well studied in plasma and urine, but have not 
previously been measured in CSF. For the time first time the glucuronide and 
sulphate metabolites of paracetamol were found to be present in the cerebrospinal 
fluid of patients receiving intravenous paracetamol (Chapter 4). 
 
The impact of these findings on research into the endocannabinoid system, FAAH 
inhibition and paracetamol will be discussed here alongside several areas still needing 
to be addressed and other recent discoveries. 
 
5.2. The expanding endocannabinoid system 
 
The endocannabinoid system is often simply defined as consisting of the cannabinoid 
receptors CB1 and CB2, the receptor’s endogenous ligands AEA and 2AG, and the 
ligand’s degradative enzymes FAAH and MAGL. It is now becoming clear that the 
players functioning in endocannabinoid signalling go beyond two receptors, two ligands 
and two enzymes. New receptors, ligands and enzymes connected with 
endocannabinoid signalling have all been identified, as has the carrier protein involved 
Chapter 5 
163 
in AEA reuptake. Furthermore new actions for the currently known ligands and 
proteins have been demonstrated, as has interaction between the endocannabinoid 
system and other lipid signalling networks. 
 
5.2.1. New receptors in the endocannabinoid system 
 
The cannabinoid receptors were originally identified as the protein in the brain that the 
bioactive components of Cannabis highly bind to, such as ∆9-THC and cannabinol.98, 99 
Endogenous lipids with the same action were later identified and named the 
endocannabinoids.100, 101 Since these discoveries, endocannabinoids have also been 
shown to activate receptors outside of the endocannabinoid system. Beyond the 
cannabinoid receptors CB1 and CB2, the endocannabinoids AEA and 2AG also activate 
the PPAR-α and TRPV1 receptors. PPAR-α appears to be integral to the 
endocannabinoid system as the analgesic effect of FAAH inhibition is completely 
reversed by antagonism of PPAR-α.223, 236 TRPV1 is also activated by AEA, although at 
higher concentrations than those required for CB1.388 However in inflammation TRPV1 
expressing sensory neurons are sensitised to AEA by PGE2, thus lower concentrations 
are required for activation.240 It remains to be elucidated as to whether the beneficial 
increases of AEA by a FAAH inhibitor in inflammatory is offset by activation of 
sensitised TRPV1 by AEA. Additionally the uncharacterised G-protein coupled receptors 
GPR18,389 GPR55 253 and GPR199 390 have all been demonstrated to be activated by 
endocannabinoids. Whether any of these receptors will become the CB3 receptor 
remains to be seen, however it is now clear that the receptors activated by 
endocannabinoids outnumber just two cannabinoid receptors. 
 
5.2.2. New ligands in the endocannabinoid system 
 
Like the receptors, the number of lipids thought to be involved in endocannabinoid 
signalling is also increasing. The endocannabinoids are hydrolysed by FAAH and MAGL. 
However in addition to AEA and 2AG, FAAH and MAGL have various other non-
endocannabinoid substrates. FAAH metabolise a class of lipids called the fatty acid 
ethanolamides, while MAGL metabolises a class of lipids called the fatty acid glycerols. 
Little is known about these lipids, which include myristoyl ethanolamide (14:0), 
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stearoyl ethanolamide (18:0), linoleoyl ethanolamide (18:2), arachidoyl ethanolamide 
(20:0), eicosapentaenoyl ethanolamide (20:5) and docosanoyl ethanolamide (22:6), 
and their glycerol counterparts.278, 391 While these lipids have been reported to be 
endogenous,179 their receptors need to be identified and whether like AEA, OEA and 
PEA, they have analgesic and anti-inflammatory properties requires further 
investigation. As OEA and PEA lack affinity for the cannabinoid receptors they are not 
defined as endocannabinoids. Although they can potentiate the action of AEA,257 
possibly due to the higher concentrations of OEA and PEA resulting in competition for 
FAAH hydrolysis. 
 
Oxidative metabolites of the endocannabinoids have been shown to possess affinity for 
the cannabinoid receptor. For example the AEA metabolite 5,6-EET-ethanolamide is a 
potent CB2 agonist.364 As already discussed, whether these AEA metabolites are 
produced physiologically is not known. Oxidative metabolism of OEA and PEA was 
demonstrated in Chapter 3. As OEA and PEA are significantly more concentrated than 
AEA, it is more likely their oxidative metabolites are formed physiologically. While this 
area requires significantly more research, oxidised fatty acid ethanolamides represent 
a novel group of lipid signalling molecules that possibly may be formed under specific 
physiological conditions. 
 
Derivatives of the haemoglobin fragment, hemopressin, have been recently identified 
as an endogenous peptide component of the brain capable of activating the 
cannabinoid receptors.392 RVD-HPα and VD-HPα are both agonists of the CB1 receptor, 
while VD-HPα also has affinity for CB2. These findings open up the possibility that the 
cannabinoid receptors are activated by both lipid and peptide signalling molecules. In 
summary, the fatty acid ethanolamides, fatty acid glycerols, oxidised endocannabinoid 
metabolites and hemopressin derivatives all represent novel lipid and peptide classes 
of molecules that are in part connected to the endocannabinoid system. Further 
research into these lipids may reveal new therapeutic approaches based on their 
manipulation. 
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5.2.3. New proteins in the endocannabinoid system 
 
In addition to the identification of new receptors and new ligands, new proteins have 
also been identified. Specifically two potentially key players in the endocannabinoid 
system, namely the AEA transporter FLAT and a second FAAH subtype FAAH-2, were 
recently discovered by Fu et al. and Wei et al. respectively.104, 160 The reuptake of AEA 
into neurons has long been known,260 with only until recently a high affinity binding 
site being identified.197 The reuptake of AEA into neurons has now been demonstrated 
to be by a FAAH variant named the FAAH-like anandamide transporter (FLAT).104 FLAT 
is a membrane bound carrier protein that lacks FAAH activity and is not inhibited by 
FAAH inhibitors. While FAAH inhibition increases intracellular AEA, the inhibition of AEA 
reuptake increases the amount of AEA in the synapse. As only a fraction of the 
increased intracellular AEA following FAAH inhibition would make it into the synapse, 
inhibition of AEA reuptake is likely to become a more attractive therapeutic target than 
FAAH. The best characterised inhibitor of AEA reuptake is AM404, which was shown in 
Chapter 4 to be formed in the human CSF as a metabolite of paracetamol. Novel 
potent inhibitors of AEA reuptake based on AM404’s action now need to be developed 
as therapeutics. CB2 is expressed mostly on immune cells. Whether FLAT, or another 
AEA carrier protein, is expressed on immune cells and therefore involved in the 
regulation of endocannabinoid signalling needs to be determined. Furthermore whether 
FLAT is also responsible for 2-AG reuptake, or whether its own carrier protein exists 
needs to be determined. 
 
The second potential new protein in the endocannabinoid system is, like FLAT, also a 
FAAH variant named FAAH-2. FAAH-2 is expressed in humans but not in rodents.160 
Despite FAAH-2 sharing only 20% sequence homology with FAAH, there is significant 
overlap in tissue distribution and substrate selectivity. This subtype could present 
complications in the development of FAAH inhibitors, as in humans FAAH-2 is 
expressed in the heart while FAAH-1 is not.160 The recently developed FAAH inhibitors 
investigated in Chapters 2 & 3, PF-3845 and PF-04457845, were specifically designed 
not to inhibit FAAH-2, thus avoiding this issue.225  
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5.2.4. New actions of the endocannabinoid system 
 
Alongside new receptors, ligands, enzymes and transport proteins, new actions of the 
currently accepted players of the endocannabinoid system have been recently 
demonstrated. While hydrolysis of AEA, OEA and PEA is the main attributed action of 
FAAH, little is known about its reverse action of conjugating fatty acids to small 
molecules. This mechanism is a route of synthesis for AEA,151 NADA 163 and AM404,164 
from ethanolamine, dopamine and 4-aminophenol respectively. While previously there 
was only evidence to suggest that FAAH could conjugate arachidonic acid to small 
molecules, here in Chapter 4 it was demonstrated that the enzyme can also conjugate 
oleic acid and palmitic acid.  
 
Several questions remain unanswered concerning this newly established action of 
FAAH. Firstly the cause of reversed FAAH activity needs to be elucidated. The activity 
of some enzymes is reversed when the concentration of the enzyme’s product is higher 
than its substrate. For FAAH a shift in the equilibrium between the enzymes substrates 
(AEA, OEA and PEA) and products (arachidonic acid, oleic acid and palmitic acid) is an 
unlikely explanation. This is because the brain concentrations of its products are 
already 1000-fold higher than the FAAH substrates.141, 180 As well as fatty acids the 
other product of FAAH is ethanolamine. It is possible that specific molecules act as 
analogues of ethanolamine, so that once such molecules reach a critical concentration 
they are capable of reversing FAAH activity. Either way the reverse activity of FAAH 
has been now proved to be a physiological occurrence in humans, as demonstrated by 
the presence of AM404 in the CSF in Chapter 4. 
 
The type of small molecule that FAAH can conjugate fatty acids to needs to be 
investigated. So far ethanolamine, 4-aminophenol and dopamine have all been 
identified. It therefore appears that the presence of an amino group is integral. FAAH 
then catalyses the dehydration / condensation reaction between this amino group and 
the carboxyl group present on fatty acids to produce a conjugate and a molecule of 
H2O. Based on the understanding of this mechanism small molecules should now be 
screened for their ability to reverse FAAH activity. Such molecules may form the basis 
of novel therapeutics. 
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Currently there are a number of fatty acid derivatives of neurotransmitters that have 
been identified, such as such as N-arachidonoyl dopamine (NADA), oleoyl dopamine, 
palmitoyl dopamine, arachidonoyl serotonin, oleoyl serotonin and palmitoyl 
serotonin.393, 394 Additionally fatty acid derivatives of amino acids have also been 
discovered, such as N-arachidonoyl glycine.395 Again these neurotransmitters and 
amino acids share an amino group. It is possible that some of these lipids are 
synthesised by reverse FAAH activity and it is therefore also possible that other FAAH 
formed derivatives of neurotransmitters and amino acids are in existence. Other novel 
fatty acid conjugates should now be identified. Furthermore whether MAGL, like FAAH, 
can also have its activity reversed needs to be investigated. 
 
5.2.5. New interactions of the endocannabinoid system 
 
It is important that the endocannabinoid system is not seen as a closed system. There 
are in fact a growing number of examples of overlap between the endocannabinoid 
system and other lipid signalling networks. Hydrolysis of the endocannabinoids 
produces arachidonic acid, a fatty acid present in numerous other lipids involved in 
pain and inflammation, such as the prostaglandins, leukotrienes and the 
lysophosphatidic acids. The latter is class of lipids released at the site of injury,396-398 
where they initiate pain.399-402 It is possible that by inhibiting endocannabinoid 
hydrolysis that less arachidonic acid would be available for the synthesis of lipids like 
the prostaglandins and lysophosphatidic acids. In Chapter 2 it was shown that 
inhibition of FAAH and MAGL decreases PGE2 production in activated macrophages. 
Whether this same effect is seen in vivo should be the subject of future research. 
 
Similarly a recent study showed that 2-AG is capable of activating neutrophils, in that 
it stimulates myeloperoxidase release, kinase activation and Ca2+ mobilisation.341 This 
effect is not reversed by cannabinoid antagonists, but is instead due to 2-AG being 
hydrolysed by MAGL into arachidonic acid and consequently being quickly converted 
into the chemoattractant LTB4. The implication of this being that a part of the anti-
inflammatory effect of MAGL inhibition is due to its influence over LTB4 levels and 
consequently neutrophil activation. Therefore due to its control of arachidonic acid, the 
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hydrolysis of the endocannabinoids results in several lipid signalling networks 
overlapping.  
 
5.2.6. Summary 
 
The endocannabinoid system is expanding in the number of receptors, ligands and 
enzymes involved in its signalling and also in terms of previously unknown actions 
being revealed and interactions with other lipid signalling networks being 
demonstrated. The work presented here has contributed to this, highlighting 
interaction between endocannabinoid hydrolysis with prostaglandin synthesis and 
revealing a new action for FAAH in its conjugation of oleic acid and palmitic acid to 
small molecules. Further unravelling of the endocannabinoid system may reveal 
potential new mechanisms for therapeutic intervention. 
 
5.3. The role of the endocannabinoid system in 
paracetamol’s action 
 
The mechanism by which paracetamol produces analgesia is often quoted as being 
largely unknown.403 Due to the adverse effects of paracetamol, such as liver toxicity, 
an improved version of the drug would be desirable. The screening of potential 
paracetamol replacements would require assays that demonstrate selectivity for its 
molecular targets. However until paracetamol’s mechanism is fully understood this is 
not possible. The reason for the confusion concerning paracetamol’s action is that it 
appears to involve multiple pathways including the serotonin receptors, and the 
prostaglandin and endocannabinoid systems. 
 
It is well accepted that paracetamol is active in the CNS. The findings from Chapter 4 
supports paracetamol being a mostly CNS active drug, demonstrating that it 
penetrates rapidly into the CSF where its presence significantly outlasts its presence in 
plasma. However despite the high concentrations reached by paracetamol in the CSF, 
no change in the CSF levels of PGE2 or 5HT were seen. Even so there is clinical 
evidence that demonstrates the interaction between paracetamol, COX and the 5HT 
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receptors in humans. For example PGE2 production in the acute inflammation of 
peripheral tissue has been shown to be suppressed following oral administration of 1 g 
of paracetamol.291 Furthermore the urinary excretion of PGE2 is reduced by 43% 
following a daily 4 g oral intake of paracetamol.404 In terms of the 5HT receptors a 
clinical study showed that the antagonism of the 5HT3 receptor reverses the effect of 
paracetamol.304  
 
Similar studies that conclusively support the integrity of the endocannabinoid system 
to paracetamol’s action are required. The finding in Chapter 4 that humans produce 
AM404 clearly proves an interaction between FAAH and paracetamol. As discussed in 
Section 4.4.4. the concentration required for AM404 to be analgesic is not known. 
Therefore the presence of AM404 still does not answer the question as to whether 
there are sufficient amounts formed to inhibit AEA reuptake, activate the cannabinoid 
receptors and produce analgesia. The definitive experiment to prove that the 
cannabinoid receptors are integral to paracetamol’s action would be to use cannabinoid 
antagonists. Unfortunately cannabinoid antagonists are no longer in use due to the 
adverse effect of depression. 
 
There is some evidence that possibly demonstrates similarity between paracetamol 
and cannabinoids. In humans evidence suggest that paracetamol can affect 
emotions,405 while in vivo studies have shown paracetamol to affect memory.406 These 
are affects not seen with other COX inhibitors, and serve as possible examples of 
cannabinoid receptor-mediated effects of paracetamol. In conclusion, while there is 
now clinical evidence for the interaction between paracetamol and FAAH, it remains to 
be determined as to whether the cannabinoid receptors are integral to its action in 
humans. 
 
5.4. The therapeutic potential of a FAAH inhibitor 
 
In Chapter 3 FAAH inhibitors that form a covalent attachment to the enzyme’s active 
site were shown to increase the levels of AEA, OEA and PEA significantly higher than 
inhibitors that form non-covalent attachments. Covalent attachments are now clearly 
the preferred mechanism for FAAH inhibitors, with PF-04457845, the first FAAH 
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inhibitor to enter clinical trials, forming a covalent bond. The FAAH substrates AEA, 
OEA and PEA, were investigated in Chapter 3 as a pharmacodynamic measurement to 
prove the action of potential inhibitors. The first clinical trial of PF-04457845 measured 
the FAAH substrates in plasma as a pharmacodynamic parameter.184 The study 
showed that the inhibitor, even at low doses, was capable of maintaining increased 
substrate levels and inhibition of FAAH activity (>97%) for several days after dosage. 
Even after the inhibitor was no longer detectable in the body, FAAH activity was still 
close to 0%. Therefore the inhibitor’s pharmacodynamics outlasted its 
pharmacokinetics.  
 
5.4.1. FAAH inhibitors as analgesics 
 
Now that potent, selective and well-tolerated FAAH inhibitors have been developed, 
their therapeutic potential remains to be determined. While FAAH inhibitors were 
originally designed for analgesia, the market for novel analgesics is already a crowded 
one. COX inhibitors count for 68% of the analgesics used for chronic pain, with the 
opioids counting for 28%.3 In Chapter 2 it was shown that FAAH inhibitors can inhibit 
PGE2 synthesis in activated macrophages, but not with the same potency as other 
COX inhibitors. It remains to be seen as to whether a FAAH inhibitor would be capable 
of competing with the already available analgesics, such as the opioid agonists, COX 
inhibitors and paracetamol.  
 
An issue only recently highlighted is the AEA occupancy of cannabinoid receptors 
following FAAH inhibition. Despite >97% inhibition of FAAH activity by PF-04457845, 
the occupancy of the CB1 and CB2 receptors by AEA is increased by only 0.1% of that 
achieved by therapeutic doses of exogenous cannabinoids.407 FAAH inhibitors were 
originally seen as an alternative to synthetic cannabinoids as a means of activating the 
cannabinoid receptors. However it now appears that the cannabinoid receptors cannot 
be significantly activated by FAAH inhibitors in humans for analgesia. This does not 
mean that the therapeutic potential of a FAAH inhibitor lies outside of analgesia. 
Currently FAAH inhibition has only been investigated clinically in relation to 
osteoarthritis pain.407 FAAH inhibitors may be more suited to other pain types. In vivo 
studies have shown that FAAH inhibition produces analgesia not just via the 
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cannabinoid receptors, but also via PPAR-α.236 Therefore OEA and PEA are just as 
integral to analgesia as AEA, meaning that occupancy of the cannabinoid receptors 
may not be essential.  
 
It may be possible for the therapeutic potential of a FAAH inhibitor to be enhanced by 
simultaneously targeting other pathways. FAAH could be inhibited alongside either AEA 
reuptake inhibition or CB2 activation. This would allow for the PPAR-α dependent anti-
inflammatory effect of increased OEA and PEA to be complimented by increased 
activation of the cannabinoid receptors, either by AEA or a synthetic agonist. It is not 
unlike analgesics to target multiple pathways, such as paracetamol, which interacts 
with the serotonin, prostaglandin and endocannabinoid systems. Furthermore 
analgesics with different mechanisms are often dosed together, such as ibuprofen and 
codeine. The targeting of FAAH alongside another pathway could be utilised by either a 
single drug with dual selectivity for two targets or by simultaneously dosing a FAAH 
inhibitor with another drug. It has already been suggested that FAAH inhibitors be 
developed that with dual selectivity for either COX or TRPV1.408 Therefore by targeting 
multiple pathways there still may be potential for FAAH in analgesia. 
 
The finding that paracetamol uses FAAH to produce an active metabolite potentially 
opens up a new approach to targeting the enzyme. Perhaps instead of drugs being 
developed that inhibit FAAH, there is now a need for a drug that FAAH can conjugate 
fatty acids to, for the formation of analgesic active metabolites. In doing so such a 
drug might inadvertently block AEA, OEA and PEA hydrolysis, and thus have a similar 
action to a FAAH inhibitor. 
 
5.4.2. Alternative uses of FAAH inhibitors 
 
Outside of analgesia FAAH inhibitors are potentially well suited to numerous disorders 
of the CNS. FAAH inhibitors have been shown/suggested in in vivo studies to be an 
effective therapeutic for Alzheimer’s disease,409 Parkinson’s disease,410 multiple 
sclerosis,411 anxiety 412 and depression.413 To further investigate the potential of FAAH 
as a target for Alzheimer’s disease, inhibitors with dual selectivity for cholinesterase 
and FAAH have been recently developed as a means to increasing neuronal 
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transmission while reducing neuroinflammation.414 Outside of disorders of the CNS, 
FAAH inhibitors possibly also have potential in the cardiovascular system. AEA has 
been shown to cause vasodilation, modulate blood flow and pressure, and to reduce 
heart rate.415 FAAH inhibitors have been demonstrated to normalise cardiovascular 
function in an in vivo model of hypertension.416  
 
5.4.3. Potential adverse effects of FAAH inhibitors 
 
While not sharing the adverse effects seen with the cannabinoids, FAAH may possibly 
come with its own associated risks. Evidence suggests that FAAH inhibition induces 
sleep in vivo by both cannabinoid receptor and non-cannabinoid receptor 
mechanisms.417 This suggests that FAAH inhibitors could possibly be used in the 
treatment of sleep disorders. Whether this effect is seen in humans needs to be 
investigated as if FAAH inhibitors do cause drowsiness, then this may lessen their 
appeal. Importantly embryo implantation and development has been shown in vivo to 
partly involve a FAAH-mediated process involving regulation of AEA.418 Furthermore a 
clinical trial of pregnant women showed that women with low lymphocyte FAAH activity 
had miscarriages.419 It remains to be determined as to whether FAAH inhibitors would 
have an adverse effect in pregnancy, which again would lessen its appeal as a novel 
analgesic. 
 
5.4.4. Conclusion 
 
Potent, well tolerated FAAH inhibitors are now available. Whether FAAH inhibitors will 
become a routinely used medicine, and if so for what conditions, is still uncertain. 
FAAH inhibitors have the already available and routinely used analgesics to compete 
with. Furthermore it is unable to inhibit prostaglandin E2 synthesis as potently as COX 
inhibitors and clinically meaningful analgesia may not be obtained due to low 
cannabinoid receptor occupancies. There are possible routes for addressing these 
issues, such as inhibitors with dual selectivity for a second target. Even if FAAH 
inhibitors are not used as analgesics, they may have potential in disorders of the CNS 
and cardiovascular system. Before they can be used clinically, outstanding issues of 
whether FAAH inhibitors cause drowsiness and effect pregnancy need to be addressed. 
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Title A Single Centre Prospective Randomised Study to Investigate the CSF 
Pharmacokinetics of Intravenous Paracetamol in Humans 
Protocol Version 
Number and Date 
Protocol Version Number 1, 19/07/2010 
Short Title Paracetamol CSF Study  
Methodology Prospective randomised study   
Study Duration Six months 
Study Centres Single Centre  
Objectives 
 
 
 
Phase of the Trial 
To measure the cerebrospinal levels of paracetamol and its metabolites 
after it has been given intravenously in humans. 
 
 
IV 
 Number of 
Subjects/Subjects  
30 
Main Inclusion 
Criteria 
Adult subjects aged 18 and 80 years from whom full written informed 
consent will be sought 
Subjects undergoing surgery who require a spinal anaesthetic and 
paracetamol as part of their routine anaesthetic 
Subjects who are ASA I−III (American Society of Anesthesiologists). 
Subjects with no known clotting abnormalities 
Statistical 
Methodology and 
Analysis 
This is a pilot study. The analysis of data will be predominantly descriptive.  
The concentration time curves will be constructed for paracetamol in 
plasma and cerebrospinal fluid.  This will also be done for the metabolites 
of paracetamol.  The CSF:Plasma ration for paracetamol will be calculated 
for the different time points.   
 Glossary of Terms and Abbreviations 
 
AE   Adverse Event   
AR   Adverse Reaction 
ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
CTA   Clinical Trial Authorisation 
CTIMP   Clinical Trial of Investigational Medicinal Product 
DMC   Data Monitoring Committee 
EC   European Commission 
EMEA   European Medicines Agency 
EU   European Union 
EUCTD  European Clinical Trials Directive 
EudraCT  European Clinical Trials Database 
EudraVIGILANCE European database for Pharmacovigilance    
GAfREC  Governance Arrangements for NHS Research Ethics 
GCP   Good Clinical Practice 
GMP   Good Manufacturing Practice  
IB   Investigator Brochure 
ICF   Informed Consent Form 
IMP   Investigational Medicinal Product 
IMPD   Investigational Medicinal Product Dossier 
ISRCTN  International Standard Randomised   
MA   Marketing Authorisation 
MHRA   Medicines and Healthcare products Regulatory Agency 
MRC   Medical Research Council 
MS   Member State 
Main REC  Main Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
PI   Principle Investigator 
QA   Quality Assurance 
QC   Quality Control 
QP   Qualified Person for release of trial drug 
RCT   Randomised Control Trial 
 REC   Research Ethics Committee 
SAR   Serious Adverse Reaction 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedures  
SmPC   Summary of Product Characteristics  
SSA   Site Specific Assessment 
SSAR   Suspected Serious Adverse Reaction 
Subject   An individual who takes part in a clinical trial 
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TMG   Trial Management Group 
TSC   Trial Steering Committee 
 1 Introduction 
 
1.1 Background 
Paracetamol is a commonly used analgesic agent for peri-operative pain management. It forms the 
step 1 of the WHO Pain Ladder and constitutes an essential component of balanced analgesia to 
produce synergistic effects while reducing the need for opioid analgesics. Although it has been 
used orally since early 19th century, it has been recently formulated as a ready to use intravenous 
preparation in 2004. This new development is potentially beneficial to subjects with an added 
advantage of 100% bioavailability and a relative ease of administration in intra- and post-operative 
period. 
 
There is evidence that, when administered intravenously, paracetamol has a fast onset of action 
within 5−10 minutes with a peak analgesic action within 15 minutes. 
 
Although paracetamol has been used for decades there is relative little evidence about its CSF 
pharmacokinetics particularly after intravenous administration in humans. Paracetamol readily 
penetrates into the cerebrospinal fluid in animal studies and in children. This could account for the 
rapid central analgesic and antipyretic action of intravenous paracetamol however this remains to 
be studied in adults yet. 
 
Following deacetylation to p-aminophenol, paracetamol is conjugated with arachidonic acid to form 
N-arachidonoylphenolamine (AM404). AM404 activates vanilloid subtype 1 receptors and inhibits 
cellular anandamide uptake, allowing cannabinoids like anandamide to remain in the synaptic 
clefts. AM404 is also a Transient Receptor Potential Vanilloid Type 1 (TPRV1) agonist, which is 
activated by capsaicin. 
 
Cannabinoids and paracetamol both probably produce descending spinal inhibition. They both 
lower body temperature clinically and have subjective effects of euphoria and relaxation shared by 
aniline analgesics. CB1 antagonists completely prevent the analgesic action of paracetamol, 
lending support to this proposed mechanism of action.   
 
1.2 Investigational Medicinal Product (IMP) 
Intravenous paracetamol is used for the short term treatment of moderate pain, especially following 
surgery. The precise mechanism of the analgesic properties of paracetamol has yet to be 
established, it may involve peripheral and central actions.  
 
1.3 Preclinical Data  
Intravenous paracetamol is already in use in humans in clinical practice. Paracetamol 
pharmacokinetics is linear up to 2g after single administration. The maximal plasma concentration 
(Cmax) of paracetamol observed at the end of 15-minutes intravenous infusion of 1g is 30 µg. The 
volume of distribution is 1l/kg. Paracetamol is not extensively bound to plasma proteins. 
Paracetamol is metabolised in the liver by glucuronic acid conjugation and sulphuric acid 
conjugation. The metabolites of paracetamol are mainly excreted in the urine.   
 
1.4 Clinical Data to Date 
In children it has been shown that paracetamol enters the CSF readily. In healthy children, 
paracetamol is detected 5 minutes after administration of an intravenous dose of 15mg/kg, but the 
concentration is below 1mg/l with peak levels appearing to occur 60-100 minutes post 
administration, ranging from 11-18mg/l. In children with head injuries and intracranial pathology, 
peak CSF concentrations of paracetamol were found at 210 minutes post paracetamol, at levels of 
20mg/ml, but nasogastric paracetamol at a dose of 40mg/kg was given. 
 
 1.5 Rationale and Risk/Benefits 
Paracetamol readily penetrates into the cerebrospinal fluid in animal studies and in children. This 
could account for the rapid central analgesic and antipyretic action of intravenous paracetamol 
however this remains to be studied in adults yet. 
 
Further the exact mechanism of action of paracetamol is not fully understood and essentially 
involves a combination of hypotheses. It is known to have a central effect perhaps by selective 
inhibiton of COX. However it is hypothesised that it could also perhaps modulate the serotoninergic 
system and may have an indirect activation of CB1 (cannabinoid) receptors, through its novel 
metabolite AM404. 
 
This study aims to elucidate cerebrospinal levels of paracetamol and to measure the concentration 
of its metabolites, including AM404 in CSF. This may, in turn, give us useful information on the 
mechanism of action of paracetamol. 
 
There are no foreseen extra risks to the subject as they will be undergoing elective surgery under 
spinal anaesthesia and receiving intravenous paracetamol as a routine part of their anaesthetic 
plan. 
 
2   Study Aims and Objectives 
 
Primary:  
To measure the cerebrospinal levels of paracetamol and its metabolites after it has been given 
intravenously in humans. 
Secondary:  
 
1. To measure the effect of paracetamol on prostaglandin synthesis in the CSF  
2. To measure the concentration of AM404 in the human CSF following intravenous administration 
of paracetamol. 
 
3   Investigational plan 
 
3.1 Overall Design 
This is a single centre prospective randomised study. Subjects will be randomised to receive 
intravenous paracetamol at three different time points prior to having a spinal block as a routine 
part of their anaesthesia. 
 
3.2 Design Format 
After obtaining informed consent, 30 subjects undergoing elective surgery under spinal anaesthesia 
as a routine part of their anaesthetic plan will be randomised to receive intravenous paracetamol at 
15 minutes, 30 minutes or 120 minutes prior to their spinal block. After the spinal tap and prior to 
administering any anaesthetic drugs, 5 ml of the cerebrospinal fluid will be sampled for analysis. A 
10 ml of blood sample will be also obtained simultaneously to measure the plasma paracetamol 
and AM404 levels. 
 
The cerebrospinal fluid and the plasma would be sent to the laboratory to be analysed. 
Paracetamol, AM404 levels and prostaglandin E2 (PGE2), used as a measure of cyclooxygenase 
(COX) activity would be measured. 
 
3.3 Overview of Study population 
Male and female subjects, between 18 and 80 years of age, for elective surgery under spinal 
anaesthesia who would receive intravenous paracetamol. 
 
 
 3.4 Target Accrual 
Subjects who are undergoing surgery who meet the criteria will be identified from the elective 
operating theatre lists. The surgeon and anaesthetist responsible for their care will be consulted. 
The subjects will be provided a subject information sheet and invited to participate into the study. 
After obtaining informed consent they would be randomised to receive paracetamol 15 minutes, 30 
minutes or 120 minutes prior to the proposed spinal anaesthetic block.  
 
4   Subject Selection  
 
4.1 Inclusion Criteria 
 
• Adult subjects aged 18 and 80 years from whom full written informed consent will be sought 
• Subjects undergoing surgery who require a spinal anaesthetic and paracetamol as part of 
their routine anaesthetic 
• Subjects who fall into the American Society of Anesthesiologists scoring system of ASA 
I−III. 
• Subjects with no known clotting abnormalities. 
 
4.2 Exclusion Criteria 
 
• Subjects with any contraindication to spinal anaesthesia 
• Subjects with known clotting abnormalities 
• Pregnant or lactating women 
• Subjects who have known hypersensitivity to paracetamol 
• Patients with severe hepatocellular insufficiency 
• Patients who are taking a regular dose of paracetamol already 
• Any subjects who are deemed unsuitable by the investigators due to medical reasons 
 
4.2.1 Females of childbearing potential must have a negative pregnancy test within 7 days prior to 
being registered for protocol therapy. 
4.2.2 NOTE: Subjects are considered not of child bearing potential if they are surgically sterile 
(they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophrectomy) or 
they are postmenopausal.  
 
5 Study Procedures and Schedule of assessments 
5.1 Informed consent procedures 
5.1.1 It is the responsibility of the Investigator, or a person delegated by the Investigator [the 
delegation log will detail who is authorised to take consent, only GCP trained individuals can 
take consent, and in line with sponsor SOPs) to obtain written informed consent from each 
subject prior to participation in this study, following adequate explanation of the aims, 
methods, anticipated benefits and potential hazards of the study.  
5.1.2 Ample time must be given for consideration by the subject before taking part. It is to be 
documented in the medical records when the subject information sheet (PIS) was given to 
the subject. The Investigator or designee must explain to the subjects that they are 
completely free to refuse to enter the study or to withdraw at any time during the study, for 
any reason. Consent will follow the process detailed in the application (IRAS) to the 
MainRec and MHRA, section A29. Subjects may have less than 24 hours to consider 
participation, however ample time will be given so that the investigator (or designated 
 individual) is confident that the subject has had time to review, ask questions, and consent 
in writing.  
5.1.3 If new safety information results in significant changes in the risk/benefit assessment, the 
consent form should be reviewed and updated if necessary. All subjects, including those 
already being treated, should be informed of the new information, giving a copy of the 
revised form and give their consent to continue in the study. 
 
5.2 Screening and registration Procedures 
Subjects who are undergoing surgery who meet the criteria will be identified from the elective 
operating theatre lists. The surgeon and anaesthetist responsible for their care will be consulted. 
The subjects will be provided with a subject information sheet and invited to participate into the 
study. After obtaining informed consent they would be randomised to receive paracetamol 15 
minutes, 30 minutes or 120 minutes prior to the proposed spinal anaesthetic block.  
 
5.3 Randomisation procedures 
Randomisation will be done by sealed envelopes with the study group allocation (sampling at 15, 
30 or 120 minutes) in the envelope. A sealed envelope will be selected at random by the 
investigator (s) or a delegated study team member, on the day of the procedure. 
 
5.4 Treatment procedures 
An intravenous cannula will be inserted either on the ward or on the holding bay in theatres. 
Intravenous paracetamol will be given. The subject will be taken to the anaesthetic room and 
routine monitoring will be instituted. The spinal block will be performed. At this time, prior to 
injecting the local anaesthetic, 5ml of CSF will be withdrawn. 10ml of blood will also be taken. The 
subject will then go into theatre to have their surgical procedure. 
 
5.5 Method for assigning subjects to treatment group 
Subjects will be randomised to one of the treatment groups. The randomisation process will be 
verified by a study statistician.  
 
5.6 Flow of assessments 
a) Pre-operative visit and informed consent obtained from subject. 
b) Subject randomised to one of three groups, to receive IV paracetamol 15, 30 or 120 minutes 
prior to their planned spinal anaesthetic block. 
c) At the time of the spinal anaesthetic block, 5ml of CSFand 10ml blood obtained 
d) Subject to go into theatre for their surgery 
e) Follow up visit by study investigator 
 
5.7 Follow up procedures 
The subject will be seen postoperatively by a study investigator to monitor if any adverse effects 
have occurred.  
 
5.8 Laboratory Assessments 
 
A copy of the trial protocol will be provided to the laboratory (laboratory manager) named in this 
trial. The lab manager will also be provided with approvals from the sponsor (JRO), MHRA and 
MainRec approvals and subsequent amendments. The lab manager (or designated individual) will 
maintain a laboratory trial file to show compliance with Good Clinical Practice.  
 
 The CSF and blood will be divided into 1ml aliquots for the different analyses, hence determination 
of the paracetamol and AM404 concentrations and PGE2 levels. 
 
Paracetamol assay 
The concentration of paracetamol in plasma and cerebrospinal samples will be measured using a 
commercial enzyme assay. This assay will be performed according to the manufacturer’s 
instructions (Cambridge Life Sciences, Cambridge, UK). 
Five microlitres of CSF or plasma from subjects treated with intravenous paracetamol will be added 
to a 96 well plate. Also, 5µl of distilled water will be added to one of the wells to act as blank and 
5µl of standard (containing 2mmol/L paracetamol) will be added to one of the wells. To each of the 
well 50µl of enzyme reagent, constituted in 10ml of assay diluent, will be added. One hundred 
microlitres of colour reagent A and 100µl of colour reagent B will be added to all the wells. The 
plate will be left at room temperature for 5min and then read at 630nm with a plate reader (GENios 
Tecan, Jencons). 
 
The concentration of paracetamol in the samples will be calculated using the equation: 
 
Paracetamol (mmol/L) = Sample Abs – blank   x 2     
      Standard Abs - blank 
 
Where: Sample Abs = absorbance in sample wells 
     Blank = absorbance in wells containing water 
     Standard Abs = absorbance in standard wells 
     2 = concentration of paracetamol in the standard 
 
Prostaglandin extraction 
 
Blood or CSF will be collected in disodium-EDTA containing 10µM indomethacin. The plasma will 
be separated from blood by centrifugation at 1,600g for 20 minutes at +4oC. Prostaglandins will 
extracted from plasma and CSF using the protocol below. and the samples will be mixed with 2N 
HCl at a 1:20 dilution (for example for 1ml of sample 50µl of 2N HCL will be added). The samples 
will be left on ice for 20 minutes. C-18 Sep-Pak cartridges will be conditioned with 4ml ethanol 
followed by 4ml distilled water at a flow rate of 5-10ml/min. The samples will then be applied to the 
columns at a flow rate of 5ml/min. The columns will then be washed in 4ml distilled water followed 
by 4ml of 15% (v/v) ethanol in distilled water. The samples will be eluted with 2ml of ethyl acetate at 
a flow rate of 5ml/min. The samples will be dried under vacuum and then stored at – 80oC ready for 
PGE2 measurement. 
 
PGE2 enzyme immunoassay 
This commercial enzyme immunoassay (EIA) kit will be carried out according to the manufacturer’s 
instructions. Briefly, the assay buffer will be diluted in 500ml distilled water to give 0.1M phosphate 
buffer pH 7.5 containing 0.9% (w/v) bovine serum albumin and 0.5% (w/v) kathon. Standard PGE2 
will be serially diluted to give concentrations between 2.5–320 pg/well. Both the anti-PGE2 antibody 
and PGE2 conjugated to horseradish peroxidase will be dissolved in 6ml assay buffer and then 
diluted 1:3 in assay buffer. The microtitre plate coated with goat anti-mouse IgG will be set with 
sufficient wells to run all the standards and samples. The following will be added to each well in the 
volumes indicated in microlitres: 
  
 Substrate blank Non-specific 
binding 
Zero Standards Samples 
Assay buffer ----------------- 100 µl 50 µl ---------- ---------- 
Standard ----------------- ------------------ ------- 50 µl ---------- 
Sample ----------------- ------------------ ------- ---------- 50 µl 
Anti-body ----------------- ----------------- 50 µl 50 µl 50 µl 
Conjugate ----------------- 50 µl 50 µl 50 µl 50 µl 
Substrate 150 µl 150 µl 150 µl 150 µl 150 µl 
  
The plate will be incubated at ambient temperature for 1hr on a microplate shaker. At the end of 
this incubation period, the plate will be washed four times with wash buffer and immediately the 
substrate (3,3’,5,5’tetramethylbenzidine (TMB)/hydrogen peroxide in 20% (v/v) dimethylformamide) 
will be added and incubated for 30 minutes. Finally, the plate will be read at 630nm and the results 
calculated using the following equation:  
%B/B0 = (standard/sample OD - NSB OD) x 100 
 (B0 OD - NSB OD) 
 
where B = Bound (peroxidase-conjugated PGE2 in samples bound to antibody) 
           B0 = Amount of peroxidase-conjugated PGE2 in zero standard wells 
           OD = Optical density (absorbance values obtained from plate reader) 
           NSB = Non-specific binding wells 
The OD values from all the duplicate wells will be averaged and the percentage binding (%B/B0) for 
the standards and samples will be calculated using the above equation. The %B/B0 for the 
standards was then plotted against the concentrations using GraphPad Prism 3.0 and the amount 
of PGE2 in the samples will then be read of the standard curve. 
 
5.9 Radiology or other procedure 
Not applicable 
 
5.10 Unblinding procedures  
Not applicable  
 
5.11 Withdrawal 
 
5.11.1 Withdrawal of subjects 
Subjects may be withdrawn from the study if any of the following occur: 
 
1. Subject withdraws consent 
2. Subjects deemed unsuitable to continue with the study protocol due to safe issues, as 
judged by the investigator(s) 
3. Subjects unable to comply with the study protocol 
4. Subjects have intolerable toxicity to the study drug 
5. Subjects experience any intercurrent illness 
 
5.11.2 When and How to withdraw subjects  
Subjects are at any time free to withdraw from the study without prejudice to further treatment. 
Such subjects will always be asked about the reason(s) and the presence of adverse events. 
 Adverse events will be followed up. As collection of blood and CSF samples is an integral part of 
this study, the subject will be withdrawn from further study participation. 
 
5.11.3 Data collection and follow-up for withdrawn subjects 
Data collection will be in the form of a case report form (CRF). The withdrawn subjects and all 
identifiable data collected will be withdrawn from the study file and excluded in the analysis. Data 
that is not identifiable by the research team will be retained. Withdrawn subjects will be followed up 
in the same way as include subjects are at a post-operative visit. The subjects who withdraw 
consent or drop out will be replaced by another subject. The withdrawal will be documented in the 
CRF and medical notes. 
 
The study conduct will remain unchanged. The participants are not obliged to give the reason for 
their withdrawal. We do not anticipate that the study procedures will cause subjects to withdraw 
their consent as most of the study protocol is part of a routine anaesthetic plan, except the blood 
and CSF sampling. Therefore, we do not anticipate that subjects withdrawing their consent will 
result in a protocol amendment. 
 
6 Investigational medicinal product(s)   
 
Definition of each IMP(s) (Paracetamol) 
 
6.1 Product sourcing manufacture and supply 
http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Manufacturersan
dWholesaleDealerslicences/index.htm] 
Bristol Meyer Squibb Pharmaceuticals PL 11184/0094 
 
6.2 Pre-meds 
Not applicable 
 
6.3 Prescription of IMP 
The IMP will be prescribed by an anaesthetist. A prescription template will be agreed with the 
clinical trials pharmacist and version controlled.  
 
6.4 Preparation and Administration of IMP 
The IMP is presented in a glass vial. It will be administered intravenously via a giving set over 15 
minutes. 
 
6.5 Prior and Concomitant Therapies 
The IMP will not be given if it has been given in the preceding 6 hours. It will not be given in 
conjunction with probenicid, enzyme inducing substances and oral anticoagulants. 
 
6.6 Dose modification/reduction/ delay 
The dose is 1g per administration for adults weighing more than 50 kg. These are the only subjects 
which will be recruited in the study. 
 
6.7 Toxicity profiles 
Toxicity occurs at doses of 7.5g or more in a single administration. Such doses will not be used in 
this study. 
 
 6.8 Labelling and packaging 
The standard packaging will be used. A clinical trial label will be used – this has been agreed with 
the clinical trial pharmacist. A copy of the trial label will be sent to the MainRec and MHRA for 
submission and approval.  
 
6.9 Blinding of IMP 
Not applicable. 
 
6.10 Receipt of IMP Supplies/Storage 
IV paracetamol is routinely stocked in theatres and given to virtually all subjects undergoing 
surgery. IMP management processes will be overseen by the trial team, and processes agreed with 
the clinical trial pharmacist.  
 
6.11 Dispensing of IMP 
The IMP will be dispensed from the theatre stock. 
 
6.12 Return or Destruction of IMP 
The empty vial will be disposed off in the sharps bin. The trial team is to maintain a log to detail IMP 
accountability and compliance. This process will be agreed with the clinical trials pharmacist.  
 
7 Pharmacovigilance 
 
7.1 General definitions 
  
7.1.1 Adverse Events (AE) 
 
An AE is any untoward medical occurrence in a subject to whom a medicinal product has been 
administered, including occurrences which are not necessarily caused by or related to that product. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporarily associated with the use of an Investigational Medicinal 
Product (IMP), whether or not considered related to the IMP. 
 
7.1.2 Adverse Reaction (AR) 
 
An AR is any untoward and unintended response in a subject to an Investigational Medicinal 
Product (IMP), which is related to any dose administered to that subject. All adverse events judged 
by either the reporting investigator or the Sponsor as having a reasonable causal relationship to a 
medicinal product qualify as adverse reactions. The expression reasonable causal relationship 
means to convey in general that there is evidence or argument to suggest a causal relationship. 
 
7.1.3 Serious Adverse event (SAE) or Serious Adverse Reaction (SAR)  
 
Serious Adverse Event (SAE) 
 
An SAE fulfils at least one of the following criteria: 
 
• Is fatal – results in death (NOTE: death is an outcome, not an event) 
• Is life-threatening 
• Requires insubject hospitalisation or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
 Suspected Serious Adverse Reaction (SSAR) 
 
An SSAR is an adverse reaction that is classed as serious and which is consistent with the 
information about the medicinal product as set out in the Summary of Product Characteristics 
(SmPC) or Investigator’s Brochure (IB) for that product.   
 
7.1.4 Suspected unexpected Serious Adverse Reaction (SUSAR)  
The definition of a SUSAR is any suspected unexpected adverse reaction related to an IMP that is 
both unexpected and serious. In this case the event is not outlined in the Summary of Product 
Characteristics (SmPC) or Investigator’s Brochure (IB) for that product.  
7.2 Investigators Assessment  
 
 Seriousness 
The Chief/Principal Investigator responsible for the care of the patient, or in his 
absence an authorised medic within the research team, is responsible for assessing 
whether the event is serious according to the definitions given in section 7.1. 
 
7.2.2       Causality 
The Investigator must assess the causality of all serious adverse events/reactions in 
relation to the trial treatment according to the definition given. If the SAE is assessed 
as having a reasonable causal relationship, then it is defined as a SAR. 
 
7.2.3       Expectedness 
The investigator must assess the expectedness of all SARs according to the 
definition given. If the SAR is unexpected, then it is a SUSAR. 
 
7.2.4       Severity 
The Investigator must assess the severity of the event according to the following 
terms and assessments. The intensity of an event should not be confused with the 
term “serious” which is a regulatory definition based on patient/event outcome 
criteria. 
 
Mild: Some discomfort noted but without disruption of daily life 
Moderate: Discomfort enough to affect/reduce normal activity 
Severe: Complete inability to perform daily activities and lead a normal life 
 
7.3 Notification and reporting Adverse Events or Reactions 
If the AE is not defined as serious, the AE is recorded in the study file and the subject is 
followed up by the research team. The AE is documented in the subject’s notes (where 
appropriate and the CRF).  
 
7.4 Notification and Reporting of Serious Adverse Events/SUSAR  
 
7.4.1  All Serious Adverse Event (SAEs) that require reporting (see section 7.6 for cases where 
reporting is not required) will be recorded in the subjects’ notes, the CRF, the sponsor SAE form 
and reported to the Joint Research and Development Office (JRO)/ IMP provider (if applicable) within 
24 hours of the CI or PI or co-investigators becoming aware of the event. Nominated co-
investigators will be authorised to sign the SAE forms in the absence of the CI. Please ensure that 
the sponsor has been informed of these nominated co-investigators. 
 
7.4.2  Suspected Unexpected Serious Adverse Reactions (SUSARs) that occur during the trial 
will be reported to the JRO within 24 hours of the CI or co-investigator becoming aware of the 
 event. SUSARs should be reported to the sponsor (JRO Office) within 24 hours as the sponsor has 
a legal obligation to report this to the MHRA within 7 days (for fatal or life-threatening SUSARs) or 
15 days for all other SUSARs. In the case of multicentre studies, the PI or the co-investigators at 
the participating site must inform the CI within 24 hours of the event. The CI or co-investigators at 
the co-ordinating site must inform the sponsor (JRO) immediately to allow reporting to the MHRA 
within the allocated timelines. The CI will need to complete the CIOMS form in conjunction with the 
sponsor SAE form to be sent to the MHRA by the sponsor. If warranted, an investigator alert may 
be issued, to inform all investigators involved in any study with the same drug (or therapy) that this 
serious adverse event has been reported. 
 
The original and any subsequent follow up of Serious Adverse Event Forms and CIOMS forms 
(where applicable), together with the fax confirmation sheet must be kept with the TMF at the study 
site. 
 
7.4.3  The Annual Safety reports (ASR) will be sent by the CI to the sponsor, the MREC and 
MHRA (the date of the anniversary is the date on the “notice of acceptance letter” from the MHRA) 
using the sponsor ASR form. The CI will carry out a risk benefit analysis of the IMPs encompassing 
all events having arisen on the trial.  
 
7.4.4 The CI will send the annual progress report to the main REC (the anniversary date is the 
date on the MREC “favourable opinion” letter from the MREC) and to the sponsor. 
 
7.5 Procedures for reporting Blinded SUSAR 
Not applicable 
 
7.6 Expected SAEs/ SARs and non reportable events 
Doses higher than those recommended entail the risk of liver damage. Such high doses will not be 
used in the study. Paracetamol is used with caution in cases of hepatocellular insufficiency, severe 
renal insufficiency (creatinine clearance of less than 30 ml/min), chronic alcoholism, chronic 
malnutrition and dehydration. Caution is taken with the concomitant use of enzyme inducing 
substances and anticoagulants.   
Adverse drug reactions are rare (<1/1000 , >1/10000) such as malaise, hypotension, and increased 
levels of hepatic transaminases. Very rare reactions (1<1/10000) are hypersensitivity, 
thrombocytopenia, leucopenia and neutropenia. 
Very rare cases of hypersensitivity reactions range from simple skin rash or urticaria to 
anaphylactic shock have been reported and require discontinuation of treatment. Cases of 
erythema, flushing, pruritus and tachycardia have been reported. 
 
7.7 Pregnancy and Urgent Safety Measures 
 
Pregnancy 
Pregnant females will not be included in the study. Clinical experience of the intravenous 
administration of paracetamol is limited. However, epidemiological data from the use of oral 
therapeutic doses of paracetamol indicate no undesirable effects in pregnancy or on the health of 
the foetus/newborn infant. 
 
Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the clinical trial 
subjects from any immediate hazard to their health and safety, in accordance with Regulation 30. 
The measures should be taken immediately. In this instance, the approval of the Licensing 
Authority Approval prior to implementing these safety measures is not required. However, it is the 
responsibility of the CI to inform the sponsor, Main Research Ethics Committee (via telephone) and 
the MHRA (via telephone for discussion with the medical assessor at the clinical trials unit) of this 
event immediately.  
 
 The CI has an obligation to inform both the MHRA and Main Ethics Committee in writing within 3 
days, in the form of a substantial amendment. The sponsor (JRO) must be sent a copy of the 
correspondence with regards to this matter. 
 
7.8 Pharmacovigilance responsibilities 
Subjects with known hypersensitivity reactions to intravenous paracetamol will not be given the 
drug. In cases where paracetamol should be used with caution, such as hepatocellular insufficiency 
and renal failure, the subjects will be not be recruited into the study. For those subjects who are 
recruited in the study, there will be anaesthetist present throughout the administration of 
paracetamol, the spinal anaesthetic, the duration of surgery and in the recovery area. The subject 
will be closely monitored during all of these procedures. 
 
8 Data Handling and Record Keeping 
 
8.1 Confidentiality 
This study will be registered with the Trust Information Governance Manager at Barts and The 
London NHS Trust, ensuring the confidentiality of personal data. A signed declaration form (data 
protection form) of the group to comply with the Data Protection Act and the Department of Health 
Code of Confidentiality will be supplied. 
 
8.2 Study Documents 
Study files will be stored in a locked Pain and Anaesthetic Research Centre (PARC) office. All 
electronic data will be stored in a password-protected computer in a locked office. All study data will 
be stored in a custom-made password protected database, which identifies the subjects only by 
initials and a study number. Only members from the research team will have access to the raw 
data. Only pooled anonymised data will be published. 
 
The principle investigator and co-investigators will have control and act as the custodian for the 
data generated by the study. 
 
8.3 Case Report Forms 
These will contain the following: eligibility/exclusion criteria checklist, visit details-date, drug and 
dose, adverse events page for toxicities, withdrawal from study, follow up of outcomes, death, 
prior/current medication, medical history, SAE/SUSAR form. 
 
8.4 Record Retention and Archiving 
Essential study documents will be retained by the investigator and other study participants in the 
PARC for a minimum of two years, and thereafter archived for a longer period (at least 20 years) at 
Barts and the London Trust after study completion. 
 
8.5 Compliance 
 
The CI&PI will ensure that this study is conducted in accordance with the latest version of the 
“Declaration of Helsinki” (http://www.wma.net/e/policy/b3.htm) and the UK Legal Framework for 
Clinical Trials of IMPs, SI 2004/1031 and subsequent relevant amendments. The study must 
adhere to the principles outlined in the Guidelines for Good Clinical Practice”. 
 
8.6 End of study definitions 
The end of study is defined as “the last visit of the last subject undergoing the study”. 
 
 9 Clinical governance issues 
 
9.1 Ethical considerations 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with the ICH/Good Clinical Practice and applicable 
regulatory requirements. 
 
The Informed Consent Form will incorporate wording that complies with relevant data protection 
and privacy legislation. 
 
An Ethics Committee will review the final study protocol, including the final version of the Informed 
Consent Form and other written information to be provided to subjects. Before enrolment of any 
subject into the study, the national regulatory authority according to local regulations will approve 
the final study protocol and Informed Consent Form. 
 
All investigators have completed Good Clinical Practice and Research Governance courses. 
 
No conflict of interest has been declared within the study. 
 
9.2 Summary monitoring plan 
The study will be monitored in accordance with the local Research and Development protocols. The 
Barts and The London monitoring template will be completed in a continuous fashion throughout 
the study and kept up to date by the co-investigators and monitors.   
 
9.3 Audit and inspection 
The study will undergo audit and inspection in line with Good Clinical Practice guidelines. Audit may 
be carried out by the Sponsor to ensure that the trial procedures and data collected comply with the 
protocol and standard operating procedures, and that the data collected is correct and complete. 
Study monitors will have full and direct access to all source documents and other trial-related data. 
 
9.4 Reporting of Serious breaches in GCP or trial protocol 
Serious breaches in GCP or trial protocol will be reported by the chief investigator to the Research 
and Development office (sponsor). 
 
9.5 Trial committee (oversight) 
This is a single centre study. The study will be monitored in accordance with the sponsor Standard 
Operating Procedures (SOPs) and the trial monitor will adhere to any sponsor monitoring tools and 
SOPs. The CI will review the trial progress and review data on a continual basis.  
 
10 Statistics 
 
10.1 Endpoints 
 
10.1.1 Primary endpoints 
To measure the cerebrospinal levels of paracetamol after it has been given intravenously. 
 
10.1.2 Secondary Endpoints 
To measure the effect of paracetamol on prostaglandin synthesis in the CSF and to measure the 
concentration of AM404 in the human CSF following intravenous administration of paracetamol. 
The plasma levels of paracetamol post administration of intravenous paracetamol will be measured 
too. The plasma to CSF ratio of paracetamol concentrations can then be calculated. 
 
 
 10.1.3 Study definitions 
 
10.2 Statistical considerations 
10.2.1 Sample Size 
30 subjects will be recruited. This is a pilot study so the sample size has not been calculated. 
 
10.2.2 Planned recruitment rate 
Subjects will be recruited on the elective operative lists. It is estimated that 3-5 subjects will be 
recruited per week. 
 
10.3 Statistical Analysis 
The concentrations of paracetamol in the cerebrospinal fluid will be plotted against time. The CSF 
concentrations and plasma concentrations of paracetamol will be plotted against time on a graph 
and the plasma to CSF ratio will be calculated. 
The transfer in and out of the CSF was assumed to be by passive diffusion, and therefore the rates 
of transfer in and out of the CSF would be dependent on concentration. The influx and efflux of 
drug would therefore be exponential processes with rate constants ka and l, respectively. The drug 
CSFconcentrations (Ct) can be fitted to a simple pharmacokinetic model. 
 
10.4 General considerations 
 
10.5 Frequency of Analysis 
The statistical analysis will take place at the end of the study by a qualified statistician. 
 
10.6 Primary end point analysis 
As above 
 
10.7 Secondary endpoint analysis 
As above 
 
10.8 Interim Analysis 
The analysis will be done at the end of the study. However the CI will maintain an oversight of data 
throughout the trial.  
 
10.9 Randomisation and Stratification 
Non-participating members from the Pain and Anaesthesia Research Group will prepare a 
randomisation table. Subjects enrolling into the study will be assigned a study number starting from 
01. Once the subject has been allocated a study number, the third party (non-blinded) researcher 
will open the appropriate numbered envelope to reveal the pre assigned randomised study group 
allocation. 
 
11 Study Finances 
 
11.1 Funding Sources 
This is an internally funded study by the Pain and Anaesthesia Research Centre. 
11.2 Subject expenses +/- payments 
Subjects will not receive further expenses or payments. 
 
12 Sponsorship and Indemnity 
 
Sponsorship and indemnity will be provided by Barts and The London NHS Trust 
 
 13 Publication policy 
 
The results of this study will be published in a peer-reviewed journal. The study results may be 
published and/or presented at scientific meetings. All manuscripts and abstracts, which refer to 
data originating from the trial, must be submitted to the Sponsor before publication. The Sponsor 
has the right to refuse the results for registration purposes, internal presentation and promotion. 
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